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Abstract 
Wir beschreiben eine neue Strategie zum Atorvastatin-Lacton mit einer Paal-Knorr 
Pyrrolsynthese über die Kondensation eines 1,4-Diketons mit einem Amin, welches bereits einen 
Großteil der Seitenkette aufweist. Das Amin beinhaltet eine syn-1,3-Diol Untereinheit und eine 
Benzylether-Funktion am Ende der Kette. Die C4-Position am Pyrrol erlaubt 
Funktionalisierungen über Iodierung, Li-X Austausch und Carboxylierung. Die 4-H Pyrrolsäure 
konnte schließlich über Amid-Bildung, Debenzylierung Oxidation und im letzten Schritt 
Lactonisierung in das Atorvastatin-Lacton überführt werden. Das Hauptfragment 2-((4R,6S)-6-
(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethanamin wurde über zwei sequentielle 
asymmetrische Transfer-Hydrier-Carbonyl-Allylierungs-Schritte nach Krische et al. erhalten. 
Um mit einem Linker verbundene Atorvastatin-Derivate zu erhalten, wurde die Pyrrol-4-
Carbonsäure mir einem Triethylenglykol mit Anillin-Terminus kondensiert, um das 
entsprechende Amid zu erhalten. Nach Immobilisierung auf Toyopearl-Beads wurde klassische 
Affinitätschromatographie durchgeführt. 
Als Alternative zur mühsamen Affinitätschromatographie beschreiben wir die Kombination der 
Osada-Strategie der Carben-basierten Immobilisierung kleiner Moleküle auf Affinitäts-Harzen 
und der Massenspektrometrie-basierten Markierung von Aminosäuren mit stabilen Isotopen in 
Zellkulturen (SILAC) für affinitätsbasierte Suche und Identifikation der biologischen Targets. 
Um dieses Konzept zu beweisen, verwendeten wir erfolgreich ein klassisches Beispiel, in dem 
wir Cyclophilin als bekanntes biologisches Target von Cyclosporin A identifzieren konnten. Des 
Weiteren wurde diese Strategie verwendet um biologische Off-Targets des Atovastatin Lactons 
und unbekannte Targets von Englerin A zu finden. Hierzu synthetisierten wir einen Diazirin-
basierten Triethylenglycol-Linker mit Carboxyl-Terminus, der auf Toyopearl AF 650 Amino 
Beads immobilisiert wurde. Die so hergestellten Beads wurden unter Verwendung der Osada-
Methode mit den kleinen Molekülen beladen, in dem man die kleinen Moleküle bestrahlte 
(Englerin A beziehungsweise Atorvastatin Lacton unter UV-Licht, 365 nm, 4 J·cm
–2
, 8 W). Das 
Fischen der Arzneimittel Targets wurde (von der Projektkollegin Yvonne Etzel) mit Zelllysat 
von HEK293T Zelllinien (Nierenzellen) durchgeführt. Die Experimente wurden sowohl mit 
Bead Kontrolle als auch mit löslichem Kompetitor durchgeführt. Die Analyse der gefischten 
Proteine wurde mit der SILAC-Technik durchgeführt. Erste Experimente ließen in der Tat einige 
potentielle Protein-Targets erkennen. Dieser kombinierte Weg könnte hilfreich für die 
Identifizierung von unbekannten biologischen Targets von unterschiedlichen kleinen Molekülen 
sein. Hinblick auf die Totalsynthese eines Naturstoffes entwickelten wir eine kurze 
Syntheseroute zu einem Schlüsselfragment von Biselyngbyasid. Dieses neue Makrolacton wurde 
aus einem marinen Cyanobakterium Lyngbya sp. aus der Präfektur Okinawa isoliert. Es zeigt 
Zytotoxizität gegenüber HeLa S3 Zellen mit einem IC50 von 0.1 mg·mL
–1
. Die mittlere 
Wachstumshemmung (GI) lag bei 0.6 mM in einer Auswahl aus 39 Zelllinien. Ein 
anspruchsvolles Zwischenfragment C1–C13 von Biselingbyaside mit Vinyliodid an einem Ende 
wurde über eine Kreuzmetathesereaktion zwischen einem Vinylalkohol und 
Homoallylbausteinen hergestellt. Das Allylalkoholfragment wurde über eine Amano PS Lipase 
unterstützte hydrolytische kinetische Resolution von racemischer 3-Hydroxy-4-
pentencarbonsäure synthetisiert, gefolgt von weiteren Modifizierungen. Das letzte Fragment, das 
zwei Stereozentren enthält, wurde unter Verwendung einer asymmetrischen Alkylierung, einer 
Wittig-Reaktion, einer Hydrozirconierung und einer Brown-Allylierung als Schlüsselschritte 
erhalten. 
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Introduction  1 
1   Introduction 
Statins are a well known class of drugs used for lowering the blood cholesterol level by 
interrupting cholesterol synthesis in the liver.
1
 They efficiently reduce the plasma cholesterol 
levels by lowering the synthesis of low density lipoprotein (LDL) at the same time increasing the 
concentration of high density lipoprotein (HDL) which leads to improved HDL to LDL ratio for 
good health. Cholesterol is a useful waxy steroid present in all mammals and is the essential 
component of cell membranes and is used to produce bile acids and steroid hormones like 
estrogen, testosterone, progesterone, cortisol and aldosterone.
2,3
 However, presence of high level 
of cholesterol is due to the abnormal increase in lipoprotein which is the carrier of cholesterol in 
the blood stream. The elevated cholesterol level in the blood is called hypercholesterolemia
4
 
which is the major reason for high risk of coronary heart disease (CHD),
5
 atherosclerosis
6
 and 
stroke.
7
 Hypercholesterolemia is a major human body disorder specifically due to the very high 
LDL level which promotes cardiovascular diseases. 
 
Figure 1. Chemical structure of cholesterol 1-1. 
Today, heart failure due to the elevated blood cholesterol level is the leading cause of mortality 
in developed countries like United States and some of the European countries.
8
 CHD causes one 
third of the total deaths (mortality) majorly in these countries. One third of all deaths worldwide, 
approximately 17 million are due to the increase in blood cholesterol level and more than one 
third of these occur in middle aged adults. In this regard, statin therapy emerged as promising 
treatment in patients having a high risk of coronary artery diseases with an increase in serum 
cholesterol level. 
2  Introduction 
Lovastatin 1-2, which is a fungal metabolite was the first approved 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inihibitor accepted as a drug.
9
 Since then, several highly 
potent statins either from natural sources or chemically synthesized became commercially 
available in the market being served for treatment of regulation of cholesterol levels. Today, 
statins are among the most selling drugs in the world. Some of the statins available in the market 
as pharmaceutical drugs are lovastatin 1-2 (mevacor),
9b
 simvastatin 1-3 (zocor),
10
 pravastatin 1-4 
(pravacol),
11
 fluvastatin 1-5 (lescol),
12
 atorvastatin 1-6 (lipitor),
13
 rosuvastatin 1-7 (crestor),
14
 and 
pitavastatin 1-8
15
 (livalo) (Figure 2 & 3). 
 
Figure 2. Statin drugs available in the market as cholesterol lowering agents. 
Other examples of statin molecules are compactin 1-10,
16
 cerivastatin 1-9
17
 etc. (see Figure 3). 
Compactin 1-10 is isolated from the mold Penicillium citrinum by A. Endo et al.,16 while 
lovastatin 1-2 is from the fermentation broth of Aspergillus terreus.
9
 Pravastatin 1-4 is derived 
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from compactin 1-10 by biotransformation while simvastatin 1-3 is a semisynthetic form of 
lovastatin 1-2. Other statins including fluvastatin 1-5, atorvastatin 1-6, rosuvastatin 1-7 and 
pitavastatin 1-8 are chemically synthesized in the laboratory.
18
 
 
Figure 3. Some other examples of statins. 
Among all statins, atorvastatin 1-6 and rosuvastatin 1-7 are highly potent while fluvastatin is the 
least potent.
1
 According to the annual report of Pfizer pharmaceuticals (2008), atorvastatin 1-6 
remained the largest selling drug in the world.
19
 Statins show minimal adverse effects like 
cognitive loss, raised liver enzymes, pancreatic and hepatic dysfunction and muscle problem. In 
contrast to this, in 2001 cerivastatin 1-9 was withdrawn from the market due to severe adverse 
effects of rhabdomyolysis in the patients.
20
 The development of compactin 1-10 was as well 
discontinued from the preclinical trial in 1980 because of its toxicity in an animal model.
18 
Though the statin drugs are used extensively for lowering the LDL and triglycerides, some 
studies over several years also revealed a range of additional, mostly positive side effects. These 
are independent of their cholesterol lowering ability and referred as pleiotropic effects. These 
beneficial effects include antioxidant properties, increased nitric oxide bioavailability, and 
particularly anti-inflammatory effects which are key contributor to atherosclerosis.
21
 Clinical and 
experimental observations strongly suggest that inhibition of inflammation contributes to the 
beneficial effect of statins.
22
 The study by Ridker et al. provided evidence that aggressive statin 
therapy achieves the target levels of LDL, independent of C-reactive protein (CRP) in patients 
having risks of myocardial infarction, and patients having acute coronary syndromes
23
 where 
CRP is known as the clinical marker of inflammation.
24
 There is no evidence seen yet for the 
relationship between lowering CRP levels and the lipid lowering ability of statins. For lovastatin 
1-2 and other decalin ring statins, it was shown that they suppress the inflammatory response in 
4  Introduction 
an animal model of peritonitis by binding to the 2 integrin leukocyte function antigen-1 (LFA-
1).
25
 But, this elucidation given by the author seems to be limited only for the statins with a 
decalin system and remained unanswered for other statins like atorvastatin 1-6. A clinical trial 
with aggressive doses (up to 80 mg/day) of atorvastatin 1-6 with patients having elevated lipid 
levels and high risk of heart diseases led to a significant improvement in inflammatory, 
thrombogenic states and as well as improvement in lipid profile.
26
 This is in agreement with the 
analysis of Pravastatin or Atorvastatin Evaluation and Infection Trial (PROVE-IT), 
Thrombolysis In Myocardial Infarction (TIMI)-22 study by Ridker et al.
22,27
 
These reports highlight the beneficial effects of atorvastatin and other statins in lowering 
inflammation which provides a new sight of clinical research. This means that in order to detect 
other cellular targets than HMG-CoA reductase (HMGR) enzyme, statins like atorvastatin as 
affinity probe might be useful. 
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2   Goal of the research  
The pharmacological therapy of different diseases with the help of numerous drug 
molecules is a cornerstone of medicine. However, the molecular mode of action of several drug 
molecules is often unclear and the cellular targets are not yet completely known. Besides, 
pharmacological and pharmacokinetic interactions of some drug molecules are very often 
different than their postulated targets. In 95% of cases, targets of drug molecules are proteins 
whose functions are primarily enzyme, receptor, ion channel, or transport proteins in cellular 
systems. In case of anti-inflammatory drugs partially effective targets are glucocorticoid 
receptor,
28
 cyclooxygenases,
29
 5-lipoxygenase,
30
 tumor necrosis factor alpha (TNF-α) and 
interleukin-1 (IL-1).
31
 In particular, inflammatory diseases like rheumatoid arthritis are very 
common chronic diseases among the Western nations. Despite the wealth of available drugs used 
in the therapy of inflammatory diseases there is still a lack of understanding of the molecular 
basis of the mechanism of action. A number of different pharmacological approaches are pursued 
in “Pain-fever-inflammation”, however the exact effects of the drugs and in particular the origins 
of the side effects are often unclear. Some examples of well served anti-inflammatory drugs 
metamizol 1-11,
32
 celecoxib 1-12,
33
 paracetamol 1-13,
34
 aspirin 1-14
35
 and clofibrate 1-15
36
 
(Figure 4) and anti-cholesterol drugs like lovastatin 1-2, atorvastatin 1-6 (Figure 2) having 
considerable positive anti-inflammatory side effects which could be part of proposed research 
program. The primary biological targets of these ligands are known, but their molecular mode of 
action as well as origin of side effects is not yet fully understood. One further example of a 
positive side effect of statin drugs could be given as their association with decreased prevalence 
of Alzheimer’s disease.37 
6  Goal of the research 
 
Figure 4. Some commonly used anti-inflammatory drugs. 
The main objective of the research program was the identification of the relevant 
pharmacological targets and to contribute to the understanding of the mechanism of action of the 
above mentioned anti-inflammatory drugs. The research program aimed to develop chemical 
methods to synthesize the proposed drugs or their modified analogues attached to some suitable 
linkers for immobilization on affinity resins, fishing the drug targets from the cell lysate using 
affinity based method and their identification using suitable methods like MALDI-MS and other 
bio-analytical methods. The functionality of the drug-target interaction will be eventually 
characterized and validated. To explore the whole concept, we succeeded with an 
interdisciplinary group of scientists and graduate students to work on the various issues during 
the course. Being a part of this research program, our goal was to synthesize atorvastatin lactone 
and their derivatives coupled to a suitable linker system without affecting the hydroxy lactone 
region, which in its open form is crucial for the HMG-CoA reductase inhibition. 
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3   Literature Review 
3.1   Mevalonate pathway of cholesterol biosynthesis2 
Isoprenoids, derived from the mevalonate pathway are essential components of cells to maintain 
membrane fluidity and to assist in cell proliferation in all plants, fungi and mammals.
38
 
Mevalonate is formed from acetyl co-enzyme A via intermediate HMG-CoA. The 4-electron 
reduction of HMG-CoA to mevalonate is an early key step in the biosynthetic pathway. The 
reaction is catalyzed by HMG-CoA reductase (HMGR) and proceeds as follows.
1
 
(S)-HMG-CoA + 2 NADPH + 2H
+
                   (R)-mevalonate + 2 NADP
+
 + CoASH 
Where NADPH is nicotinamide adenine dinucleotide phosphate and NADP
+
 is the oxidized form 
of NADPH. 
 
Figure 5. Mevalonate pathway in animal cells. 
8  Literature Review 
Mevalonate is converted into isoprene based molecules named as isopentenyl pyrophosphate 
(IPP) and dimethyl allyl pyrophosphate (DMPP) with adenosine triphosphate (ATP) dependent 
CO2 loss. Here IPP remains in equilibrium with DMPP by isomerization of the double bond.
2
 
Synthesis continues with the formation of geranyl-pyrophosphate (GPP) by condensation of one 
molecule of IPP with one molecule of DMPP. GPP then enters into the synthesis of squalene via 
farnesyl pyrophosphate (FPP) as an intermediate which is formed by combination of one GPP 
and one IPP. Squalene is then converted to cholesterol after 21 intermediate steps.
2
 Isoprenoid 
intermediates (FPP) are also diverted to the synthesis of other biological important compounds 
like heme A, dolichol and ubiquinone (Figure 5). 
 
3.2   Binding mechanism of atorvastatin in cholesterol metabolism 
All statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGR). As discussed above, a crucial step in the cholesterol biosynthesis is the conversion of 
HMG-CoA to mevalonate which is blocked by the so called statins. They all share a HMG-like 
moiety in the structure as either active hydroxy acid form or as inactive lactone form which is 
enzymatically hydrolyzed to the active form in vivo.
1,39
  
 
Figure 6. (A) Active site of human HMGR in complex with HMG, CoA, and NADP; (B) Mode 
of binding of atorvastatin (1-6) with HMGR.
1 
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The structural similarity of the statin’s heptanoic acid functional group to HMG suggests that 
these agents interfere with HMG-CoA binding to the HMGR enzyme. Indeed, all statins are 
competitive inhibitors of HMGR with respect to binding of HMG-CoA, but not with respect to 
binding of NADP(H).
1
 In particular, an X-ray structure revealed that the HMG like moiety of 
atorvastatin occupies the active site (cis loop of residues 682-694) of HMGR enzyme while the 
bulky hydrophobic part of the statins is located in a shallow groove that is formed after 
rearrangement of the C-terminal residues of the enzyme (Figure 6).
1
 As a result, there is no 
access for the substrate HMG-CoA to HMGR enzyme which is blocked after binding of a statin. 
The surface complementarity between HMGR and the hydrophobic part of atorvastatin is present 
in the statin-enzyme complex which is possible because atorvastatin adopts a conformation that 
allows its hydrophobic group to maximize contact with the hydrophobic region of the protein.
39 
Comparing the substrate-bound HMGR structures with the inhibitor-bound structures (Figure 6) 
illustrates that a rearrangement of the active site is required to accommodate the statin. 
Interactions that distinguish atorvastatin from decalin ring containing statins are hydrogen 
bonding between Ser
565
 OH group of the protein and either carbonyl oxygen or O-5 hydroxyl of 
atorvastatin. Also, the fluorophenyl group of atorvastatin stacks on the guanidinium group of 
Arg
590
 where polar interactions between guanidine nitrogens and fluorine atom are observed. The 
tight binding of atorvastatin is probably due to the large number of van der Waal interactions 
between atorvastatin and HMGR. 
 
3.3   Development of atorvastatin calcium by Bruce Roth 
Atorvastatin, a completely synthetic drug was first prepared by Bruce Roth in 1985 while 
working as medicinal chemist at Parke-Davis Warner-Lambert Company (now Pfizer 
pharmaceuticals). It is a penta-substituted pyrrole having a 3-hydroxy-3-methylglutaryl (HMG) 
like moiety on the terminus of the amine side chain. The design of atorvastatin was partly based 
on molecular modeling comparisons of the structures of fungal metabolites and other 
synthetically derived analogues.
40
 For the design and discovery of this highly potent drug, Roth 
and coworkers had screened 30 pyrrole analogues out of which only the analogue with a 4-
fluorophenyl at the 2-position and an isopropyl substituted at the 5-position of the pyrrole ring 
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led to good potency. Furthermore they screened about 20 analogues having different substituents 
at the 3 and 4-positions of the ring where they settled with a phenyl ring and phenyl amide group 
at the respective positions. With these substituents they found the best potency (IC50 = 0.007M) 
among all other analogues.
40 
 
3.3.1   Enantioselective linear synthesis of atorvastatin lactone 
One of the two subgroups working under the supervision of Bruce Roth explored a synthesis that 
would achieve the fully functionalized pyrrole ring. Thus, treatment of acylated amino acid 1-16 
with Ac2O generated an intermediate that reacted with acetylene 1-17, containing the 
carboxamide group, in a [3+2] cycloaddition manner and led to the penta-substituted pyrrole 1-
18. The reaction was found to be highly regioselective with regard to the orientation of the 
substituents and high yielding. 
 
Scheme 1. [3+2] cycloaddition of azalactone 1-16 and phenyl acetylene 1-17. 
To improve the yield of the reaction, an excess of 1-17 was required but its removal in the 
workup was difficult in the large scale synthesis. This experience made them to look for other 
options like Paal-Knorr cyclodehydration using diketone 1-19 and various amines to generate the 
penta-substituted ring. But the reaction failed to give the corresponding cyclodehydration 
products (Scheme 2) under a variety of conditions. 
An alternative option was to a make pyrrole ring with a tetra-substituted ring without the 
carboxamide group and to install it in later stage of synthesis. 
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Scheme 2. Attempts for the synthesis of pyrrole bearing phenyl carboxamide. 
The precursor for the Paal-Knorr cyclodehydration was prepared by heating a mixture of 4-
fluorobenzaldehyde 1-24 and unsaturated ester 1-25 under Stetter conditions followed by 
saponification and decarboxylation of ketoester 1-26 to afford 1,4-diketone 1-27. Paal-Knorr 
cyclization of 1,4-diketone 1-27 with amine 1-21 proceeded smoothly to furnish pyrrole 1-28.
41
 
The N-phenyl carboxamide was introduced by bromination at the 4-position of pyrrole 1-28 
followed by subsequent Li–Br exchange and treatment with phenyl isocyanate. Hydrolysis of the 
diethylacetal provided aldehyde 1-29 which after a diastereoselective aldol condensation with the 
dianion of (S)-(+)-2-acetoxy-1,1,2-triphenylethanol resulted in the diastereomeric mixture of an 
intermediate (60% yield and 97% ee) which upon treatment with NaOMe at 0 °C gave ester 1-30 
in 68% yield. Reaction of ester 1-30 with the lithium enolate of tert-butyl acetate followed by 
reduction with Et3B-NaBH4 mixture yielded intermediate syn-dihydroxyester enantioselectively. 
Base hydrolysis using NaOH followed by reflux in toluene and then purification by 
recrystallization from EtOAc/hexane afforded final lactone (+)-1-31 (Scheme 3) as 100% 
enantiomerically pure.
40,41
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Scheme 3. Synthesis of atorvastatin lactone by subgroup of Roth et al. 
Despite the successful isolation of highly enantiomerically pure (+)-1-31 on gram scale, the 
reaction scheme involved several low temperature reactions, low yielding steps particularly in 
the final stage and a final recrystallization making this synthesis less efficient for kilogram scale 
synthesis. This made Roth and coworkers to think for a more economical and more efficient 
route. 
Literature Review  13 
3.3.2   Convergent route towards the synthesis of atorvastatin calcium40 
Therefore, the Paal-Knorr route was reinvestigated and the Roth subgroup from the chemical 
development eventually found suitable conditions for this transformation. The required diketone 
1-19 was prepared by condensation of commercially available isobutyrylacetanilide 1-32 with 
benzaldehyde in presence of -alanine and acetic acid to afford enone system 1-33 in 85% 
yield.
42
 Reaction of 4-fluorobenzaldehyde 1-24 with 1-33 under Stetter conditions using an N-
ethylthiazolium catalyst (Scheme 4) furnished substituted 1,4-diketone 1-19 in 80% yield. After 
extensive investigation of the classical Paal-Knorr condensation, success in the cyclodehydration 
was achieved by refluxing diketone 1-19 and acetal protected propanal amine 1-21 in presence of 
a full equivalent of pivalic acid in a ternary mixture (1:4:1) of the solvents toluene/THF/heptane 
providing fully functionalized pyrrole 1-23 in 43% yield. 
 
Scheme 4. Synthesis of pyrrole ring bearing phenyl carboxamide group. 
Now, a route could be foreseen in which the amine side chain having the complete functionality 
required for the synthesis could be condensed with diketone 1-19 to access the complete 
molecule in one step. To this end, a versatile intermediate (S)-methyl-4-bromo-hydroxybutyrate 
1-37
43
 which is known from the synthesis of other HMG reductase inhibitors was converted to 
amine building block 1-41. 
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This intermediate was efficiently synthesized from isoascorbic acid 1-34 by treating it with H2O2 
in presence of CaCO3 and K2CO3 to afford the salt of trihydroxy acid 1-35 which on further 
bromination and then esterification led to -bromoester 1-36 using HBr, AcOH and methanol. 
Further catalytic hydrogenation of -bromoester 1-36 using Pd/C yielded versatile intermediate 
1-37.
44
 Protection of the hydroxyl group followed by substitution of the bromide with cyanide 
provided 1-38 (Scheme 5) as an advanced precursor. 
 
Scheme 5. Synthesis of an advanced intermediate 1-38. 
Afterwards, hydrolysis of methyl ester 1-38 and its subsequent activation using N,N-
carbodiimidazole (CDI) followed by treatment with the magnesium salt of t-butyl malonate and 
removal of silyl ether using buffered fluoride afforded -hydroxy--ketoester 1-39. 
 
Scheme 6. Synthesis of functionalized amine side chain 1-41. 
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Stereoselective reduction of the keto group using NaBH4 and Et2BOMe at low temperature (−90 
°C) led to syn-1,3-diol;45 then acetonide protection of the resulting diol using acetone dimethyl 
acetal produced 1-40 in 65% yield as crystalline solid and excellent diastereoselectivity (100:1) 
which was improved to 350:1 after recrystallization.
46
 Catalytic reduction using molybdenum 
doped Raney nickel catalyst under 50 psi hydrogen pressure of nitrile 1-40 delivered amine 1-41 
(Scheme 6) with outstanding enantiomeric excess (ee) value (>99.5).47 
Cyclodehydration of the functionalized and enantioenriched amine side chain 1-41 with fully 
substituted 1,4-diketone 1-19 was carried out under carefully derived conditions (1 equiv pivalic 
acid and 1:4:1 mixture of toluene/heptane/THF) which yielded 75% of the desired pyrrole 1-42. 
Further deprotection of the acetonide ester and treatment with Ca(OH)2 provided 
stereochemically pure calcium salt of atorvastatin 1-6 (Scheme 7). This convergent route is high 
yielding and commercially viable for the large scale synthesis of the molecule. 
 
Scheme 7. Synthesis of atorvastatin calcium from functionalized precursors. 
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4   Retrosynthesis 
Since atorvastatin in its lactone form is easier to prepare and is a precursor for its 
dihydroxy carboxylate as active form, our proposed synthesis aimed at atorvastatin lactone with 
the possibility to attach a ethylene glycol linker to the aniline ring of carboxamide group. 
Retrosynthetic analysis of atorvastatin lactone (1-31 or 1-43) suggests a first retrosynthetic cut at 
lactone C–O bond which directs acetonide acid (1-44 or 1-45) as synthetic equivalent which 
could be functionalized by oxidation of primary alcohol. Amide function on the pyrrole ring 1-44 
or 1-45 can be developed by insertion of the carboxyl group at 4-position on the ring of pyrrole 
1-46 followed by coupling with simple amine 1-47 or derived amine 1-48 (Figure 7). 
 
Figure 7. Retrosynthetic analysis of atorvastatin lactone and derived analogues. 
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Here, to build a polyethylene glycol derived linker system to the phenyl ring of the carboxamide 
part of the molecule might be suitable to provide flexibility to the resulting derivative in target 
fishing experiments. A fundamental building block, pyrrole 1-46 could be obtained from 
diketone 1-27 and functionalized amine side chain 1-49 using an acid catalyzed classical Paal-
Knorr cyclization. Diketone 1-27 is a known starting material which might be synthesized easily 
according to the literature procedures. 
 
Figure 8. Retrosynthetic consideration for amine side chain 1-49. 
The synthesis of the functionalized amine side chain 1-49 containing a syn-1,3-diol could be 
achieved in different ways. Here we proposed two different routes to prepare it from simple 
mono protected propanediol 1-52 as its earliest precursor (Figure 8). The first proposed strategy 
is based on Krische’s approach48 of iterative enantioselective carbonyl allylations to build the 
syn-1,3-polyol subunit by using iridium catalysis. This strategy involves two fold asymmetric 
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allylation followed by ozonolysis to provide tetraol derivative 1-50 as an advanced precursor 
which can be modified to amine 1-49 via simple functional group interconversions. 
An alternative approach is based on a vinylogous Mukaiyama aldol reaction (VMAR)
49
 of 
aldehyde prepared from alcohol 1-52 leading towards -hydroxy-,-unsaturated ester 1-54 as 
key intermediate (Figure 8) which introduces one asymmetric center in the molecule. The 
second asymmetric center can be brought in via base catalyzed intramolecular conjugate addition 
of hemiacetal derived alkoxide of benzaldehyde to -hydroxy enoate 1-54 followed by 
protection-deprotection steps to fashion syn-dihydroxy ester 1-53. Towards the end of the side 
chain synthesis the methyl ester function can be transformed to amine 1-49 via its conversion to 
intermediate amide. 
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5   Results and Discussion 
5.1   Initial attempts of synthesis and functionalization of the pyrrole ring 
We decided first to synthesize achiral 1,4-diketone 1-26 containing a methyl ester for further 
manipulation towards the corresponding carboxamide. According to the literature procedure,
41
 
commercially available 4-methyl-3-oxopentanoate 1-55 was condensed with benzaldehyde in 
toluene under reflux condition whereby water was removed azeotropically yielding enone 1-25 
as shown in Scheme 8. Under Stetter reaction conditions, using thiazolium salt 1-56 as catalyst, 
enone 1-25 was converted to 1,4-diketone 1-26 and further to 1-27 by base hydrolysis. 
 
Scheme 8. Synthesis of 1,4-diketone 1-27. 
As initial approach, we planned to try cyclodehydration of diketone 1-26 with the amine 1-21 to 
check the feasibility of the reaction in presence of a methyl ester group present in 1-21, and if it 
would be successful then we could modify the synthesis towards our goal. Accordingly, we 
attempted the condensation of diketone 1-26 with acetal protected 1-amino-3-propanal 1-21, 
using p-TSA•H2O as catalyst in a Dean-Stark apparatus for azeotropic removal of water but no 
desired conversion to the corresponding pyrrole has been observed (TLC). Repeated attempts 
provided the same result. Similar results were obtained when we used various amines under 
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different conditions
41,50
 as shown in Scheme 9 and prolonged heating. TLC always showed a 
series of spots as well as in LC-MS we did not observe the target compounds (1-60a-e). 
 
Scheme 9. Screening of different conditions for synthesis of methyl ester functionalized pyrrole. 
Consequently, we proposed to make a pyrrole without a methyl ester function with the 
speculation that it could be functionalized after pyrrole formation. Therefore, methyl ester 1-26 
was converted to analogous diketone 1-27 by using 3N NaOH while vigorously stirring the 
mixture at room temperature (as shown in Scheme 8). Then, diketone 1-27 was refluxed with 
amine 1-21 under acidic conditions in toluene over 48 h. The reaction completed successfully 
and delivered pyrrole in 85% yield. Next task was to establish a carboxylic group at the C-3 
position of the pyrrole ring. As proposed, the C-4 position of pyrrole 1-28 was brominated using 
NBS at room temperature in good yield.
51
 Bromopyrrole 1-61 was subjected to lithium-bromine 
exchange using n-BuLi at −78 °C. The resulting organo-lithium species was quenched with ethyl 
chloroformate to furnish pyrrole ester 1-62 in 83% yield. 
Results and Discussion  21 
 
Scheme 10. Synthesis of pyrrole with carboxyl acid 1-63. 
In the next step, hydrolysis of the ethyl ester 1-62 was attempted using various bases and 
solvents (Scheme 10). However, very harsh conditions like repeated addition of base and high 
reflux temperature were required; despite this high yields could not be obtained in a reproducible 
way. This problem was resolved later successfully by the use of solid CO2 as an electrophile to 
deliver acid 1-63 directly in a single step. Treatment of bromopyrrole 1-61 with t-BuLi followed 
by addition of excess of dry ice provided acid 1-63 in 82% yield in one step. Here, we used t-
BuLi as base rather than n-BuLi followed by immediate quenching of the metalated species with 
hope to minimize the formation of 10–15% of pyrrole 1-28 as side product but only little 
improvement in the yield of the reaction was observed. Most probably the formation of pyrrole 
1-28 as a side product is due to the moisture associated with the addition of solid dry ice. 
With enough amount of acid 1-63 in hand, we were set to carry out a reaction with 4-
bromoaniline for amide bond formation. We screened a variety of coupling agents under 
different conditions as stated in Scheme 11 but only the reaction using PyBrOP and DIPEA was 
completed successfully to yield amide 1-64 in excellent yield. 
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Scheme 11. Attempts made for synthesis of amide 1-64 using suitable coupling conditions. 
For further extension, we treated amide 1-64 with THP protected and propargyl derived TEG 
linker 1-66 (received from M. Golkowski) under Sonogashira conditions
52
 (Pd(PPh3)2Cl2, CuI, 
Et3N in THF) at room temperature but no conversion to the desired product has been observed. 
Repeated attempts of the reaction as well as solvent change to CH3CN with longer stirring and 
heating to reflux did not produce linker coupled product 1-67 (Scheme 12). However, replacing 
the bromo derivative 1-64 with iodo derivative 1-65 which is prepared by using 4-iodo aniline, 
then heating the mixture in THF together with 1-66 at 60 °C, provided coupling product 1-67 in 
45% yield. But, this reaction always remained low yielding in the poor range of 40–45% which 
was insufficient to carry out further transformations in order to reach atorvastatin lactone 
connected to a linker. 
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Therefore, we skipped this route and planned to design a better route towards atorvastatin lactone 
and derived analogues. 
 
Scheme 12. Synthesis of pyrrole amide 1-67 under Sonogashira conditions. 
We proposed to synthesize the pyrrole without ester function using diketone 1-27 and 
commercially available amine 1-41, then introduction of amide on pyrrole ring would be 
followed by functionalization of the lactone in the subsequent steps. As well as, after 
disappointing results with the Sonogashira coupling, we proposed to synthesize linker derived 
aniline(s) which could be coupled via amide bond formation with the carboxyl derived pyrrole. 
 
5.2   Atorvastatin lactone synthesis using commercially available side chain 
Accordingly, diketone 1-27 and amine 1-41 were refluxed in toluene to remove water as 
azeotrope under acidic condition using catalytic p-TSA•H2O to afford pyrrole 1-68. Subsequent 
bromination was completed within 30 min using NBS in DMF yielding bromopyrrole 1-69 in 
74% yield over two steps. The next step was challenging since we had to carry out metal-halogen 
exchange selectively in presence of the sensitive t-butyl ester group. Obviously, n-BuLi and t-
BuLi would not be useful under these circumstances for selective metal-halogen exchange while 
keeping an ester group intact. We tried some other selective reagents like mesityl lithium,
53
 
Zn•LiCl/CuCN•2LiCl,54 and i-PrMgCl•LiCl55 (Scheme 13) but we did not observe metal-
halogen exchange; also TLC supported this observation.  
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Scheme 13. Attempts towards the chemoselective Li–Br exchange on bromide 1-69 with various 
reagents. 
The alternative solution for this issue was to change the t-butyl ester group to another functional 
group and then to carry out the metal-halogen exchange reaction. As a consequence, the t-butyl 
ester group of 1-68 (Scheme 13) was first reduced using DiBAL-H at −40 °C and protected as 
TBS ether 1-72 quantitatively using t-butyldimethylsilyl chloride and imidazole. Iodination at C-
3 position using NIS in DMF at room temperature provided intermediate iodo analogue 1-73 
quantitatively. Here, we used NIS as mild agent rather than NBS to avoid possible TBS group 
removal which we noticed while carrying out bromination of analogous TES ether of 1-72 using 
NBS at room temperature. 
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Scheme 14. Synthesis of intermediate 1-75 from amine side chain 1-41. 
Li–I exchange using t-BuLi at −78 °C followed by addition of excess of solid CO2 furnished acid 
1-73 in 80% yield. Aniline was coupled to 1-74 under predeveloped coupling conditions as 
shown in Scheme 11. Now turning to the side chain part, the TBS group was removed using 
TBAF•3H2O as 0.2M solution in THF which led to alcohol 1-76. Oxidation using Dess-Martin 
periodinane in CH2Cl2 followed by subsequent oxidation of the resulting aldehyde with buffered 
NaClO2,
56
 in aq t-BuOH provided corresponding acid 1-44 in 96% yield. To complete the 
synthesis, acetonide acid 1-44 was treated with catalytic amount of camphorsulphonic acid in 
various solvents including CH3CN, THF and methanol at room temperature. Among these, 
reaction in CH3CN provided higher yield than in the other two solvents and we were able to 
isolate pure atorvastatin lactone 1-31 (Scheme 15) in 90% yield. Recrystallization from 
petroleum ether and ethyl acetate provided 1-31 as a white solid powder. Spectroscopic data of 
this final lactone were almost identical with the reported one.
57
 Optical rotation of 1-31 was 
determined to be +25.5 (c 0.2, CHCl3; Lit.
47
 value +26.05). 
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Scheme 15. Synthesis of atorvastatin lactone 1-31. 
The only drawback of this synthesis was that the amine side chain 1-41 was quite expensive to 
purchase. And it was necessary to have gram scale intermediates in hand to synthesize TEG 
derived analogues of atorvastatin lactone. Therefore, we decided to synthesize the amine side 
chain by a novel route which would provide it on gram scale for further modifications. 
 
5.3   Synthesis of functionalized amine side chain  
As described in literature, amine 1-41 is generally prepared from tert-butyl-2-[(4R,6S)-6-
(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate 1-77 (Figure 9) via chain extension.
58
 
Several examples about synthesis of the side chain have been reported.
59
 Some biocatalytic 
methods have been used to reduce prochiral precursors like 4-chloro/4-bromo-3-oxobutyrate 1-
80 or 3,5-dioxy-6-benzyloxyhexanoate 1-86.
60
 Also, there are reports about an efficient, scalable 
enzyme catalyzed synthesis towards 3-hydroxyglutaronitrile 1-85
61
 or from 3-hydroxyglutaric 
acid ethyl ester 1-84.
62
 
Results and Discussion  27 
 
Figure 9. Various routes from the literature towards the synthesis of amine 1-41. 
Other publications have described the synthesis of versatile intermediate 1-77 from 1-chloro-3-
(p-methylbenzyloxy)-2-propanol 1-81 derived from racemic epichlorohydrin,63 (4R,6S)-6-
(chloromethyl)-4-hydroxytetrahydro-2H-pyran-2-one 1-83 by sequential aldol reaction of 
azidoaldehyde and acetaldehyde catalyzed by Schiff’s base 2-deoxyribose-5-phosphate aldose 
(DERA)
64
 and other one starting from L-malic acid 1-79.65 Among all, a highly practical route to 
the precursor 1-77 includes Noyori type hydrogenation of ethyl-4-benzyloxy acetoacetate 1-78 
followed by Claisen condensation and syn reduction of the hydroxy ketone.
66
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5.3.1   Amine side chain by Krische’s iterative approach 
Recently Krische et al.
48
 published an approach for the synthesis of syn or anti-1,3-polyols by 
iterative asymmetric transfer hydrogenative carbonyl allylation. In their work, they also reported 
an efficient synthesis of a possible precursor for the side chain namely syn-1,3-diol subunit 1-93 
(see Scheme 17). This intermediate would be a useful starting point towards the synthesis of an 
amine side chain with a benzyl protected alcohol which could be functionalized to the lactone 
ring in the final steps of the synthesis as described above (Scheme 15). 
The syn-1,3-diol subunit 1-93 was fashioned from 3-benzyloxy-1-propanol (1-87)67 by two 
iterative asymmetric transfer hydrogenative carbonyl allylation reactions. Thus, reaction of 
alcohol 1-87 with allyl acetate in presence of a catalyst generated in situ from [Ir(COD)2Cl2], 
(R)-(+)-Cl,MeO-BIPHEP, and 4-chloro-3-nitro-benzoic acid in THF at 120 °C yielded homoallyl 
alcohol 1-88 in 90% yield. As shown below, the iridium catalyst performs a redox reaction 
converting the alcohol to an aldehyde and using hydride ion to generate an allyl anion equivalent. 
The enantiomeric excess of homoallyl alcohol 1-88 was determined to be 92% by chiral GC 
analysis. Next, alcohol 1-88 was protected to the corresponding TBS ether 1-89 which was then 
subjected to ozonolysis employing Sudan III (2-3 drops, 1% in methanol) as an indicator. The 
completion of reaction was indicated by a change in color of the solution from pink to colorless. 
The reaction mixture upon in situ reduction using excess of NaBH4 delivered an alcohol 1-90 in 
97% yield (Scheme 16). Alcohol 1-90 under similar allylation conditions furnished syn-diol 1-91 
in 93% yield which was then subjected to in situ deprotection of the silyl ether and protection of 
the diol as acetonide function to deliver the corresponding derivative 1-92 in 80% yield. Some 
alternative routes for the synthesis of intermediate 1-92 are reported in the literature.
68
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Scheme 16. Synthesis of an intermediate acetonide 1-92 using Krische’s iterative approach. 
Building block 1-92 was converted under ozonolysis conditions in a binary mixture of 
methanol/CH2Cl2 to acetonide alcohol 1-93. Transformation of alcohol 1-93 to azide 1-95 was 
completed in two steps via intermediate tosylate 1-94 followed by treatment with NaN3 in DMF 
in high yield (83%, over 2 steps). Reduction of azide 1-95 with PPh3
69
 in a water/THF mixture 
(1:9) for overnight provided the targeted amine side chain 1-96 (Scheme 17) in excellent yield. 
 
Scheme 17. Synthesis of amine chain 1-96 from intermediate 1-92. 
30  Results and Discussion 
5.3.2   Proposed mechanistic pathway for Krische’s transfer hydrogenative carbonyl 
allylation 
A plausible mechanism
70
 for the iridium catalyzed hydrogenative carbonyl allylation reveals the 
association of chelating phosphine ligand and 4-Cl-3-NO2-BzOH with [Ir(COD)2Cl2] to give 
iridium carboxylate II which shows equilibrium with ortho-cyclometalated complex I. Here, 
oxidative addition of allyl acetate to complex II should deliver an iridium carboxylate, which 
should be predisposed to acetate-assisted ortho-metalation through six membered transition state 
III to furnish the σ-allyl C,O-benzoate complex IV. The complex IV remains in rapid 
equilibrium with -allyl haptomer V which could be characterized by single crystal X-ray 
diffraction analysis (where Ln = (R)-BINAP).
70
 
 
Figure 10. Postulated catalytic mechanisms for the iridium catalyzed transfer hydrogenative 
coupling from the alcohol or aldehyde oxidation level.
70 
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Participation of an aldehyde in this cycle generates a new homoallyl oxy-iridium complex VI 
which is formed by the allylic transfer to the aldehyde through a chair like transition structure.
70
 
Configurational stability of the resulting homoallyl alcohol is most probably due to the co-
ordination of iridium (III) with the olefin moiety of the homoallylic alcohol which in turn 
disables -hydride elimination pathways. At this stage, exchange of the resulting homoallyl 
alcohol by the reactant alcohol ensue the conversion of VI to VII, a free co-ordination site 
becomes available and -hydride elimination delivers complex VIII. Dissociation of the 
aldehyde regenerates back the ortho-cyclometallated complex I (Figure 10). 
A stereochemical model accounting for the observed sense of absolute stereoinduction is based 
on the coordination mode as evident in the crystal structure of complex V. Complexation of the 
aldehyde with -allyl haptomer IV is postulated to occur at the indicated position adjacent to the 
C,O-benzoate. In this way, the sterically less demanding allyl moiety is placed between the 
napthyl and phenyl moieties of the ligand, allowing the aldehyde to reside in a more open 
environment. In the favored mode of addition, the aldehyde is bound in such a way that the 
aldehyde C−H bond projects into the -face of a phenyl moiety of the ligand, giving rise to a 
weakly attractive aldehyde C−H -interaction. In the disfavored mode of action, the aldehyde is 
bound such that the aldehyde “R group” projects into the -face of a phenyl moiety of the ligand, 
giving rise to a severe non-bonded interaction (Figure 11).
70
 
 
Figure 11. Study of stereochemical model accounting for the observed sense of absolute 
stereoinduction using (R)-BINAP ligand.70 
 
32  Results and Discussion 
5.3.3   Synthesis via vinylogous Mukaiyama aldol reaction (VMAR) 
As an alternative for the synthesis of an amine side chain, we developed a new route by using a 
method published by Kalesse et al.
49
 Recently he reported an oxazaborolidinone mediated 
synthesis of -hydroxy ,-unsaturated esters with high enantioselectivity. This strategy has 
been proven to be very useful to build intermediates in the synthesis of natural products.
71
 
Kalesse and coworkers accomplished the synthesis of described intermediates from 
corresponding aldehydes using a tryptophan derived B-phenyloxazaborolidinone complex and 
freshly prepared O,O-silyl ketene acetal 1-98. This methodology was found to be quite useful in 
our case to provide an alternative approach for the synthesis of the amine side chain. 
Starting compound benzyloxy propanal 1-101 was prepared from 1-87 according to the literature 
procedure for Swern oxidation.
72
 The other required reagents O,O-silyl ketene acetal 1-98 and N-
Ts-(L)-tryptophan 1-100 were synthesized from trans-methyl crotonate 1-97 and L-tryptophan 1-
99 respectively (Scheme 18) according to the literature procedure.
49
  
 
Scheme 18. Synthesis of reagents 1-98 and 1-100 required for VMAR. 
With these reagents in hand, we initiated the synthesis by treating suspensions of tryptophan 1-
100 with dichlorophenyl borane under N2 atmosphere. The resulting boron complex was then 
exposed under nitrogen with a mixture of aldehyde 1-101, O,O-silyl ketene acetal 1-98 and 2-
propanol in stoichiometric amounts in n-butyronitrile at −78 °C for 4 h and consequently 
produced hydroxy enoate 1-103 in 60% yield (Scheme 19). 
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Scheme 19. Synthesis of intermediate hydroxy enoate 1-103 by VMAR from aldehyde 1-101. 
The enantiomeric excess of alcohol 1-103 was determined to be 88% by Mosher ester analysis 
(Figure 12). Significant shift differences were seen for 2-H and 3-H. 
 
Figure 12. Mosher ester analysis of alcohol 1-103 using 
1
H NMR spectrum. 
As mentioned, the B-phenyloxazaborolidinone (OXB) 1-102 was prepared from 
phenyldichloroborane and N-Ts-(L)-tryptophan 1-100. The proposed transition state73,74 of the 
OXB-catalyzed aldol reaction involves the shielding of aldehyde’s si-face through the indole 
moiety (see, Figure 13). As a result, nucleophilic attack of the O,O-silyl ketene is favored from 
the re-face of aldehyde to provide high enantioselectivity of the corresponding alcohol. Isopropyl 
alcohol in the reaction serves as an additive which suppresses the racemic TBS catalyzed 
pathway and enhances the enantioselectivity of the reaction. 
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Figure 13. Proposed transition state of VMAR. 
For the insertion of the second hydroxyl function, hydroxy enoate 1-103 was subjected to the 
conjugate addition of hemiacetal derived benzyloxy anion generated by PhCHO and t-BuOK at 0 
°C
75
 which afforded benzylidene acetal protected syn-dihydroxyl ester 1-104 as shown in 
Scheme 20. This oxy-Michael addition reaction proceeds via the intermediate hemiacetal 
alkoxide anion. Afterwards, deprotection of the benzylidene group followed by acetonide 
protection of resulting diol was achieved via a one pot synthesis in good yield. This 
transformation was completed successfully by heating benzylidene acetal 1-104 in a 1:1 mixture 
of 2,2-dimethoxypropane in CH2Cl2 in presence of catalytic p-TSA•H2O within 24 h and led to a 
95% of acetonide ester 1-105. Here,  values of acetonide methyl groups are at 19.7 and 30.0 
ppm while the quaternary carbon resonates at 98.8 in 
13
C NMR indicating the formation of the 
1,3-diol in syn fashion (Figure 14).76 
 
Figure 14. Confirmation of syn 1,3-diol formation by 13C NMR of acetal 1-105. 
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Thereafter, ester 1-105 was converted to corresponding amide 1-106 which worked successfully 
in 24 h by refluxing the ester 1-105 in a mixture (1:2) of 25% aq NH3 and methanol providing 
the amide in 76% yield. The outcome of this conversion was better than that in THF. In the end 
of the sequence, amide 1-106 was reduced using LiAlH4 under reflux conditions in THF which 
yielded amine 1-96 (Scheme 20) in about 72% yield. 
 
Scheme 20. Preparation of amine side chain 1-96 from 5-hydroxy enoate 1-103. 
Prior to the synthesis of benzyl protected amine side chain 1-96 using the above mentioned route, 
we attempted the same route to synthesize PMB protected analogous amine of 1-96 from p-
methoxybenzyl protected analogue of hydroxy enoate 1-103 by following the same path 
(Scheme 20). Unwillingly, in the next step of pyrrole synthesis the PMB ether did not survive 
under reflux conditions using xylene in presence of catalytic p-TSA•H2O. Removal of the PMB 
group was observed (LC-MS) during the reaction. Accordingly, we relied on the benzyl 
protecting group for the transformations indicated in the Scheme 20. 
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5.4   Atorvastatin lactone using benzyl protected amine side chain 
In 2003, Ӧhrlein et al. published the synthesis of full functionalized pyrrole from side chain 
containing azide substituent and functionalized diketone 1-19 (see Scheme 7) by aza-Wittig 
reaction.
62
 The reaction proceeds via an imine intermediate promoted by a tri n-butyl phosphine 
and triisopropyl benzoic acid as a weak, sterically hindered acid. Using this reaction pyrrole can 
be obtained directly from azide containing side chain. Therefore we treated azide 1-95 with PBu3 
in dry toluene at room temperature then resulting imine intermediate was heated (60 °C) with 
2,4,6-triisopropyl benzoic acid and diketone 1-27 for nearly 72 h. TLC showed very little 
conversion to the desired pyrrole 1-108 along with some other side products. 
 
Scheme 21. Attempt for the synthesis of pyrrole 1-108 by aza-Wittig reaction. 
Therefore we skipped this reaction and the substrates, diketone 1-27 and amine 1-96 were in 
hand subjected to Paal-Knorr condensation under the described conditions (p-TSA•H2O, toluene, 
reflux) where it was expected to complete a synthesis smoothly as we did before (see, Scheme 
13). But surprisingly, progress of the reaction was very slow and the reaction did not complete 
even after 10 days. Addition of excess of catalyst was risky because of possible acetonide 
deprotection as well as there was a possibility to form a furan ring from diketone 1-27. 
Therefore, we refluxed the reaction at elevated temperature by changing the solvent to xylene. 
This amendment brought a better change in the progress of reaction. TLC showed nearly 
completion of the reaction within 6–7 days. After flash chromatographic purification, the isolated 
yield of the resulting pyrrole 1-108 was 68%. Interestingly, the acetonide group was found to be 
incredibly stable under the stated conditions. 
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Next, pyrrole 1-108 was treated with NIS to yield 91% of iodo pyrrole 1-109 which was further 
metallated using t-BuLi and quenched subsequently with excess of dry ice at −78 °C to furnish 
carboxyl derived pyrrole acid 1-110 in 81% yield. Modification to amide 1-111 using PyBrOP 
and debenzylation of the side chain from 1-111 by transfer hydrogenation using 20% of Pd(OH)2 
on carbon and cyclohexene yielded corresponding alcohol 1-76.
77,78
 Further oxidation using 
Dess-Martin periodinane and subsequently buffered NaClO2 to acid 1-76 followed by CSA 
catalyzed lactone ring formation (as described in Scheme 15) delivered atorvastatin lactone 1-31 
(Scheme 22) in high yield. 
 
Scheme 22. Synthesis of atorvastatin lactone using side chain 1-96. 
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A characteristic peak in the 
1
H NMR spectrum of 1-31 indicating lactone ring formation is the  
3-H proton at  value ranging between 4.43–4.56 ppm (Figure 15). All carbon peaks from the 
molecule were in accordance with the literature data. Our synthesis provides a new approach for 
the highly enantioselective synthesis of atorvastatin lactone. The key feature of the synthesis 
includes the development of the amide function on the pyrrole ring via the corresponding 
carboxylic acid. The developed strategy opens the way to new amide derivatives of atorvastatin 
and allows attachment of a linker to the pyrrole carboxylic group. 
 
Figure 15. Fragment of the 
1
H NMR spectrum of final atorvastatin lactone 1-31. 
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5.5   Synthesis of triethylene glycol derived atorvastatin lactone for 
application in pull-down experiments 
According to our revised synthesis plan, one alternative for obtaining an aniline based linker was 
to combine a nitro styrene with an allyl ether containing the remaining linker atoms via cross 
metathesis. For example, this could be achieved from cross metathesis reaction between p-nitro 
styrene 1-114 and the corresponding hydroxyl and acid derived O-allyl linkers. The resulting 
system would be reduced to the desired aromatic amines 1-112 and could be coupled to the 
intermediate acid 1-110. 
 
Figure 16. Retrosynthesis of functionalized TEG coupled aniline derivatives. 
Therefore, we intended the synthesis of p-nitro styrene 1-114 from p-nitro benzaldehyde 1-117 
under Wittig conditions at −40 °C for 3 h using the salt prepared from CH3Br and PPh3. 
However, the resulting less polar crude product containing small impurity turned out to be 
difficult to separate from the product using flash chromatography. 
 
Scheme 23. Synthesis of 4-nitrostyrene 1-114. 
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Alternatively, p-nitro styrene 1-114 with high purity and higher yield was obtained by Takai-
Nozaki olefination using CH2I2 as the methylene source in combination with Ti(OiPr)4 and 
activated zinc dust (Scheme 23).
79
 Under these conditions, styrene 1-114 was obtained in 94% 
isolated yield. 
 
5.5.1   Synthesis of a TEG linker with a hydroxyl function 
Triethylene glycol 1-116 was first protected with t-butyldimethylsilyl chloride using NaH as base 
in THF to yield mono protected TEG 1-118. Allylation of the remaining hydroxyl group was 
carried out using tetra n-butyl ammonium hydrogen sulfate (TBAHS) as phase transfer catalyst 
and NaOH in a biphasic mixture of benzene and H2O to furnish O-allyl TEG 1-119 in 76% 
yield.
80
 Next, O-allyl TEG 1-119 and p-nitro styrene 1-114 were subjected to the olefin cross 
metathesis
81
 in dry and degassed toluene at 70 °C. The cross metathesis product was isolated as a 
mixture of isomers (trans/vinylic trans/vinylic cis) in 53% yield. Subsequently the mixture of 
cross metathesis products was reduced using 10% Pd/C furnished 75% of pure amine 1-121 
(Scheme 24). 
 
Scheme 24. Synthesis of t-butyldimethylsilyl protected linker 1-121. 
Similarly, TEG 1-116 was protected with t-butyldiphenylsilyl chloride to afford TBDPS 
protected TEG 1-122. This was followed by allylation using allyl bromide under basic condition 
providing the corresponding allyl ether derivative 1-123.  
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Further extension was fashioned using a cross metathesis reaction
81
 under the same conditions to 
yield a mixture (trans/vinylic trans/vinylic cis) of cross metathesis products 1-124 which were 
further reduced to amine 1-125 as shown in Scheme 25. 
 
Scheme 25. Synthesis of TBS protected TEG linker derived amine 1-125. 
 
5.5.2   Synthesis of TEG linker having carboxylic acid terminus 
For the synthesis of amine 1-129 (Scheme 26), TEG was modified to mono O-allyl TEG 1-126 
using allyl bromide and NaH at room temperature in 89% yield. Subsequent alkylation of 1-126 
was completed by treating it with t-butyl bromoacetate in a biphasic mixture of 50% aq NaOH 
and benzene using catalytic TBASH as a phase transfer catalyst to furnish 85% of 1-127. Cross 
metathesis
81
 of styrene 1-114 and modified TEG 1-127 using 5 mol% of Grubb’s 2nd catalyst in 
CH2Cl2 under reflux condition yielded 80% of metathesis product 1-128 with very high E-
selectivity. Hydrogenation using catalytic 10% Pd/C in methanol under hydrogen balloon 
pressure provided carboxyl functionalized 1-129 in 75% yield. 
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Scheme 26. Synthesis of t-butyl ester derived linker 1-129. 
 
5.5.3   Synthesis of atorvastatin lactone containing TEG linker with hydroxyl function 
With functionalized aniline 1-125 and pyrrole acid 1-110 in hand, we accomplished their 
coupling through the formation of a peptide bond to yield 1-130 using PyBrOP and DIPEA in 
CH2Cl2 at room temperature. Thereafter, the benzyl ether present on side chain was removed by 
hydrogenation using 20% Pd(OH)2/C in EtOAc under balloon pressure in 8 h to give alcohol 1-
131. Oxidation to acid 1-132 was completed quantitatively in two steps using Dess-Martin’s 
reagent followed by buffered NaClO2 in 50% aq t-butanol in 74% yield. Then, the acetonide acid 
1-132 was cyclized to lactone 1-133 using CSA in very good yield. Finally, silyl group was 
removed using a mixture of 70% HF•pyridine at 0 °C to afford the TEG alcohol of atorvastatin 
lactone 1-134 (Scheme 27). 
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Scheme 27. Synthesis of hydroxyl TEG derived atorvastatin lactone 1-134. 
 
5.5.4   Synthesis of atorvastatin lactone coupled with the carboxyl derived TEG linker 
To synthesize the carboxyl derived atorvastatin analogue, acid 1-110 and aniline 1-129 were 
coupled under similar conditions (PyBrOP, DIPEA, CH2Cl2, and rt) to afford the corresponding 
amide 1-135. Subsequent debenzylation by hydrogenation on the surface of catalytic 20% of 
Pd(OH)2 in EtOH on carbon under hydrogen balloon pressure afforded alcohol 1-136. Oxidation 
to acetonide acid 1-137 was completed in two steps (Scheme 28). Then, lactone 1-138 was 
prepared using catalytic CSA in CH2Cl2 at room temperature followed by cleavage of the t-butyl 
ester from the linker part using a solution of 85 wt% aqueous phosphoric acid
82
 which was 
delivered acid 1-139 in 75% yield over two steps. 
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In this case, t-butyl ester removal using TFA in CH2Cl2 at room temperature did not work well, 
while using mild acid (85 wt% H3PO4) at room temperature received the best result. 
 
Scheme 28. Synthesis of carboxylic acid derived atorvastatin lactone analogue 1-139. 
 
5.5.5   Synthesis of TEG linker coupled pyrrole from 2-phenyl ethylamine 
Since target fishing approaches either require beads with a control lacking the crucial target 
molecule or are performed with soluble controls, we decided to prepare the pyrrole 1-144 
(Scheme 29) lacking the lactone. Accordingly, 1,4-diketone 1-27 and 2-phenylethyl amine were 
refluxed in presence of catalyst p-TSA in toluene in a Dean-Stark apparatus for 72 h to afford 
pyrrole 1-140 in 98% yield. Bromination to 1-141 using NBS in DMF at room temperature and 
subsequent Li–Br exchange using t-BuLi at −78 °C followed by addition of excess of solid CO2 
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produced analogous acid 1-142 in 93% yield. Coupling of linker amine 1-121 with carboxylic 
acid 1-142 using PyBrOP in CH2Cl2 at room temperature provided corresponding amide 1-143 in 
67% yield. Subsequent silyl removal using TBAF•3H2O in THF afforded final penta-substituted 
pyrrole 1-144 coupled with a linker (Scheme 29) in high yield. 
 
Scheme 29. Synthesis of TEG derived simple penta-substituted pyrrole 1-144. 
We submitted these three modified analogues 1-134, 1-139 and 1-144 samples to our project 
colleagues (Yvonne Etzel, Felix Behnke) for immobilization on suitable affinity beads and 
further target fishing experiments. We used here 1-134 and 1-139 analogues as hit compound 
while 1-144 was used as control for the analogue 1-134. 
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5.6   Results of affinity based target fishing experiments with atorvastatin 
lactone derived analogues 
First, hydroxyl derived analogue 1-134 and 1-144 were immobilized on Toyopearl AF epoxy 650 
beads while acid derived analogue 1-139 was immobilized on Toyopearl AF amino 650 beads. 
The hydroxyl derived analogue 1-134 was tested against A549 lung cell lines whereas carboxylic 
acid analogue 1-139 was tested against HEK239T cell lines (Human Embryonic Kidney 293 
cells) for which AcOH blocked amino beads were used as a control in the experiment. 
 
Figure 17. Detection of binding proteins for TEG hydroxyl functionalized atorvastatin lactone 1-
134 (A) and TEG acid functionalized atorvastatin lactone 1-139 (B). In picture A, Lane 1: A549 
cell lysate; Lane 2: Immobilized atorvastatin lactone analogue 1-134 in A549 cell lysate; Lane 3: 
penta-substituted pyrrole 1-144 as control in A549 cell lysate. In picture B, Lane 4: HEK239T 
cell lysate; Lane 5: AcOH blocked control beads with HEK239T cell lysate; Lane 6: 
Immobilized atorvastatin lactone analogue 1-139 in HEK239T cell lysate. 
From the data of biological testing received from the colleagues responsible for biological 
experiments it was seen (Figure 17) that there are no distinguishing protein bands observed for 
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the analyzed molecule which were different from the control experiments in both cases of 
hydroxyl and acid derived analogues. However lane 6 indicates a more selective binding of 
proteins as compared to the control (lane 5). The probable reason for these disappointing results 
could be that the position where linker is connected on the molecule might not be suitable to 
preserve the biological activity of the molecule or the target proteins are of low abundance. Also 
the fact was that HMG-CoA reductase (98 or 19 kDa) was not found either. It can be explained 
by the absence of the dihydroxy carboxylate form of atorvastatin lactone. 
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6   Conclusion I 
In summary, we have developed a novel and efficient route towards the synthesis of 
atorvastatin lactone from 1,4-diktone 1-27 and the newly developed amine side chain 1-96 
derived from simple 1,3-propanediol. The achiral part of the molecule, 1,4-diketone 1-27 was 
easily prepared from methyl-4-methyl-3-oxopentanoate 1-55 within 3 steps in overall 48% yield 
according to the literature procedure (Scheme 30). 
 
Scheme 30. Synthesis of 1,4-diketone 1-27. 
The asymmetric part of the molecule, aliphatic amine side chain 1-96 has been efficiently 
synthesized using two alternative routes. The first route involves as key steps of the synthesis, 
two Krische allylation reactions followed by ozonolysis associated with in situ NaBH4 reduction 
to introduce the syn-1,3-diol subunit. Amine 1-96 was synthesized in 9 steps with overall 44% 
yield starting from alcohol 1-87 (Scheme 31). 
 
Scheme 31. Amine side chain by Krische’s iterative allylation approach. 
Alternatively, amine side chain 1-96 was prepared by using a vinylogous Mukaiyama aldol 
reaction (VMAR) in a comparatively shorter route than Krische’s iterative approach. This route 
provided amine 1-96 in 5 steps from aldehyde 1-101 (Scheme 32). The overall yield of the 
sequence was 23% and included a single step deprotection of the benzylidene acetal and diol 
protection as acetonide.  
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Aqueous NH3 mediated conversion of the ester to amide was used to establish the primary 
amine. This route provides the aliphatic side chain in fewer steps than Krische’s iterative 
approach but isolated yields of various steps are in the range of moderate to high yield as well as 
enantioselectivity at VMAR step is somewhat less (< 88%). 
 
Scheme 32. Synthesis of the amine side chain 1-96 using a vinylogous Mukaiyama aldol 
reaction. 
After the synthesis of the amine side chain, atorvastatin lactone 1-31 was obtained successfully 
over 8 steps from diketone 1-27 and amine 1-96 (Scheme 33). Crucial intermediate steps 
involved carboxyl insertion at the C-3’ position of the pyrrole via metalation and trapping of the 
anion with CO2 followed by coupling with aniline. Thereafter, the benzyl ether in the aliphatic 
side chain was converted to the desired lactone over 4 steps. Overall yield of the total synthesis 
in the longest chain sequence (17 steps) is 13% starting from alcohol 1-87 via Krische’s 
approach. 
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Scheme 33. Synthesis of atorvastatin lactone 1-31 from functionalized amine side chain 1-96. 
Aniline derived TEG linkers 1-121, 1-125 and 1-129 were synthesized from p-nitro styrene 1-
114 and hydroxyl as well as carboxyl functionalized TEG 1-119, 1-123 and 1-127 respectively 
(Scheme 34). These linkers were synthesized in four steps for each. 
 
Scheme 34. Synthesis of aniline derived triethylene glycol linkers. 
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Using these linkers 1-125 and 1-129 respective atorvastatin analogues 1-134 and 1-139 were 
obtained efficiently from acid 1-110 by following the above mentioned route to establish the 
corresponding lactone. Deprotection of protective groups under suitable conditions led to the 
corresponding analogues (Scheme 35). Our strategy provides efficient approaches towards linker 
derived analogues of atorvastatin useful for affinity based target fishing. 
 
Scheme 35. Synthesis of triethylene glycol derived atorvastatin analogues. 
In summary, the atorvastatin lactone analogues 1-134 and 1-139 were successfully immobilized 
on Toyopearl AF epoxy and amino beads, respectively. The choice of the Toyopearl beads was 
based on the positive experience of the co-workers from the biology section in other pull downs. 
Unfortunately, after incubation of the cell extracts with the loaded and control beads, the SDS-
PAGE did not reveal a significant fishing. There were no distinct bands that differed between 
control and probe lanes. One might conclude that the linked analogues were either not 
biologically active, meaning the point of attachment interfered with protein binding or the 
concentration of the fished proteins was too low to be detected by SDS-PAGE. Accordingly, we 
were looking into a strategy that would allow for a simplified immobilization of small molecules 
and more sensitive detection methods. 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
Chapter II 
A New Strategy for Photoaffinity based Identification and 
Evaluation of Biological Targets of Atorvastatin Lactone and 
Englerin A 
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7   Introduction 
Bioactive small molecules (BASMs) are useful as affinity probes for the identification of 
their target proteins and other biological studies.
83
 Their ability to induce phenotypic changes in 
a cellular system by modulating protein function has made them valuable as tools for the study of 
complex cellular processes and consequently as pharmaceutical drugs. Small molecules typically 
bind non-covalently to their biological targets which deserves high importance in the study of 
complex cellular processes. Cellular targets and the mode of action of many potent BASMs and 
drugs available today are known but at the same time the targets of several other BASMs are still 
unknown.
83,84
  
Thus, determination of the protein-target interactions of BASMs is a focal challenge towards the 
increasing diversity of drug targets. Several methods of affinity purification of protein targets for 
biologically active small molecules have been developed in the context of chemical genetic 
studies.
85,86
 Despite several target identification techniques available, affinity based 
chromatography still remains a widely used method. The target identification process basically 
involves relevant modification of the molecule of interest, coupling of the molecule to a 
biotinylated system or an affinity matrix via a suitable linker system. Then, the whole system is 
incubated with cell lysate of the desired body organ or cell lines. After washing procedures 
tightly bound proteins are eluted with excess of free drug or using highly denaturing conditions. 
Thereafter, the eluted proteins are analyzed by SDS-PAGE and protein bands isolated are 
identified by mass spectrometry (Figure 18).
87
 As a classical example, Schreiber and co-workers 
reported that the immunosuppressant FK-506 (2-1) (see Figure 20) immobilized on agarose 
beads and incubated with cell lysate, bound to a protein called FKBP-12.
87d
 The major protein 
target (FKBP-12) turned out to be a cis-trans prolyl isomerase with a moleculer weight of around 
12 kDa. The strong binding of FK-506 (2-1) to FKBP-12 could be proven in separate binding 
experiments and by X-ray crystallography. 
Although affinity chromatography has been used widely, it has some certain drawbacks. The 
ideal point of attachment of the small molecule to the linker must be developed according to the 
structure-activity relationships (SAR) which is time consuming. Even when available, many 
small molecules modified with a linker could affect the bioactivity of the small molecule. 
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However, an advantage of these affinity based methods is that they rely solely on binding of the 
drug to its target proteins.
88
 Another big problem in affinity based methods is a non-specific 
binding of proteins to the linker part. Nowadays, small molecules are usually immobilized via 
polyethylene glycol linkers. The hydrophilic nature of these linkers reduces non-specific binding 
of proteins to the affinity matrices. 
 
Figure 18. Schematic representation of the affinity matrix strategy for target identification.
86c
 
To avoid the lengthy and cumbersome process of small molecule modification, recently a new 
method was introduced to immobilize small molecules on glass solid supports coated with a 
functionalized diazirine based photoaffinity linker.
89
 A thought was to apply a solution of a small 
molecule to these glass slides and after UV exposure of the dried plates, the resulting reactive 
carbene would insert in a functional group independent manner in a C–H or X–H bond.89 This 
approach provided a rapid access towards the development of small molecules immobilized on 
affinity matrices and the application of these conjugates in the field of proteome research. Taking 
an advantage of this approach, Sugawara et al.
90
 and Osada et al.
91
 successfully extended this 
technique to immobilize small molecules on photoaffinity linked beads as shown in Figure 19. 
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Figure 19. Preparation of PALC agarose beads and photo cross-linking of a small molecule.
91
 
This strategy was quite successful for the identification and purification of target proteins of the 
small molecule cyclosporin A (2-2) and other agents.
91
 Even though this strategy cannot be 
practical to those molecules that degrade upon UV irradiation, it should be advantageous to a 
wide range of small molecules and to facilitate the identification of the cellular targets of these 
small molecules. 
 
Figure 20. Structures of FK-506 (2-1), cyclosporin A (2-2) and englerin A (2-3). 
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As discussed in Chapter I (Section 5.6), we were not fortunate to find off-targets of triethylene 
glycol linker modified atorvastatin lactone using the classical affinity based method of 
immobilization on beads. It appeared to us that this photoaffinity based method for 
immobilization of small molecules might be useful for atorvastatin lactone and several other 
small molecules. So we changed our strategy to the carbene based immobilization of small 
molecules as an alternative approach with the hope that this would give us a promising outcome. 
Besides atorvastatin lactone we planned to study a recently isolated new antitumor molecule, 
englerin A (2-3).
92
 Its core structure has been lately synthesized in our group.
93
 Englerin A (2-3) 
shows antitumor activity against renal cancer cell lines in the NCI 60 cell panel
94
 with GI50 
values from 1–87 nM. A COMPARE analysis133 of the englerin A 60 cell panel data against NCI 
standard agents did not suggest a known mechanism of action. All this information increased our 
interest to find out its protein target and binding properties. 
Since the previous fishing experiments indicated that proteins bound to atorvastatin lactone are 
of low abundance, we furthermore planned to combine the Osada method with a highly sensitive 
mass spectrometry based technique called SILAC (vide infra). 
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8   Results and Discussion 
8.1   Synthesis of photoaffinity based TEG derived linker 
For fishing experiments, the initial task was to synthesize a suitable linker to immobilize it on the 
surface of amino functionalized Toyopearl-AF-Amino-650 beads. In that case, a carboxylic acid 
derived triethylene glycol linker system which is coupled to 3-trifluoromethyl-3-phenyl 
diazirine
95
 appeared as a best option. 
 
8.1.1   Synthesis of carboxyl functionalized triethylene glycol linker 2-8 
According to the proposed plan, we initiated with the synthesis of amine and t-butyl ester 
functionalized TEG linker 2-8 from triethylene glycol 2-4. TEG was first mono tosylated to 2-5 
by p-toluenesulphonyl chloride and Et3N in CH2Cl2 followed by its subsequent modification to 
azide 2-6
96
 using NaN3 in 85% yield over two steps (Scheme 36). Now, the free hydroxyl 
function of 2-6 was alkylated using tert-butyl bromoacetate and NaH in DMF which delivered  
2-7 in 76% yield. Further reduction of azide of 2-7 under mild conditions using PPh3
69
 in a 
THF/H2O (10:1) mixture provided TEG derived amine t-butyl ester 2-8 ready for coupling with 
the photoaffinity tag. 
 
Scheme 36. Synthesis of functionalized TEG linker 2-8. 
60  Results and Discussion 
8.1.2   Synthesis of 4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoic acid 2-16. 
Phenyl diazirine is widely used in the field of chemical biology for photoaffinity labeling. 
Several reports are available about its application in affinity based target fishing.
86a,91,97
 As 
consequence, their synthesis in various applications have been studied.
98
 Using some of these 
efficient literature procedures we synthesized desired diazirine 2-16 in high overall yield. 
In the beginning, ketone 2-11 was prepared by a Grignard reaction using 4-bromotoluene 2-9 
derived Grignard reagent and the amide 2-10
98a
 as electrophile. Ketone 2-11 on treatment with 
NH2OH•HCl in a mixture of pyridine and ethanol
98c
 followed by subsequent modification using 
tosyl chloride delivered tosyl oxime 2-13 in 83% yield over 2 steps. The tosylated oxime 2-13 
was then treated with liq NH3
98a
 in a closed flask to furnish a 93% yield of diaziridine 2-14. In 
presence of freshly prepared Ag2O, diaziridine 2-14 was readily converted to the required 
diazirine 2-15 in excellent yield.
98c
 In the final step, the methyl group of toluene derivative 2-15 
was oxidized using KMnO4 in aq pyridine at room temperature to provide target acid 2-16
98a
 in 
56% yield ready for coupling with the TEG derived linker (Scheme 37). 
 
Scheme 37. Synthesis of carboxyl derived phenyl diazirine 2-16. 
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Thereafter, phenyl diazirine 2-16 and amine 2-8 were coupled together using PyBrOP which 
yielded amide 2-17. Deprotection of t-butyl ester using a mixture (1:3) of TFA in CH2Cl2 
provided photo labeled cross linker 2-18 (Scheme 38) ready for immobilization on affinity 
beads. As a precaution, diazirine containing compounds were protected from light. 
 
Scheme 38. Synthesis of linker 2-18 from diazirine 2-16 and TEG derived amine 2-8. 
 
8.1.3   Preparation of small molecule immobilized affinity beads 
To obtain the affinity beads with a photo label at the terminus, we immobilized the diazirine 
coupled linker system 2-18 on amino functionalized Toyopearl AF 650 Amino beads (Tosoh 
Bioscience) using the standard protocol recommended for the immobilization of ligand or linker 
systems on these beads. According to the standard protocol, in the immobilization process for 1 
mL of a 10% aq ethanol suspension of Toyopearl affinity beads, 330 mol of linker (or ligand) 
and 233 L of DIC were used. Here, we preferred DMF as a solvent rather than DMSO to avoid 
possible oxidation
99
 of secondary hydroxyl groups present on Toyopearl beads. Carboxyl 
functionalized photo cross linker 2-18 and amino functionalized beads were gently shaken in 
absence of light at room temperature using DIC as a coupling agent for 72 h at room 
temperature. Then, the remaining free amino groups still present on the resulting beads 2-19 
were blocked with 10% aq AcOH by gentle shaking on shaker instrument in presence of the 
condensing agent for 4 h (Scheme 39). After washing with appropriate solvents like 50% aq 
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dioxane, washing buffers (pH ~4 and pH ~8), dd H2O and 20% aq ethanol, the resulting dry 
beads 2-19 were stored at 2–3 °C as suspensions in 20% aq ethanol and the total volume of the 
bead suspensions were recorded to consider its molar concentration. According to the 
concentration of these bead suspensions in 20% ethanolic solution, in the subsequent 
immobilization process for 1 equiv of photo labeled beads 2-19 from the suspensions, about 1 
equiv of small molecule were used for UV irradiation. The whole process was carried out 
carefully to maintain the concentration of used beads. After UV irradiation of the mixture, we 
estimated that at least 10% loading of small molecule on the beads was achieved. 
 
Scheme 39. Immobilization of the linker 2-18 on Toyopearl affinity beads and photo cross 
linking of the small molecules. 
In a proof of concept study we decided to apply this target fishing approach to a small molecule 
with a known target. Thus, cyclosporin A (2-2) appeared as the best example in our eye to find 
its known cellular target cyclophilin.
100
 Also, Osada and coworkers had used successfully the 
same example to prove their approach on Affigel loaded beads. To carry out this model 
experiment, cyclosporin A (2-2) immobilized on photoaffinity labeled Toyopearl beads was 
prepared. For this, an ethanolic solution of cyclosporin A 2-2 (~ 1 equiv) was added to the dry 
beads. Then the suspension was concentrated and dried under vacuum. These dry beads were 
then irradiated under a UV lamp (365 nm, 4 J cm
−2
, 4 watts) for 2 h, washed with ethanol, water 
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and 50% aq ethanol in a sintered glass funnel. The resulting dry beads were diluted with 20% aq 
ethanol (200 L) and handed over to the project colleague (Yvonne Etzel) responsible for 
performing the pull down experiments. As outcome of the target fishing approach using lung 
cells and further mass spectrometry analysis, cyclophilin was identified in abundance as a target 
protein with the mass of 18 kDa. For this fishing experiment lung cells (A549 cells) were used. 
In the SDS-PAGE a strong and distinct band with a molecular weight of 18 kDa could be seen 
(Figure 21). This band was further analyzed by mass spectrometry and Mascot analysis, which 
proved it to be cyclophilin. 
 
Figure 21. Detection of the binding proteins for cyclosporin A 2-2 immobilized beads. Lane 1: 
A549 cell lysate; Lane 2: A549 cell lysate with cyclosporin immobilized beads; Lane 3: cell 
lysate with atorvastatin 1-31 immobilized beads; Lane 4: 2-19 as control beads with cell lysate; 
Lane 5: cell lysate with englerin A 2-3 immobilized beads. 
Inspired by the results of model experiment, we prepared three different sets of photoaffinity 
linker immobilized beads and irradiated them in presence of atorvastatin lactone (1-31), 
cyclosporin A (2-2) and englerin A (2-3) respectively as mentioned above. After washing with 
the solvents, the resulting bead samples and an additional sample of photoaffinity linker 
immobilized beads without irradiation as a control were provided to the colleague (Yvonne 
Etzel) to validate the binding ability of these small molecules. The results of the SDS-PAGE 
analysis showed again a band for the cyclosporin A binding protein (cyclophilin). But in case of 
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atorvastatin lactone (1-31) and englerin A (2-3) the resulting gel pattern was looking similar like 
the lane from the control beads. The exact reason here could be substantial non-specific binding 
of proteins and low abundance of target proteins. To find out the specifically or non-specifically 
bound protein targets of these molecules stable isotope labeling by amino acids, 
SILAC101appeared as the ideal better option. In this situation, we decided to carry out SILAC 
experiments to encounter the specifically bound proteins. For this, to perform SILAC experiment 
with solubility control as well as bead control might provide comparative information about 
binding proteins.
102
 Since we were also interested in finding the putative targets of englerin A 
which shows selectivity towards renal cell lines, the HEK239T cells were chosen for the pull 
down experiments with the three samples. Consequently, we provided samples of small 
molecules (englerin A and atorvastatin lactone) immobilized bead samples as well as affinity 
labeled bead sample for bead control experiment together with solutions of the small molecules 
(1.53 mM solution of atorvastatin lactone and 1.14 mM of englerin A in 50 L each of EtOH) 
for the solubility control experiments. 
 
8.2   Stable isotope labeling by amino acids, SILAC 
SILAC is a metabolic labeling technique for mass spectrometry (MS) based quantitative 
proteomics. In this technique, cells are cultivated in cell culture. One group of cells is fed with 
growth medium containing normal particular amino acids (light) while another set is fed with 
growth medium containing non-radioactive stable isotopes (heavy) of amino acids (generally 
leucine, or lysine or arginine). Consequently, heavy and light amino acids are incorporated into 
all proteins after several rounds of cell divisions. There is a hardly difference between heavy and 
light cells after incorporation, except the difference in mass of comparable proteins. 
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Figure 22. Schematic work flow of the SILAC technique.103 
In the target fishing approach the heavy and light cells are individually lysed. One population of 
the cell lysate serves as the control and is either treated with control beads or with loaded beads 
in presence of small molecule competitor. Here one has to take care that the lysed cells are 
treated similarly in order to avoid errors. After the pull downs the cell extracts were combined 
heavy/light or heavy/medium respectively and subjected to the SILAC analysis. Typically SDS-
PAGE gels are cut into 10 pieces, extracted and each of these portions is analyzed by LC coupled 
to an orbitrap mass detector. High ratios (high log2 values) indicate potential hits. Pairs of 
chemically identical peptides of different stable-isotope composition can be differentiated and 
assigned in a mass spectrometer owing to their mass difference. The ratio of peak intensities in 
the mass spectrum for such peptide pairs reflects the abundance ratio for the two proteins. 
Potential hits are those proteins where the peptide pairs have high log2 values in the intensity 
ratios, of course later then needs to be confirmed by separate biological experiments. 
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8.3   Outcome of SILAC experiment 
In the SILAC experiments, for SDS-PAGE analysis 50 L each of dry, loaded beads and control 
beads each with 2 mg of labeled HEK239T cells or lysate respectively were used. The cells were 
fed with heavy, medium and light labeled lysine and arginine using to the standard protocol 
which was performed by project colleague (Yvonne Etzel). The labeling of the amino acids 
lysine and arginine in cell lysate was as shown in Table 1. The loaded beads (small molecule 
immobilized) are mixed with heavy (H) labeled cells. The loaded beads and the small molecule 
solution (as soluble competitor) were mixed with medium (M) labeled cells and the unloaded 
beads (2-19) were mixed with light (L) labeled cells. 
Table 1. Distribution of labeled amino acids in cell lysates. 
Labels Lysine Arginine 
Light Lys 0 Arg 0 
Medium Lys 4 Arg 6 
Heavy Lys 8 Arg 10 
 
Here for example, in medium (M) label Lys 4 refers to Lysine with 
2
H4 labeling and Arg 6 
means 
13
C6-arginine. The heavy (H) label contains 
15
N2 
13
C6 labeled lysine and 
15
N4 
13
C6-
arginine as supplement. Light (L) label contains Lys 0 and Arg 0 without labeled atoms. After 
the pull downs which were performed by Yvonne Etzel, the further steps (digestion with trypsin) 
and quantification by LC-HRMS were done in the Proteome Zentrum, Tübingen headed by Prof. 
Dr. Boris Macek. The results from the analysis were presented to us as an excel table containing 
various columns including protein ID numbers, Gene names and in particular the H/L and H/M 
ratios for each protein as determined from their respective fragments. The ratios are listed in 
unnormalized ratios and normalized form. For generation of graphs in Figure 23 we used the 
unnormalized ratios. 
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In graph A and C the H/M ratios were converted to their log2 values and then sorted in 
descending order. The protein index is just an integer number with the lowest index being the 
highest ratio. Our coworkers recommended two ways of identifying interacting hits. In method 
one, a ruler is aligned to the almost linear line in the middle section. Proteins with the ratio above  
this line are likely binding to the immobilized small molecule. The right panel reflects procedure 
two. In principle the bead control experiment (H/L) and the soluble competitor experiment 
(H/M) should identify similar proteins. Thus, the cross-sectional graph would show interacting 
proteins if they have high ratios in both experiments. The loaded beads were mixed with heavy 
(H) labeled cells. The loaded beads containing small molecule and the small molecule solution 
(soluble competitor) were mixed with medium (M) labeled cells and the unloaded beads (2-19) 
were treated with light (L) labeled cells.  
 
 
Figure 23. a) Plots of log2 SILAC ratios against proteins sorted by their ratios in descending 
order (A and C); b) logarithmic cross-sectional graphs of H/M ratio against H/L ratio (B and D). 
According to the graphs A and C (Figure 23), proteins having higher log2 numbers can be 
possible target proteins while cross-sectional graphs B and D of H/M ratio against H/L ratio 
A 
C D 
B 
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provides distribution of bound proteins. The proteins from the (upper right) of graphs B and D 
(Figure 23) could be possible binding targets of atorvastatin lactone and englerin A. The 
proteins from graphs B and D are shortlisted in the following Table 2 (for atorvastatin lactone) 
and Table 3 (for englerin A) as probable binding targets of these molecules. 
For atorvastatin lactone, top ten possible binding targets are listed while for englerin A top 
fourteen binding targets are listed. Certainly some of the possible listed candidates will be non-
specific binding partners. There are some candidates in both lists which are common. If we 
cancel these commonly found protein candidates from both experiments then from Table 2, 
acylglycerol kinase (AGK) is the only candidate that remains for atorvastatin lactone. For 
englerin A, RNA-binding protein 39 (RBM39), DnaJ homolog subfamily C member 9 (DNAJC9), 
Coiled-coil-helix-coiled-coil-helix domain-containing protein 3 (CHCHD3), Complement 
component 1 Q subcomponent-binding protein (C1QBP), ATP synthase subunit gamma 
(ATP5C1) and Stomatin-like protein 2 (STOML2) are the remaining candidates for further 
validation. There is some literature available for non-specific binding partners of the sepharose 
beads where some candidates like prohibitin, voltage dependent anion channel-2 and 3, 
transitional endoplasmic reticulum ATPase are reported as non-specific binders.
104
 Therefore, it 
is not clear to us weather these proteins bind similarly with Toyopearl beads. 
It is reported that acylglycerol kinase may regulate lysophosphatidic acid (LPA) induced pro- 
and anti inflammatory signals which regulate innate immunity in the airway epithelium.
105
 This 
could be a hot binding target for atorvastatin lactone. The analysis for englerin A points to a 
mode of action which interferes with electron transport. Thus, ATP synthase subunit gamma 
which provides energy to a cell could be one of the possible targets for englerin A. Also, among 
all possible targets listed in Table 3 for englerin A, prohibitin is a known tumor suppressor 
protein which could be a major binding target. It is known to interact with histone deacetylase 1 
(HDAC1),
106
 Ratinoblastoma protein,
107
 Ratinoblastoma like protein-1 and 2,
107
 Akt (protein 
kinase B).
108
 But in this case we are not sure if prohibitin binds specifically or non-specifically. 
Therefore, further analysis would now be required to validate these findings. In any way one can 
say that this strategy appears promising in narrowing down potential protein targets of small 
molecules. 
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Table 2. List of top 10 possible binding targets of atorvastatin lactone from SILAC experiment.a 
ID Protein Names 
Gene 
Names 
Uniprot ID 
Ratio H/M 
R04_ATV 
365 Prohibitin-2 PHB2 Q99623, Q9BXV3 12.623 
417 
Voltage-dependent anion-selective 
channel protein 3 
VDAC3 Q9Y277-2, Q9Y277 10.79 
323 
Voltage-dependent anion-selective 
channel protein 2 
VDAC2 P45880-1, P45880 8.1318 
307 
Transitional endoplasmic reticulum 
ATPase 
VCP P55072, Q0IIN5 7.2552 
151 Sideroflexin-1 SFXN1 Q9H9B4, D6RFI0 5.3494 
253 Prohibitin PHB P35232, A8K401 4.2044 
556 
Voltage-dependent anion-selective 
channel protein 1 
VDAC1 P21796, B3KTS5 3.9563 
470 Rab-like protein 3 RABL3 Q5HYI8, C9JXM3 2.067 
385 KIAA1715 protein KIAA1715 B7ZLA8, B7Z829 1.8009 
269 Acylglycerol kinase AGK Q53H12-1, Q53H12 1.4674 
 
 
 
 
 
                                                   
a
 Only two Uniprot IDs are listed. 
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Table 3. List of top 15 possible binding targets of englerin A from SILAC experiment. 
ID Protein Names 
Gene 
Names 
Uniprot ID 
Ratio H/M 
R05_Eng A 
365 Prohibitin-2 PHB2 Q99623, Q9BXV3 134.6 
253 Prohibitin PHB P35232, A8K401 41.52 
417 
Voltage-dependent anion-selective channel 
protein 3 
VDAC3 Q9Y277, Q9Y277-2 40.616 
556 
Voltage-dependent anion-selective channel 
protein 1 
VDAC1 P21796, B3KTS5 37.787 
323 
Voltage-dependent anion-selective channel 
protein 2 
VDAC2 P45880-1, P45880 31.453 
492 RNA-binding protein 39 RBM39 Q14498-1, Q14498 19.222 
470 Rab-like protein 3 RABL3 Q5HYI8, C9JXM3 12.854 
307 Transitional endoplasmic reticulum ATPase VCP P55072,Q0IIN5 6.8867 
385 KIAA1715 protein KIAA1715 B7ZLA8, B7Z829 4.9266 
488 DnaJ homolog subfamily C member 9 DNAJC9 Q8WXX5, B2RMW6 3.0186 
234 
Coiled-coil-helix-coiled-coil-helix domain-
containing protein 3 
CHCHD3 C9JRZ6, Q9NX63 1.6941 
151 Sideroflexin-1 SFXN1 Q9H9B4, D6RFI0 1.552 
226 
Complement component 1 Q subcomponent-
binding protein 
C1QBP Q07021, A8K651 1.4169 
765 ATP synthase subunit gamma ATP5C1 P36542-1, P36542 1.3018 
739 Stomatin-like protein 2 STOML2 Q9UJZ1, B4E1K7 1.2746 
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As a summary, we used the Osada method of photo-immobilization of small molecules on the 
surface of photo labeled affinity beads and SILAC based proteomics for the identification of 
biological targets. These strategies as a combined approach could be quite useful to identify the 
target proteins out of the non-specific binding proteins. For this we prepared a diazirine coupled 
suitable linker system containing a carboxyl group at the terminus (2-18) which is suitable to 
immobilize it on the Toyopearl affinity beads (Scheme 40). The small molecule immobilized 
affinity beads were prepared according to the Osada protocol. 
 
Scheme 40. Preparation of small molecule immobilized affinity beads using UV irradiation. 
We successfully proved this as a combined approach by the fishing of cyclophilin (18 kDa) as a 
binding target of cyclosporin A from A549 cell lysate. With the same approach we were able to 
fish some possible binding targets of atorvastatin lactone (Off-targets) and englerin A as shown 
in Table 2 and 3. In general we could say that this combined approach can be quite useful for the 
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fishing of biological targets of small molecules without any structural modification prior to the 
pull down experiments. In particular this strategy appears advantageous for protein targets of low 
abundance and small affinity. 
 
  
 
 
 
 
 
 
 
 
Chapter III  
Synthesis of the C1-C13 Fragment of Biselyngbyaside 
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10   Introduction 
Natural products, especially those from terrestrial plants and microbes, have long been a 
traditional source of drug molecules. Indeed, pharmacologically active compounds from plants 
and microbes represent an important pipeline for new investigational drugs.
109
 Around half of the 
pharmaceutical drugs currently available in the market are of natural product origin.
110
 Marine 
organisms are relatively new sources of medicines for the treatment of human disorders in 
comparison with the terrestrial organisms. About 70% of the area of earth is covered by wide 
spread ocean. Over the last few decades, marine sources have attracted much attention of 
biologists and chemists in the world due to their diverse biologically potent activity and ability of 
treating human diseases like malaria, cancer, AIDS, etc.
111
  
The collection and extraction of marine species like sponges, fish, coral, bryozoans, tunicates, 
algae and other microorganisms has led to a wealth of novel bioactive drugs with anti-
inflammatory, antiviral, antitumor activity and many more.
112
 Basic scientific research in the 
field of chemistry and pharmacology of marine natural products and its directed efforts in the 
drug development delivered a fruit for marine based drug discovery. Ziconotide (3-1), a synthetic 
form of -conotoxin MVIIA113 (isolated from the marine cone snails) became a first marine 
derived natural product approved as a medicine for the treatment of chronic pain.
114
 Several 
other structurally unique isolated secondary metabolites from marine organisms and their 
structurally derived analogues have reached preclinical and phase I–III clinical trials.115 
Discodermolide (3-2),
116
 E-7369 (3-3, halichondrin analogue),
117
 halichondrin B (3-4),
118
 
bryostatin 1 (3-5),
119
 kahalalide F (3-6)
120
 and dolastatin 10 (3-8)
121
 (Figure 24 and Figure 25) 
are a few examples being tested as such or their synthetic analogues in different phases of 
clinical trials.
122
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Figure 24. Examples of marine metabolites in clinical different clinical trials. 
Among all marine sources, cyanobacterium (blue green algae) is one of the widespread marine 
species having the ability of producing biologically active chemicals as their secondary 
metabolites which show powerful anti-tubulin and anti-actin properties.
123
 Cyanobacteria is a 
phylum of bacteria which live in water and can manufacture their own food through 
photosynthesis. It is one of the richest sources of leading therapeutic agents and their synthetic 
analogues for the treatment of cancer. Curacin A (3-7),
124
 dolastatin 10 (3-8),
121
 symplostatin 1 
(3-9),
125
 dolastatin 15 (3-10)
126
 and apratoxin A (3-11)
127
 are few examples (Figure 25) of the 
antitumor substances isolated from different marine cyanobacteria.
128
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Figure 25. Antitumor substances isolated from marine cyanobacteria. 
Today, cancer accounts for one in every eight deaths worldwide; more than HIV/AIDS, 
tuberculosis, and malaria combined. According to an estimate of the American Cancer Society 
(2008), out of 12.7 million cases of cancer diagnosed, 7.6 million people died due to cancer 
around the world.
129
 Despite of the availability of several anticancer drugs in the market, there is 
an urgent need of new potent anticancer drugs. It is observed that tumor cells are developing 
resistance against presently available drugs like vinca alkaloids and taxanes etc. which is 
becoming a major cause of failure in the chemotherapeutic treatment of cancer.
130
 As a result, 
treatment of cancer still remains as a challenge for worldwide researchers to find a better 
solution. 
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Figure 26. Marine cyanobacterium Lyngbya sp. and structure of biselyngbyaside. 
In this context, biselyngbyaside is a new promising macrolide isolated from the marine 
cyanobacterium Lyngbya sp. (Figure 26) at Okinawa prefecture.131 Biselyngbyaside 3-12 was 
isolated from the polar methanol extract. The polarity of the compound is likely due to the sugar 
moiety attached to the molecule which itself is somewhat unusual because it contains methoxy 
group at 3-position. Preliminary assays of biselyngbyaside 3-12 displayed cytotoxicity against 
HeLa cell lines with an IC50 value of 0.1 g mL
−1
. In addition, average growth inhibition (GI) 
value across 39 human cancer cell lines was 0.6 M and with differential cytotoxicities. The 
central nervous system cancer SNB-78 (GI50 0.036 μM) and lung cancer NCI H522 (GI50 0.067 
μM) cell line were especially sensitive.132 Negative results of COMPARE analysis133 of 
biselyngbyaside indicated that it likely inhibits cancer cell proliferation through a novel 
mechanism.
134
  
Recently Woo et al. reported that biselyngbyaside 3-12 inhibits receptor activator nuclear factor 
B ligand (RANKL) induced osteoclastogenesis in mouse monocytic RAW264 cells and 
primary bone marrow-derived macrophages at a low concentration.
135
 Bone remodeling occurs 
continuously to maintain the bone mass during life, and is comprised of opposing processes 
involving bone resorption by osteoclasts and bone formation by osteoblasts. Osteoclasts are 
differentiated from hematopoietic cells of the monocyte/macrophage lineage, and the bone lytic 
function of osteoclasts is involved in many bone-destructive diseases, such as osteoporosis, 
hypercalcemia, rheumatoid arthritis, bone tumor metastasis, periodontitis and Paget’s disease.135 
Therefore, suppression of osteoclastogenesis with drug is a major therapeutic target for these 
diseases. Biselyngbyaside 3-12 suppresses bone resorption via inhibition of osteoclastogenesis 
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and induction of apoptosis. Thus, biselyngbyaside 3-12 may also be useful for the prevention of 
bone lytic diseases.
135
 Quite recently a related molecule called biselyngbyolide was described in 
the literature.
136
 It is devoid of the sugar part and instead of the C4-C5 double bond there is a 
hydroxyl function at C5. 
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Biselyngbyaside 3-12 is a 18 membered macrolactone consisting of six carbon-carbon 
double bonds and four asymmetric centers and a 3’-methoxyglucose moiety at C3-position. From 
a structural point of view, the presence of one isolated double bond, one conjugated double bond 
and four allylic alcohols make this macrolide very challenging for a chemical synthesis. 
 
Figure 27. Retrosynthetic analysis of biselyngbyaside (3-12). 
An initial option would be the formation of the macrolactone ring at C4 and C5 carbons via ring 
closing metathesis before glycoside bond construction. But the presence of many double bonds 
in the molecule could make this strategy impractical. In that case, the most favorable option for 
ring closing appears to be macrolactonization via classical reactions like Yamaguchi 
esterification
137
 or Mitsonobu esterification
138
 from seco acid 3-13 (Figure 27) as an advanced 
precursor. Disconnection at the C13-C14 bond would suggest formation of fragment 3-15 and 
vinyl stannane 3-14. In this case, side chain C18-C23 will be established after macrolactone 
formation. 
Synthesis of fragment 3-15 (Figure 28) bearing three asymmetric centers should be possible by 
cross metathesis reaction between homoallyl fragment 3-16 and allyl alcohol 3-17. 
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Figure 28. Retrosynthetic analysis for seco acid 3-15. 
Further retrosynthetic simplification suggest that the C5-C13 fragment 3-16 (Figure 29) can be 
synthesized using a Wittig reaction of aldehyde 3-19 providing advanced aldehyde 3-18, which 
could be modified to fragment 3-16 using hydrozirconation/iodination and asymmetric allylation 
as intermediate steps in the synthetic pathway. Aldehyde 3-19 could possibly be synthesized by 
stereocontrolled alkylation of a chiral propionate derivative. 
 
Figure 29. Retrosynthetic consideration for fragment 3-16. 
The C1-C4 fragment 3-17 can be synthesized from its racemic precursor 3-20 by enzymatic 
kinetic resolution. In this case racemic 3-20 can be prepared from commercially available 
acrolein 3-21 and tert-butyl acetate (Figure 30). 
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Figure 30. Retrosynthetic analysis of fragment 3-17. 
 
Results and Discussion  83 
 
12   Results and Discussion 
12.1   Synthesis of fragment C1-C13 
12.1.1   Synthesis of fragment C1-C4 by enzymatic resolution 
As discussed in the retrosynthetic section, preparation of fragment 3-17 could be possible by 
enzyme catalyzed kinetic resolution of racemic tert-butyl 3-hydroxypent-4-enoate 3-20. Initially 
(rac)-3-20 was prepared according to the literature procedure from commercially available 
acrolein and tert-butyl acetate in presence of LDA.139 Alcohol (rac)-3-20 was subjected to 
resolution using Amano PS lipase enzyme (Sigma-Aldrich Co.), vinyl acetate, and powdered 4 Å 
molecular sieves in dry pentane at 30 °C for 16 h.
140
 The progress of reaction was followed by 
1
H NMR. After about 16 h, a 50% conversion could be observed. The mixture was separated by 
flash chromatography to (S)-acetate 3-22 and alcohol (R)-3-20 (Scheme 41). 
 
Scheme 41. Enzymatic kinetic resolution of (rac)-3-20 by Amano PS lipase enzyme. 
Thereafter, (S)-acetate 3-22 was treated with anhydrous K2CO3 in methanol at −10 °C under 
controlled condition (TLC) to avoid hydrolysis of the ester function yielding (S)-3-20 in 82% 
yield. Enantiomeric excess (ee) of resulting allyl alcohol (S)-3-20 was determined by chiral gas 
chromatography which was found to be 98.5% as shown in Figure 31. 
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Figure 31. Chiral GC analysis of (S)-3-23; conditions: (column: 6-tert-butyl-2,3-di-O-ethyl--
cyclodextrin, mobile phase: H2, detection: FID, temperature: 70 °C, pressure: 75 kPa. 
Thereafter, alcohol 3-20 was protected as silyl ether 3-23 using t-butyldimethylsilyl chloride and 
the carboxylic group was reduced to alcohol 3-24 using DIBAL-H (1M in hexane) in CH2Cl2 at 
−78 °C. Protection of the primary alcohol 3-24 was performed at room temperature using 
pivaloyl chloride in presence of Et3N to provide fragment 3-25 quantitatively (Scheme 42). 
 
Scheme 42. Synthesis of advanced fragment 3-25. 
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12.1.2   Synthesis of fragment C5-C13 
In fragment 3-15 besides C3, there are two more stereocenters at C7 and C10. Those could be 
introduced accordingly at C7 by asymmetric Brown allylation and at C10 by stereocontrolled 
alkylation of propionyl chloride derivative 3-27 derived from the Seebach auxiliary 3-26.
141
 
 
Scheme 43. Stereocontrolled propargylation of Seebach auxiliary 3-27 to 3-28. 
Therefore, chiral oxazolidinone 3-26 on treatment with n-BuLi (2.5M in hexane) followed by 
addition of freshly distilled propionyl chloride at 0 °C delivered propionyl oxazolidinone 3-27
142
 
(Scheme 43) quantitatively. Asymmetric alkylation
143
 of 3-27 using NaHMDS (2.0M in THF) 
and propargyl bromide within the temperature range of −78 °C to −15 °C over 20 h permitted 
propargyl analogue 3-28 in 95% yield. The diastereoselectivity of 3-28 was found to be 23:1, 
from 
1
H NMR spectrum as shown in Figure 32. 
 
Figure 32. Diastereoselectivity ratio determination of 3-28 from 
1
H NMR spectra. 
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Reductive cleavage of the auxiliary from 3-28 by NaBH4 in a mixture (4:1) of THF and water led 
to alcohol 3-29
144
 as volatile liquid and roughly 70% of the auxiliary. Here, loss of 3-29 was 
observed under high vacuum because of its low molecular weight. Therefore, alcohol 3-29 was 
isolated from the solution under vacuum not less than 300 mbar. 
To reduce the volatile nature of alcohol 3-29 and further analogues, the acetylene proton was 
protected using TMSCl and n-BuLi (2.5M in hexane) to yield TMS acetylene 3-30145 which was 
further converted to the aldehyde 3-31 by using Swern oxidation
72
 in very good yield. Aldehyde 
3-31 was extended to enoate 3-33 by Wittig reaction with stabilized ylide 3-32 in toluene at 80 
°C with high E-selectivity. Here, the stabilized ylide 3-32 (Scheme 44) for the Wittig extension 
was prepared according to the literature procedure
146
 by heating PPh3 and ethyl-2-
bromopropionate without solvent followed by proton abstraction with the use of aqueous 
solution of NaOH (only 1 equiv) to avoid possible racemization in the Wittig reaction. Keeping 
this in mind, we tested the enantioselectivity of enoate 3-33 after Wittig reaction to check 
sensitivity of the chiral center substituent towards racemization. 
 
Scheme 44. Synthesis of fragment 3-33 by Wittig reaction using stabilized ylide 3-32. 
Racemic adduct (rac)-3-33 was easily prepared in a 5 step sequence (see Scheme 45) from tert-
butyl propionate 3-34 by propargylation to have ester 3-35 which was then reduced to 
corresponding alcohol using DIBAL-H (1M in THF) and acetylene group was subsequently 
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protected by TMS chloride yielding (rac)-3-30. Swern oxidation of (rac)-3-30 provided aldehyde 
(rac)-3-31 in quantitative yield which on Wittig extension using stabilized ylide 3-32 furnished 
enoate (rac)-3-33. 
 
Scheme 45. Synthesis of rac-3-34 for enantiomeric excess determination. 
Optical purity of (ent)-3-33 by chiral gas chromatography analysis was found to be 89.8% as 
shown in Figure 33. 
 
Figure 33. Chiral GC of Wittig product 3-33; major isomer. tR = 52.67, minor isomer tR = 54.75; 
resolution was done using chiral column: AKS50 6-tert-butyl-2,3-di-O-ethyl--cyclodextrin, 
mobile phase: H2, detection: FID, temperature: 100 isotherm, pressure: 75 kPa. 
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In the next step, enone 3-33 was reduced to corresponding alcohol using DIBAL-H (1.0M in 
hexane) followed by removal of the TMS group using K2CO3 in methanol at room temperature 
which provided modified alcohol 3-36. The subsequent hydrozirconation
147,148
 of alcohol 3-36 
was done on the di-isobutylalkoxy derivative of alcohol 3-36, it was generated by combination of 
3-36 and DIBAL-H (1.0 equiv) at 0 °C. This solution was then added to the suspension of in situ 
generated Cp2ZrHCl (Schwartz’s reagent)
149
 from Cp2ZrCl2 and DIBAL-H (1.0M in hexane). 
The resulting vinyl metal species was quenched by addition of molecular iodine as a THF 
solution at low temperature (−78 °C) to yield vinyl iodide 3-37 in 79% yield (Scheme 46). At 
this stage, the hydroxyl group of 3-37 was oxidized to aldehyde 3-38 using Dess-Martin 
periodinane. This aldehyde was then subjected to the Brown allylation reaction.
150
 (+)-Ipc2Ballyl 
was generated in situ by treatment of (−)-Ipc2BOMe with allyl magnesium bromide at −78 °C 
followed by dropwise addition of aldehyde 3-38 in THF into the boron complex solution at −90 
°C. The resulting complex was quenched with H2O2/NaOH providing homoallyl alcohol 3-39 as 
a mixture of distereoisomers in 66% yield. Extending the synthesis, secondary alcohol function 
of 3-39 was methylated using Meerwein’s reagent (Me3OBF4)
151,152,153
 and proton sponge to 
have building block 3-16 ready for cross metathesis reaction (Scheme 46). 
 
Scheme 46. Synthesis of fragment 3-16 from Wittig product 3-33. 
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The diastereomeric ratio of homoallyl alcohol 3-39 was found to be 18:1, determined from the 
1
H NMR spectrum considering integration of the 7-CH3 group (Figure 34). This result indicated 
independently that the racemization of an aldehyde 3-31 during the Wittig reaction to yield 3-33 
was minimal. 
 
Figure 34. Determination of diastereoisomeric ratio of alcohol 3-39 after Brown allylation from 
1
H NMR spectra. 
 
12.1.3   Mechanistic pathway of Brown allylation 
According to the well accepted model, the Brown allylation proceeds through a six membered 
chair like transition state (Figure 35). The large substituent R of the aldehyde occupies an 
equatorial position and the aldehyde facial selectivity derives from minimization of steric 
interactions between the Ipc ligand and the approaching aldehyde.
154
 Boron as Lewis acid helps 
to activate the aldehyde and coordinates to the oxygen atom in the transition state. 
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Figure 35. Mechanistic pathway for Brown allylation via six membered transition state. 
 
12.2   Cross metathesis approach for the synthesis of fragment C1-C13 
Recently, Oishi et al. demonstrated that a highly chemoselective cross metathesis reaction
81
 
between allyl alcohols can be successfully achieved in presence of an iodo-olefin.
155
 They found 
that the vinyl iodide remains intact in the course of the cross metathesis reaction. Taking an 
advantage of this strategy, protected allyl alcohol 3-23 and homoallyl alcohol 3-16 were 
subjected to the cross metathesis reaction in dry and degassed CH2Cl2 as well as toluene 
simultaneously under various conditions (Scheme 47) but none of the Grubb’s 2nd 3-43,156 
Hoveyda-Grubb’s 2nd 3-44,157 or Grela catalyst 3-45158 offered the successful transformation. 
This was in agreement with the result reported by Yamamoto et al. during their stereocontrolled 
synthesis of the AB ring segment of ciguatoxin.
159
 In this regard, they had better success after the 
deprotection of the homoallylic alcohol. In addition to this report, some other successful 
examples of cross metathesis between unprotected allyl alcohols and its metathesis partners have 
been reported.
160
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Scheme 47. Attempts made for cross metathesis reaction. 
Accordingly, we altered silyl ether 3-25 to the free hydroxyl analogue 3-46 using p-TSA•H2O in 
methanol in 94% yield. Modified analogue 3-46 and fragment 3-16 were then subjected to the 
cross metathesis reaction with Grubb’s 2nd catalyst in CH2Cl2 at room temperature but no 
progress in the reaction was observed while after refluxing the reaction mixture for longer period 
(~ 24 h), only slow conversion was experienced. After changing the solvent to toluene and upon 
heating (80 °C), TLC showed conversion to a new spot and LC-MS confirmed the desired cross 
metathesis product 3-47. After 24 h, nearly complete consumption of 3-16 was observed on TLC 
without formation of notable side products. Purification by flash chromatography provided 
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metathesis product 3-47 (Scheme 48) in 44% yield as colorless oil. After this successful reaction 
between free allyl alcohol 3-16 and homoallyl alcohol 3-46, we attempted cross metathesis 
between free hydroxyl ester 3-20 with homoallyl alcohol 3-16 in presence of Grubb’s 2nd catalyst 
but surprisingly the allylic alcohol 3-20 did not engage in the cross metathesis reaction with 3-16 
(Scheme 47). Only the cross metathesis reaction between 3-16 and pivaloyl analogue 3-46 
worked best in this case. 
 
Scheme 48. Synthesis of a fragment 3-47 by cross metathesis reaction. 
The exact mass of the building block 3-47 was determined by high resolution mass spectroscopy 
(HRMS). The optical rotation of the final building block was measured as []D
22
 = +11.72 in 
CHCl3 (c 1.0). 
1
H NMR, 
13
C NMR, H–H and C–H correlation spectra confirmed the structure of 
the building block 3-47. Figure 36 confirms the formation of the C4-C5 double bond in addition 
to the presence of double bonds at C12-C13 and C8-C9. 
 
Figure 36. Down field region of fragment 3-47 in the 
1
H NMR spectrum. 
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After the successful and efficient synthesis of fragment 3-47, further research towards the total 
synthesis of biselyngbyaside is under progress in our group. 
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In conclusion, we have developed a practical route for the synthesis of fragment 3-47 
towards the total synthesis of the novel macrolide biselyngbyaside. The key features of this 
strategy include synthesis of fragment 3-46 (Scheme 49) via a very efficient and highly 
enantioselective enzyme catalyzed resolution in overall 26% yield over 6 steps starting from 
racemic alcohol (rac)-3-20. 
 
Scheme 49. Summary of the synthesis of fragment 3-46. 
Fragment 3-32 was synthesized from N-propionyl derivative of Seebach auxiliary 3-26 including 
a stereoselective propargylation, reductive cleavage to the corresponding alcohol and Swern 
oxidation as key intermediate steps. Further chain extension was achieved by Wittig reaction 
using a stabilized Wittig ylide followed by DIBAL-H mediated reduction of corresponding ethyl 
ester. Hydrozirconation of the triple bond using in situ generated Schwartz reagent followed by 
iodination provided alcohol 3-37 as advanced precursor. Further, Dess-Martin oxidation, 
allylation using Brown conditions, and afterward methylation by Me3OBF4 and proton sponge of 
this hydroxyl group produced intermediate 3-16 as a precursor for cross metathesis reaction. 
After the crucial cross metathesis reaction, the longest chain yielded fragment 3-47 in around 8% 
overall yield (Scheme 50). 
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Scheme 50. Summary of the synthesis of final fragment 3-47. 
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14   Experimental Section 
14.1   General Remarks 
14.1.1   Chemicals and working techniques 
The chemicals were purchased from the firms Acros, Aldrich, Applichem, Fluka, Lancaster, 
Merck, STREM and TCI. All reagents were obtained from commercial suppliers, and were used 
without further purification unless otherwise stated. All solvents were distilled and/or dried prior 
to use by standard methodology except for those, which were reagent grade. The applied 
petroleum ether fraction had a boiling point of 40–60 °C. Anhydrous solvents were obtained as 
follows: THF, diethyl ether and toluene by distillation from sodium and benzophenone;  
dichloromethane and chloroform by distillation from calcium hydride; acetone by distillation 
from phosphorous pentoxide. Absolute triethylamine and pyridine and diisopropylethylamine 
were distilled over calcium hydride prior to use. Unless and otherwise mentioned, all the 
reactions were carried out under a nitrogen atmosphere and the reaction flasks were pre-dried 
with a heat gun under high vacuum. All the chemicals, which were air or water sensitive, were 
stored under inert atmosphere. Compounds that are not described in the experimental part were 
synthesized according to the literature. 
 
14.1.2   NMR-spectroscopy 
All the spectra were measured on a Bruker Avance 400 spectrometer, which operates at 400 
MHz for 
1
H and 100 MHz for 
13
C nuclei, respectively. 
1
H (400 MHz) and 
13
C NMR (100 MHz) 
spectra were recorded at 295 K either in CDCl3 or CD3OD; chemical shifts are calibrated to the 
residual proton and carbon resonance of the solvent: CDCl3 (δH = 7.25 ppm, δC = 77.0 ppm), 
CD3OD (δH = 3.30 ppm, δC = 49.0 ppm). Data are reported as follows: chemical shift 
(multiplicity: s = singlet, d = doublet, t = triplet, ap. sept = apperent septet, dd = doublet of 
doublet, ddd = doublet of doublet of doublet, dddd = doublet of doublet of doublet of doublet, m 
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= multiplet, br = broadened, J = coupling constant (Hz), integration, peak assignment in italic 
form). 
 
14.1.3   Mass Spectrometry 
Mass spectra were recorded on a Finnigan Triple-Stage-Quadrupol Spectrometer (TSQ-70) from 
Finnigan-Mat. High-resolution mass spectra were measured on a modified AMD Intectra MAT 
711 A from the same company. The used mass spectrometric ionization methods were electron-
impact (EI), fast-atom bombardment (FAB) or field desorption (FD). HR-FT-ICR mass spectra 
were measured on an APEX 2 spectrometer from Bruker Daltonic with electrospray ionization 
method (ESI). Analytical HPLC-MS: HP 1100 Series connected with an ESI MS detector 
Agilent G1946C, positive mode with fragmentor voltage of 40 eV, column: Nucleosil 100–5, C-
18 HD, 5 mm, 70 × 3 mm Machery Nagel, eluent: NaCl solution (5 mM)/acetonitrile, gradient: 
0/10/15/17/20 min with 20/80/80/99/99% acetonitrile, flow: 0.6 mL min
−1
. High resolution mass 
(HRMS) are reported as follows: (ESI): calcd mass for the related compound followed by found 
mass. 
 
14.1.4   Polarimetry 
Optical rotations were measured on a Perkin-Elmer Polarimeter Model 341. They are reported as 
follows: [α]temperature D (concentration, solvent). The unit of c is g/100 mL. Anhydrous CH2Cl2, 
CHCl3 or MeOH was used as a solvent. For the measurement the sodium D line = 589 nm was 
used. 
 
14.1.5   Melting Points 
Melting points were determined with a Büchi Melting point B-540 apparatus and were not 
corrected. 
Experimental Section  99 
 
14.1.6   Chromatographic Methods 
Flash chromatography was performed using flash silica gel (40-63 μm, 230-400 mesh ASTM) 
from Macherey-Nagel. Gas chromatography was performed on a CHROMPACK CP 9000 using 
a flame ionization detector, and carrier gas H2. Chiral gas chromatographic analyses were carried 
out on 13.5 m × 0.25 mm column filled with deactivated fused silica with 30% 6-TBDMS-2,3-
diacetyl-β-cyclodextrin in PS 086 (df = 0.13 μm) and carrier gas H2 at 50 kPa and 30 °C. For GC-
MS coupled chromatography, a GC-system series 6890 with an injector series 7683 and MS-
detector series 5973 from Hewlett Packard was used, with EI method, and carrier gas He. 
Analytical HPLC was performed on a Hewlett Packard HP 1100 system. Analytical thin layer 
chromatography (TLC) was performed on precoated with silica gel 60 F254 plates (Merck) or 
Polygram Sil G/UV254 (Macherey Nagel). The compounds were visualized by UV254 light and 
the chromatography plates were developed with an aqueous solution of molybdophosphorous 
acid or an aqueous solution of potassium permanganate (heating with the hot gun). For 
preparation of the molybdate solution 20 g ammonium molybdate [(NH4)6Mo7O24·4H2O] and 0.4 
g Ce(SO4)2·4H2O were dissolved in 400 mL of 10% H2SO4. The potassium permanganate 
solution was prepared from 2.5 g KMnO4 and 12.5 g Na2CO3 in 250 mL H2O. 
 
14.2   Experimental Procedures 
All the experimental procedures are arranged to reflect the synthetic sequences shown in the  
Schemes. 
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2-Benzylidene-4-methyl-3-oxo-pentanoic acid methyl ester (1-25)
41
 
 
A solution of 4-methyl-3-oxo-pentanoic acid methyl ester 1-55 (10 g, 9.9 mL, 69.4 mmol), 
benzaldehyde (7.74 mL, 76.3 mmol), piperidine (0.4 mL) and acetic acid (1.2 mL) was refluxed 
in toluene (50 mL) to remove water as azeotrope. After 12 h, the reaction was cooled to room 
temperature, diluted with diethyl ether (150 mL) and washed with 1N HCl (70 mL) followed by 
saturated NaHCO3 solution (70 mL) and saturated NaCl solution. The organic layer was 
separated, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The 
crude concentrate was purified by flash chromatography (EtOAc/petroleum ether, 1:9) to yield 
unsaturated ester 1-25 (13.1 g, 81%) as orange-red oil as mixture of two isomers. Rf = 0.28 
(ethyl acetate/petrol ether, 1:9); 
1
H NMR (400 MHz, CDCl3): major isomer 1.07 (d, 6H, J = 
6.8 Hz, CH(CH3)2), 2.55 (ap. septet, 1H, J = 6.8 Hz, CH(CH3)2), 3.72 (s, 3H, OCH3), 7.31 (m, 
5H, Ar), 7.48 (s, 1H, C=CHPh); minor isomer  = 0.94 (d, 6H, J = 6.8 Hz, CH(CH3)2), 2.55 
(sept, 1H, J = 6.8 Hz, CH(CH3)2), 3.71 (s, 3H, OCH3), 7.29 (m, 5H, Ar), 7.69 (s, 1H, C=CHPh); 
13
C NMR (100 MHz, CDCl3): major isomer = 17.9 (CH(CH3)2), 36.1 (CH(CH3)2), 52.4 
(OCH3), 128.8 (2CH, Ar), 129.7 (2CH, Ar), 130.4 (CH, Ar), 133.1 (C, Ar), 133.3 (C=CHPh), 
141.5 (C=CHPh), 165.3 (C=O, ester), 209.2 (C=O, ketone); minor isomer = 18.9 (CH(CH3)2), 
36.1 (CH(CH3)2), 52.5 (OCH3), 128.8 (2CH, Ar), 129.4 (2CH, Ar), 130.6 (CH, Ar), 133.2 
(C=CHPh), 140.9 (C=CHPh), 168.5 (C=O, ester), 201.0 (C=O, ketone). 
 
1-(4-Fluoro-phenyl)-5-methyl-2-phenyl-hexane-1,4-dione (1-27)
41
 
 
A mixture of 2-benzylidene-4-methyl-3-oxo-pentanoic acid methyl ester 1-25 (13.1 g, 56.4 
mmol), 4-fluorobenzaldehyde (6.35 mL, 59.2 mmol), thiazolium salt 3-benzyl-5-(2-
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hydroxyethyl)-4-methyl-1,3-thiazolium chloride (2.42 g, 15 mol%) as catalyst and Et3N (8 mL) 
was heated at 70 °C for 24 h. The reaction mixture was diluted with diethyl ether (100 mL), 
washed with water (100 mL), 1N HCl solution (75 mL) followed by saturated NaHCO3 (75 mL) 
and saturated NaCl solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was subjected for vigorous stirring in a 
mixture of THF (100 mL) and 3N NaOH (50 mL) solution. After 15 h, the reaction mixture was 
acidified with 2N HCl solution to pH~5, and extracted with diethyl ether (3 × 100 mL). The 
combined organic layers were washed with saturated NaHCO3 solution and saturated NaCl 
solution, dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The crude 
product was purified by flash chromatography (EtOAc/petroleum ether, 1:9) to provide 1,4-
diketone 1-27 (9.82 g, 59%, over 2 steps) as colorless thick oil. Rf = 0.32 (EtOAc/petroleum 
ether, 1:9); 
1
H NMR (400 MHz, CDCl3):  = 1.05 (d, J = 6.8 Hz, 3H, 6-H), 1.10 (d, J = 6.8 Hz, 
3H, 5-CH3), 2.62 (ap. septet, J = 6.8 Hz, 1H, 5-H), 2.78 (dd, J = 17.9, 3.8 Hz, 1H, 3-H), 3.62 (dd, 
J = 17.9, 10.1 Hz, 1H, 5-H), 5.06 (dd, J = 10.1, 3.8 Hz, 1H, 4-H), 7.01 (m, 2H, Ar-H), 7.15–7.31 
(m, 5H, Ar-H), 7.98 (m, 2H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 18.1 (5-CH3, C-6), 40.7 
(C-4), 45.1 (C-3), 48.5 (C-2), 115.5 (d, JCF = 22.0 Hz, 2CH, Ar), 127.3 (CH, Ar), 128.0 (2CH, 
Ar), 129.2 (2CH, Ar), 131.4 (d, JCF = 9.5 Hz, 2CH, Ar), 132.7 (d, JCF = 2.9 Hz , 2CH, Ar), 138.4 
(C, Ar), 165.5 (d, JCF = 254.0 Hz, C, Ar), 197.4 (C-4), 212.7 (C-1). 
 
tert-Butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-
2,2-dimethyl-1,3-dioxan-4-yl)acetate (1-68) 
 
A mixture of 1,4-diketone 1-27 (800 mg, 2.9 mmol), amine 1-41 (873 mg, 2.9 mmol) and p-
toluenesulphonic acid (111 mg, 20 mol%) as catalyst in toluene (10 mL) was refluxed for 5 days 
in a Dean-Stark apparatus to remove water as azeotrope. After completion of reaction the 
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mixture was cooled to room temperature and diluted with diethyl ether (20 mL) and washed with 
saturated NaHCO3 (10 mL) solution followed by saturated NaCl solution. The organic layer was 
dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The crude mixture was 
purified by flash chromatography (diethyl ether/petroleum ether, 1:30) to afford pyrrole 1-68 
(950 mg, 85%) as white solid, m.p. 45–55 °C. Rf = 0.35 (diethyl ether/petroleum ether, 1:20); 
[α]D
20
 = +10.5 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 0.98 (dd J = 11.6, 11.9 Hz, 1H, 
5’-H), 1.23–1.38 (m, 13H, 5’-H, CH(CH3)2, 2’-CH3), 1.42 (s, 9H, C(CH3)3), 1.46–1.60 (m, 2H, 
NCH2CH2), 2.14–2.26 (m, 1H, CH2CO2tBu), 2.28–2.40 (m, 1H, CH2CO2tBu), 3.00 (ap. septet, J 
= 6.6 Hz, 1H, CH(CH3)2), 3.52–3.64 (m, 1H, 4’-H), 3.73–3.88 (m, 1H, NCH2CH2), 3.96 (ddd, J 
= 14.1, 9.1, 4.8 Hz, 1H, NCH2CH2), 4.05–4.18 (m, 1H, 6’-H), 6.18 (s, 1H, 4-H, pyrrole), 6.98–
7.18 (m, 6H, Ar-H), 7.22–7.40 (m, 3H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.6 (2’-CH3), 
23.3 (CH(CH3)2), 23.7 (CH(CH3)2), 25.5 (CH(CH3)2), 28.1 (C(CH3)3), 29.9 (2’-CH3), 36.0 (C-
5’), 37.8 (NCH2CH2), 39.7 (NCH2CH2), 42.5 (CH2CO2tBu), 65.9 (C-6’), 66.1 (C-4’), 80.6 
(C(CH3)3), 98.6 (C-2’), 103.4 (C-4, pyrrole), 115.6 (d, JCF = 21.2 Hz, 2CH, Ar), 122.1 (C, Ar), 
124.6, 124.8 (CH, Ar), 127.3, 127.5 (2CH, Ar), 127.8 (C, Ar), 127.9, 127.9 (2CH, Ar), 128.5, 
129.1, 129.8 (d, JCF = 3.7 Hz, C, Ar), 131.2, 132.9 (d, JCF = 8.0 Hz, 2CH, Ar), 133.9, 136.5 (C, 
Ar), 136.7, 140.3, 140.4 (C, Ar), 162.2 (d, JCF = 247.4 Hz, C, Ar) 170.2 (CO2tBu); HRMS (ESI): 
[M+Na]
+
 calcd for C33H42FNO4Na 558.29901, found 558.299441. 
 
2-((4S,6R)-6-(2-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-
dimethyl-1,3-dioxan-4-yl)ethanol (1-71) 
 
A solution of pyrrole 1-68 (1.07 g, 2.0 mmol) in absolute CH2Cl2 (15 mL) was cooled to −40 °C 
then DIBAL-H (6 mL, 6.0 mmol, 1M in hexane) was added dropwise slowly over 15 min using a 
syringe pump and the mixture stirred 10 min at same temperature. The reaction mixture was 
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allowed to stir at room temperature for overnight and the mixture was cooled to 0 °C, then 
methanol was added slowly followed by addition of saturated NH4Cl solution. The mixture was 
stirred vigorously at room temperature for 1 h before it was extracted with CH2Cl2 (3 × 60 mL). 
The combined organic layers were washed with saturated NaCl solution, dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. Purification by flash chromatography 
(ethyl acetate/petroleum ether, 3:7) afforded corresponding alcohol 1-71 (723 mg, 78%) as white 
solid, m.p. 45–60 °C. Rf = 0.22 (EtOAc/petroleum ether, 3:7); [α]D
20
 = +0.6, (c 1.0, CHCl3);
 1
H 
NMR (400 MHz, CD3OD):  = 0.89 (dd, J = 12.9, 11.6 Hz, 1H, 5’-H), 1.18 (dt, J = 12.9, 2.3 Hz, 
1H, 5’-H), 1.26 (s, 3H, 2’-CH3), 1.29 (d, J = 6.8 Hz, 3H, CH(CH3)), 1.32 (d, J = 6.6 Hz, 3H, 
CH(CH3)2), 1.34 (s, 3H, 2’-CH3), 1.41–1.63 (m, 4H, NCH2CH2, CH2CH2OH), 3.04 (ap. sept, J = 
6.8 Hz, 1H, CH(CH3)2), 3.51–3.61 (m, 2H, CH2CH2OH), 3.63 (dddd, J = 11.8, 9.3, 5.0, 2.3 Hz, 
1H, 4’-H), 3.80–4.04 (m, 3H, 6’-H, NCH2CH2), 6.11 (s, 1H, 4-H, pyrrole), 6.95–7.42 (m, 9H, 
Ar-H); 
13
C NMR (100 MHz, CD3OD):  = 20.1 (2’-CH3), 23.7 (CH(CH3)2), 24.2 (CH(CH3)2), 
26.7 (CH(CH3)2), 30.5 (2’-CH3), 37.8 (C-5’), 39.0 (NCH2CH2), 40.1 (CH2CH2OH), 40.7 
(NCH2CH2), 59.0 (CH2CH2OH), 67.3 (C-6’), 67.6 (C-4’), 99.7 (C-2’), 104.3 (C-4, pyrrole), 
116.5 (d, JCF = 21.9 Hz, CH, Ar), 123.5 (C, Ar), 125.6, 125.7 (CH, Ar), 128.5 (2CH, Ar), 128.9 
(2CH, Ar), 129.2 (C, Ar), 129.7, 130.4 (C, Ar), 131.6 (d, JCF = 3.7 Hz, C, Ar), 132.5, 134.4 (d, 
JCF = 8.8 Hz, 2CH, Ar), 135.5, 138.3 (C, Ar), 138.4, 141.5, 141.6 (C, Ar), 163.7 (d, JCF = 245.9 
Hz, C, Ar); HRMS (ESI): [M+Na]
+
 calcd for C36H41FN2O4Na 488.25714, found 488.2569987. 
 
1-(2-((4R,6S)-6-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-
2-(4-fluorophenyl)-5-isopropyl-3-phenyl-1H-pyrrole (1-72) 
 
To a stirred solution of alcohol 1-71 (640 mg, 1.3 mmol) in DMF (10 mL), at room temperature 
was added imidazole (187 mg, 2.7 mmol) followed by the addition of tert-butyldimethylsilyl 
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chloride (227 mg, 1.512 mmol) in one portion and the reaction mixture was allowed to stir at 
room temperature for 1 h. The reaction was diluted with diethyl ether (30 mL) and washed with 
saturated NaHCO3 solution (10 mL), water (3 × 50 mL), and saturated NaCl solution. The 
organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
residue was purified by flash chromatography (diethyl ether/petroleum ether, 1:10) to isolate 
protected alcohol 1-72 (781 mg, 98%) as pale yellow oil. Rf = 0.37 (diethyl ether/petroleum 
ether, 1:20); [α]D
20
 = +1.89, (c 1, CHCl3); 
1
H NMR (400 MHz, CD3OD):  = 0.03 (s, 6H, 2 
Si(CH3)2), 0.88 (s, 9H, SiC(CH3)3), 0.82–0.94 (m, 1H, 5’-H), 1.13–1.19 (m, 1H, 5’-H), 1.25 (s, 
3H, 2’-CH3), 1.27–1.32 (m, 6H, CH(CH3)2), 1.32 (s, 3H, 2’-CH3), 1.40–1.55 (m, 4H, NCH2CH2, 
CH2CH2OTBS), 3.04 (m, 1H, CH(CH3)2), 3.52–3.71 (m, 3H, CH2CH2OTBS, 4’-H), 3.80–4.02 
(m, 3H, NCH2CH2, 6’-H), 6.11 (s, 1H, 4-H, pyrrole), 6.93–7.13 (m, 6H, Ar-H), 7.21–7.39 (m, 
3H, Ar-H); 
13
C NMR (100 MHz, CD3OD):  = −5.22 (Si(CH3)2), 19.1 (SiC(CH3)3), 20.2 (2’-
CH3), 23.7 (CH(CH3)2), 24.2 (CH(CH3)2), 26.4 (C(CH3)3), 26.7 (CH(CH3)2), 30.5 (2’-CH3), 37.9 
(C-5’), 39.0 (NCH2CH2), 40.4 (CH2CH2OTBS), 40.8 (NCH2CH2), 59.9 (CH2CH2OTBS), 66.8 
(C-6’), 67.7 (C-4’), 99.7 (C-2’), 104.4 (C, Ar), 116.5 (d, JCF = 21.2 Hz, 2CH, Ar), 123.3, 123.6 
(C, Ar), 125.6, 125.8 (CH, Ar), 128.5, 128.6 (2CH, Ar), 128.9, 128.9 (2CH, Ar), 129.2 (C, Ar), 
129.7, 130.5, 131.6 (d, JCF = 3.7 Hz, C, Ar), 132.5, 134.4 (d, JCF = 8.0 Hz, 2CH, Ar), 135.5, 
138.3 (C, Ar), 138.4, 141.5, 141.6 (C, Ar), 163.7 (d, JCF = 245.9 Hz, C, Ar); HRMS (ESI): 
[M+Na]
+
 calcd for C35H50FNO3SiNa 602.34362, found 602.344059. 
 
1-(2-((4R,6S)-6-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-
2-(4-fluorophenyl)-4-iodo-5-isopropyl-3-phenyl-1H-pyrrole (1-73) 
 
N-iodosuccinimide (353 mg, 1.6 mmol) was added to a solution of pyrrole 1-72 (758 mg, 1.3 
mmol) in DMF (8 mL) and the mixture was stirred at room temperature. After 1 h, the mixture 
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was diluted with diethyl ether, washed with saturated NaHCO3 solution, water (3 × 15 mL), 10% 
aq Na2S2O3 solution and saturated NaCl solution. The organic layer was dried over Na2SO4, 
filtered and concentrated under vacuum. Purification by flash chromatography (ethyl 
acetate/petroleum ether, 1:9) furnished iodopyrrole 1-73 (835 mg, 91%) as brown colored oil. Rf 
= 0.24 (petroleum ether/EtOAc, 1:9); [α]D
21
 = −2.96 (c 1, CHCl3); 
1
H NMR (400 MHz, 
CD3OD):  = 0.04 (s, 6H, Si(CH3)2), 0.88 (s, 9H, SiC(CH3)3); 0.92 (ddd, J = 12.6, 11.6, 11.6 Hz, 
1H, 5’-H), 1.20 (ddd, J = 12.9, 2.5, 2.3 Hz, 1H, 5’-H), 1.23 (s, 3H, 2’-CH3), 1.32 (s, 3H, 2’-CH3), 
1.47 (d, J = 7.1 Hz, 3H, CH(CH3)2), 1.48 (d, J = 7.1 Hz, 3H, CH(CH3)2), 1.50–1.65 (m, 4H, 
NCH2CH2, CH2CH2OTBS), 3.37 (ap. septet, 1H, J = 7.1 Hz, CH(CH3)2), 3.57–3.72 (m, 3H, 4’-
H, CH2CH2OTBS), 3.84–3.98 (m, 2H, NCH2CH2, 6’-H), 4.01–4.13 (m, 1H, NCH2CH2), 6.96–
7.29 (m, 9H, Ar-H); 
13
C NMR (100 MHz, CD3OD):  = −5.2 (Si(CH3)2), 19.1 (SiC(CH3)3), 20.2 
(2’-CH3), 21.8 (CH(CH3)2), 26.4 (CH(CH3)2), 30.5 (2’-CH3), 37.8 (C-5’), 39.5 (NCH2CH2), 40.4 
(CH2CH2OTBS), 42.2 (NCH2CH2), 59.9 (CH2CH2OTBS), 64.0 (C-4, pyrrole), 66.7 (C-6’), 68.0 
(C-4’), 99.7 (C-2’), 116.0 (d, JCF = 22.0 Hz, 2CH, Ar), 126.9, 127.0 (CH, Ar), 128.2 (C, Ar), 
128.4, 128.5 (2CH, Ar), 129.2, 130.4 (d, JCF = 3.7 Hz, C, Ar), 131.2 (C, Ar), 132.1 (2CH, Ar), 
132.2, 132.6, 134.5 (d, JCF = 8.0 Hz, 2CH, Ar), 137.7 (C, Ar), 137.8, 138.1, 138.2 (C, Ar), 163.6 
(d, JCF = 245.9 Hz, C, Ar); HRMS (ESI): [M+Na]
+
 calcd for C35H49FINO3SiNa 728.24026, 
found 728.240251. 
 
1-(2-((4R,6S)-6-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-
5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (1-74) 
 
To a cooled (−78 °C) solution of iodo pyrrole 1-73 (820 mg, 1.2 mmol) in THF (10 mL) t-BuLi 
(1.0 mL, 2.4 mmol, 1.6M in pentane) was added dropwise slowly. The resulting yellow colored 
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solution was stirred for additional 15 min and excess of solid CO2 was added to the reaction 
mixture. After 10 min of stirring at −78 °C, the reaction was allowed to warm to the room 
temperature to evaporate excess of CO2. The reaction was quenched by addition of saturated 
NH4Cl solution and the mixture was extracted with ether (3 × 30 mL). The combined organic 
layers were washed with brine, dried over anhydrous Na2SO4, filtered, concentrated under 
vacuum and the residue was purified by flash chromatography (ethyl acetate/petroleum ether, 
2:8) to afford acid 1-74 (580 mg, 80%) as white solid, m.p. 127–129 °C. Rf = 0.28 
(EtOAc/petroleum ether, 1:4); 
1
H NMR (400 MHz, CD3OD):  = 0.04 (s, 6H, Si(CH3)2), 0.89 (s, 
9H, SiC(CH3)3), 0.93 (dd, J = 12.6, 11.6, Hz, 1H, 5’-H), 1.20–1.27 (m, 1H, 5’-H), 1.24 (s, 3H, 
2’-CH3), 1.33 (s, 3H, 2’-CH3), 1.46 (d, J = 7.1 Hz, 3H, CH(CH3)2), 1.47 (d. J = 7.3 Hz, 3H, 
CH(CH3)2), 1.49–1.56 (m, 2H, CH2CH2OTBS), 1.57–1.67 (m, 2H, NCH2CH2), 3.52–3.74 (m, 
4H, CH(CH3)2, 4’-H, CH2CH2OTBS), 3.82–4.00 (m, 2H, NCH2CH2, 6’-H), 4.01–4.12 (m, 1H, 
NCH2CH2), 6.96–7.11 (m, 6H, Ar-H), 7.13–7.21 (m, 2H, Ar-H), 7.24–7.31 (m, 1H, Ar-H); 
13
C 
NMR (100 MHz, CD3OD):  = −5.2 (Si(CH3)2), 19.1 (SiC(CH3)3), 20.2 (2’-CH3), 21.6 
(CH(CH3)2), 21.7 (CH(CH3)2), 26.4 (SiC(CH3)3), 27.2 (CH(CH3)2), 30.5 (2’-CH3), 37.8 (C-5’), 
39.2 (NCH2CH2), 40.4 (CH2CH2OTBS), 41.9 (NCH2CH2), 59.9 (CH2CH2OTBS), 66.7 (C-6’), 
67.9 (C-4’), 99.7 (C-2’), 112.6 (C-4, pyrrole), 116.0 (d, JCF = 21.9 Hz, 2CH, Ar), 125.9 (C, Ar), 
126.5, 126.6 (CH, Ar), 128.1, 128.2 (2CH, Ar), 128.7, 129.2, 130.0 (d, JCF = 3.7 Hz, C, Ar), 
130.8, 131.6 (2CH, Ar), 132.0 (C, Ar), 132.9, 133.9 (C, Ar), 134.9 (d, JCF = 8.0 Hz, 2CH, Ar), 
137.3 (C, Ar), 137.4, 143.3, 143.5 (C, Ar), 163.7 (d, JCF = 246.6 Hz, C, Ar), 170.4 (COO). 
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1-(2-((4R,6S)-6-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-
5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (1-75) 
 
A solution of acid 1-74 (100 mg, 0.16 mmol) and aniline (16 μL, 0.18 mmol) in CH2Cl2 (5 mL) 
was cooled to 0 °C (salt-ice bath) then diisopropylethylamine (82 μL, 0.48 mmol) was added 
followed by subsequent addition of PyBrOP (112 mg, 0.24 mmol). The reaction mixture was 
allowed to stir at room temperature for overnight (~ 12 h). The reaction was diluted with CH2Cl2, 
washed with saturated NaHCO3 solution (5 mL), water (5 mL), and saturated NaCl solution. The 
organic layer was dried over anhydrous Na2SO4, filtered and concentrated under vacuum. 
Purification by flash chromatography (ethyl acetate/petroleum ether, 1:9) provided amide 1-75 
(110 mg, 98%) as yellow colored oil. Rf = 0.43 (EtOAc/petroleum ether, 1:4); 
1
H NMR (400 
MHz, CDCl3):  = 0.02 (s, 6H, Si(CH3)2), 0.87 (s, 9H, SiC(CH3)3), 1.03 (ddd, J = 12.6, 11.6, 
11.6 Hz, 1H, 5’-H), 1.26 (ddd, J = 12.6, 2.8, 2.0 Hz, 1H, 5’-H), 1.30 (s, 3H, 2’-CH3), 1.34 (s, 3H, 
2’-CH3), 1.53 (d, J = 7.1 Hz, 6H, CH(CH3)2), 1.49–1.76 (m, 4H, NCH2CH2, CH2CH2OTBS), 
3.52–3.73 (m, 4H, CH(CH3)2, 4’-H, CH2CH2OTBS), 3.76–3.98 (m, 2H, NCH2CH2, 6’-H), 4.03–
4.12 (m, 1H, NCH2CH2), 6.85 (s, 1H, CONH), 6.93–7.32 (m, 14H, Ar-H); 
13
C NMR (100 MHz, 
CDCl3):  = −5.4 (Si(CH3)2), 18.2 (SiC(CH3)3), 19.8 (2’-CH3), 21.5 (CH(CH3)2), 21.7 
(CH(CH3)2), 25.9 (C(CH3)3), 26.1 (CH(CH3)2), 30.1 (2’-CH3), 36.6 (C-6’), 38.2 (NCH2CH2), 
38.3 (CH2CH2OTBS), 40.9 (NCH2CH2), 58.7 (CH2CH2OTBS), 65.3 (C-6’), 66.6 (C-4’), 98.4 (C-
2’), 115.3 (d, JCF = 22.0 Hz, 2CH, Ar), 119.5, 121.7, 123.5, 126.4, 126.5, 127.6, 125.2 (d, JCF = 
3.7 Hz, C, Ar), 128.3, 128.6, 128.8, 130.5, 130.5, 132.3, 133.2 (d, JCF = 8.0 Hz, CH, Ar), 134.6, 
134.8, 138.4, 141.5, 162.2 (d, JCF = 247.4 Hz, C, Ar); HRMS (ESI): [M+Na]
+
 calcd for 
C42H55FN2O4SiNa 721.38073, found 721.380841. 
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5-(4-Fluorophenyl)-1-(2-((4R,6S)-6-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2-
isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (1-76) 
 
Silyl ether 1-75 (180 mg, 0.26 mmol) was treated with 0.2M solution of tetra n-butyl ammonium 
fluoride in THF (5 mL) at room temperature for overnight (~12 h). The reaction was diluted with 
ethyl acetate, washed with water and saturated NaCl solution, dried over anhydrous MgSO4, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography (petroleum ether/EtOAc, 7:3) to furnish alcohol 1-76 (150 mg, 97%) as white 
amorphous solid, m.p. 75–85 °C. Rf = 0.26 (EtOAc/petroleum ether, 1:1); []D
20
 = −6.0, (c 1, 
CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.11 (ddd, J = 12.6, 11.4, 11.1 Hz, 1H, 5’-H), 1.21 
(ddd, J = 12.6, 2.9, 2.3 Hz, 1H, 5’-H), 1.31(s, 3H, 2’-CH3), 1.36 (s, 3H, 2’-CH3), 1.52 (d, J = 7.1 
Hz, 6H, CH(CH3)2), 1.52–1.65 (m, 4H, NCH2CH2, CH2CH2OH), 3.56 (ap. septet, J = 7.1 Hz, 
1H, CH(CH3)2), 3.62–3.88 (m, 4H, NCH2CH2, 4’-H, CH2CH2OH), 3.96–4.13 (m, 2H, 
NCH2CH2, 6’-H), 6.85 (s, 1H, NH), 6.92–7.10 (m, 5H, Ar-H), 7.11–7.23 (m, 9H, Ar-H); 
13
C 
NMR (100 MHz, CDCl3):  = 19.9 (2’-CH3), 21.6 (CH(CH3)2), 21.7 (CH(CH3)2), 26.1 
(CH(CH3)2), 30.4 (2’-CH3), 37.7 (5’-H), 39.4 (NCH2CH2), 40.1 (CH2CH2OH), 41.4 (NCH2CH2), 
59.0 (CH2CH2OH), 67.3 (C-6’), 67.8 (C-4’), 99.8 (C-2’), 115.2 (d, JCF = 22.0 Hz, CH, aryl), 
115.3 (C, aryl), 119.5 (CH, aryl), 121.8 (C, aryl), 123.5 (CH, aryl), 126.5 (CH, aryl), 128.3 (d, 
JCF = 3.7 Hz, C, aryl), 128.3 (CH, aryl), 128.7 (CH, aryl), 128.7 (C, aryl), 130.5 (CH, aryl), 
133.2 (d, JCF = 8.0 Hz, CH, aryl), 134.6 (C, aryl), 138.3 (C, aryl), 141.5 (C, aryl), 162.2 (d, JCF = 
248.1 Hz, C, aryl), 164.8 (CONH); HRMS (ESI): [M+Na]
+
 calcd for C36H41FN2O4Na 
607.29426, found 607.294097. 
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2-((4R,6R)-6-(2-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-
1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetic acid (1-44) 
 
To a cooled (salt-ice bath) solution of alcohol 1-76 (147 mg, 0.25 mmol) in CH2Cl2 (10 mL) 
Dess-Martin periodinane (145 mg, 0.50 mmol) was added and the reaction mixture was stirred at 
room temperature for 1 h. Then a mixture (1:1) of saturated NaHCO3 and 0.1M Na2S2O3 solution 
(4 mL) was added into the reaction mixture and this mixture was extracted with CH2Cl2 (3 × 5 
mL). The combined organic layers were washed with saturated NaCl solution, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude aldehyde was dissolved in 
t-butanol (10 mL) and 2-methyl-2-butene (1.2 mL) was added. The mixture was cooled in an ice 
bath and a solution of NaH2PO4•2H2O (224 mg, 1.4 mmol) and NaClO2 (43 mg, 0.48 mmol) in 
H2O (10 mL) was added dropwise and the reaction mixture was allowed to stir at room 
temperature for 6 h. The mixture was diluted with saturated NaCl solution (5 mL) and extracted 
with ethyl acetate (3 × 15 mL). The combined organic extracts were dried over anhydrous 
MgSO4, filtered, concentrated and purified by flash chromatography (CH2Cl2/methanol/AcOH, 
25:1:0.1) to furnish acid 1-44 (144 mg, 96%). Rf = 0.33 (CH2Cl2/methanol/AcOH, 25:1:0.1); 
[]D
20
 = +5.0 (c 1, CHCl3); 
1
H NMR (400 MHz, CD3OD):  = 0.92–1.03 (m, 1H, 5’-H), 1.25 (s, 
3H, 2’-CH3), 1.28–1.35 (m, 1H, 5’-H), 1.37 (s, 3H, 2’-CH3), 1.46 (d, J = 7.1 Hz, 3H, CH(CH3)2), 
1.47 (d, J = 6.8 Hz, 3H, CH(CH3)2), 1.57–1.69 (m, 2H, NCH2CH2), 2.24–2.39 (m, 2H, 
CH2COOH), 3.31–3.40 (m, 1H, CH(CH3)2), 3.70–3.82 (m, 1H, 4’-H), 3.85–3.94 (m, 1H, 
NCH2CH2), 4.03–4.12 (m, 1H, NCH2CH2), 4.16–4.26 (m, 1H, 6’-H), 7.00–7.36 (m, 14H, Ar-H); 
13
C NMR (100 MHz, CD3OD):  = 20.0 (2’-CH3), 22.6 (CH(CH3)2), 22.8 (CH(CH3)2), 27.6 
(CH(CH3)2), 30.3 (2’-CH3), 37.1 (NCH2CH2), 39.4 (C-5’), 41.4 (CH2COOH), 42.2 (NCH2CH2), 
67.2 (C-6’), 67.7 (C-4’), 100.0 (C-2’), 116.3 (d, JCF = 22.0 Hz, 2CH, Ar), 118.1 (C, Ar), 121.5 
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(2CH, Ar), 123.3 (C, Ar), 125.1 (CH, Ar), 126.9 (CH, Ar), 128.8, 128.9 (2CH, Ar), 129.0, 129.5, 
129.6 (2CH, Ar), 129.6, 129.8 (d, JCF = 2.9 Hz, C, Ar), 131.0 (2CH, Ar), 131.8, 132.8, 134.8 (d, 
JCF = 8.0 Hz, 2CH, Ar), 136.3 (C, Ar), 139.0 (C, Ar), 139.8 (C, Ar), 163.8 (d, JCF = 246.6 Hz, 
Ar-C), 169.5 (C=O, amide), 174.6 (C=O, acid); HRMS (ESI): [M+Na]
+
 calcd for 
C36H39FN2O5Na 621.27352, found 621.27359. 
 
5-(4-Fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-
isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (1-31) 
 
A solution of acid 1-44 (52 mg, 0.08 mmol) and a catalytic amount of camphorsulphonic acid in 
THF (2 mL) was stirred at room temperature for 3 h. The mixture was concentrated and the 
residue purified by flash chromatography (diethyl ether/methanol, 50:1) to afford atorvastatin 
lactone 1-31 (38 mg, 90%) as white solid. It was recrystallized from petroleum ether/ethyl 
acetate to give an amorphous white solid, m.p. 150–155 °C {ref.57 160–162 °C}. Rf = 0.25 
(diethyl ether/methanol, 50:1); [α]D
20
 = +25.5 (c 0.2, CHCl3) {ref.
47
 []D +26.05 (c 1, CHCl3), 
ref.
41
 []D
23
 +24.53 (0.53% in CHCl3)}; 
1
H NMR (400 MHz, CD3OD):  = 1.50–1.53 (m, 6H, 
CH(CH3)2), 1.55–1.60 (m, 1H, 5’-H), 1.65–1.77 (m, 2H, NCH2CH2, 3’-H), 1.82–1.91 (m, 1H, 
NCH2CH2), 2.37 (s, 1H, OH), 2.49–2.66 (m, 2H, 5’-H), 3.48–3.58 (m, 1H, CH(CH3)2), 3.98–
4.10 (m, 1H, NCH2CH2), 4.16–4.29 (m, 2H, NCH2CH2, 4’-H), 4.44–4.54 (m, 1H, 2’-H), 6.87 (s, 
1H, NH, amide), 6.95–7.33 (m, 14H, Ar-H); 13C NMR (100 MHz, CD3OD):  = 21.7 
(CH(CH3)2), 22.0 (CH(CH3)2), 26.1 (CH(CH3)2), 35.6 (C-3'), 37.0, 37.1 (NCH2CH2), 38.5 (C-
5’), 40.7 (NCH2CH2), 62.4 (C-4’), 73.0 (C-2’), 73.1, 115.6 (d, JCF = 22.0 Hz, 2CH, Ar), 115.6 
(C-4, Ar), 119.7 (2CH, Ar), 122.1 (C, Ar), 123.7 (CH, Ar), 126.6 (CH, Ar), 128.0 (d, JCF = 2.9 
Hz, C, Ar), 128.3, 128.4 (2CH, Ar), 128.4, 128.7 (2CH, Ar), 128.7 (C, Ar), 130.4 (2CH, Ar), 
Experimental Section  111 
 
131.3, 133.1 (d, JCF = 8.1 Hz, 2CH, Ar), 134.4 (C, Ar), 138.2 (C, Ar), 141.3 (C, Ar), 162.3 (d, 
JCF = 248.8 Hz, C, Ar), 164.9 (C=O, amide), 169.4 (C=O, lactone); HRMS (ESI): [M+Na]
+
 
calcd for C33H33FN2O4Na 563.23166, found 563.23154. 
 
3-(Benzyloxy)propan-1-ol (1-87)
161
 
 
A mixture of NaH (2.89 g, 72.3 mmol) in dry THF (300 mL) and DMSO (75 mL) was stirred for 
30 min at room temperature. Then, 1,3-propanediol (5.0 g, 65.7 mmol) in THF (250 mL) was 
added dropwise over 30 min followed by slow dropwise addition of benzyl bromide (8.60 mL, 
72.3 mmol) in THF (140 mL). Subsequently, tetra n-butylammonium iodide (12.1 g, 32.6 mmol) 
was added in one portion. The reaction mixture was stirred at 60 °C for ~12 h (overnight). After 
cooling, water (500 mL) was added to the reaction mixture which was then extracted with diethyl 
ether (3 × 150 mL). The combined organic layers were washed with saturated NaCl solution, 
dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (petroleum ether/EtOAc, 7:3) to give alcohol 1-87 (7.02 g, 64%) as pale yellow 
colored oil. Rf = 0.26 (petroleum ether/EtOAc, 7:3); 
1
H NMR (400 MHz, CDCl3):  = 1.86 
(pentet, J = 5.8 Hz, 2H, BnOCH2CH2), 2.43 (s, 1H, CH2OH), 3.65 (t, J = 5.8 Hz, 2H, 
CH2CH2OH), 3.77 (t, J = 5.8 Hz, 2H, BnOCH2), 4.52 (s, 2H, OCH2Ph), 7.26–7.37, (m, 5H, 
phenyl); 
13
C NMR (100 MHz, CDCl3):  = 32.0 (CH2), 61.7 (CH2OH), 69.3 (BnOCH2), 73.2 
(PhCH2), 127.6 (2CH, phenyl), 127.7 (C, phenyl), 128.4 (2CH, phenyl), 136.0 (CH, phenyl). 
 
(R)-1-(Benzyloxy)hex-5-en-3-ol (1-88) 
 
In an oven dried screw cap glass bottle, a mixture of alcohol 1-87 (4.0 g, 24.1 mmol), allyl 
acetate (5.24 mL, 48.1 mmol), [Ir(cod)Cl]2, (404 mg, 2.5 mol%), (R)-(+)-Cl,MeO-BIPHEP, (784 
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mg, 5 mol%), 4-Cl-3-NO2-benzoic acid (485 mg, 2.4 mmol), and Cs2CO3 (1.57 g, 4.8 mmol) in 
THF (130 mL) was heated at 120 °C under nitrogen for 20 h. The reaction mixture was adsorbed 
on silica gel and purified by flash chromatography (EtOAc/petroleum ether, 1:4) to furnish 
alcohol 1-88 (4.50 g, 90%, 92% ee by Mosher ester method) as colorless oil. Rf = 0.34 
(EtOAc/petroleum ether, 1:4); []D
20
 = +2.7 (c 1.0, CHCl3); (Ref.
162
 +2.2, c 1.0, CHCl3; Ref.
59b
 
+2.08, c 1.25, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.73–1.81 (m, 2H, 2-H), 2.21–2.28 (m, 
2H, 4-H), 2.60 (s, br, 1H, OH), 3.61–3.67 (m, 1H, 1-H), 3.71 (ddd, J = 9.3, 5.3, 5.3 Hz, 1H, 1-
H), 3.83–3.92 (m, 1H, 3-H), 4.52 (s, 2H, OCH2Ph), 5.06–5.14 (m, 2H, Ar-H), 5.78–5.88 (dddd, J 
= 16.9, 10.1, 7.3, 7.1 Hz, 1H, 5-H), 7.26–7.36 (m, 5H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 
35.8 (C-2), 41.9 (C-4), 68.9 (C-1), 70.3 (C-3), 73.3 (OCH2Ph), 117.5 (C-6), 127.6 (2CH, 
phenyl), 127.7 (CH, phenyl), 128.4 (2CH, phenyl), 134.8 (C-5), 137.9 (C, phenyl). 
 
(R)-((1-(Benzyloxy)hex-5-en-3-yl)oxy)(tert-butyl)dimethylsilane (1-89) 
 
A mixture of alcohol 1-88 (877 mg, 4.3 mmol), imidazole (723 mg, 10.6 mmol) and TBSCl (1.28 
g, 8.5 mmol) in DMF (5 mL) was stirred overnight at 50 °C. Thereafter, water (10 mL) was 
added and the mixture extracted with diethyl ether (3 × 30 mL). The combined organic extracts 
were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash 
chromatography (diethyl ether/petroleum ether, 1:50) to give silyl ether 1-89 (1.27 g, 91%) as 
colorless oil. Rf = 0.34 (petroleum ether/diethyl ether, 50:1); []D
20
 = −17.3 (c 1, CHCl3); 
1
H 
NMR (400 MHz, CDCl3):  = 0.03 (s, 3H, Si(CH3)2), 0.05 (s, 3H, Si(CH3)2), 0.87 (s, 9H, 
SiC(CH3)3), 1.69 (dddd, J = 13.9, 7.8, 6.1, 6.1 Hz, 1H, 2-H), 1.79 (dddd, J = 13.9, 7.1, 7.1, 4.5 
Hz, 1H, 2-H), 2.16–2.29 (m, 2H, 4-H), 3.52–3.55 (m, 2H, 1-H), 3.85–3.93 (m, 1H, 3-H), 4.43 (d, 
J = 11.9 Hz, 1H, OCH2Ph), 4.49 (d, J = 11.9 Hz, 1H, OCH2Ph), 4.99–5.06 (m, 2H, 6-H), 5.80 
(dddd, J = 17.7, 9.6, 7.3, 7.3 Hz, 1H, 5-H), 7.26–7.36 (m, 5H, Ar-H); 13C NMR (100 MHz, 
CDCl3):  = −4.4 (Si(CH3)2), 18.1 (SiC(CH3)3), 25.8 (SiC(CH3)3), 36.7 (C-2), 42.3 (C-4), 67.0 
(C-1), 68.9 (C-3), 72.9 (OCH2Ph), 116.9 (C-6), 127.5 (CH, phenyl), 127.6 (2CH, phenyl), 128.3 
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(2CH, phenyl), 134.9 (C-5), 138.5 (C, phenyl); HRMS (ESI): [M+Na]
+
 calcd for C19H32O2SiNa 
343.20638, found 343.206354. 
 
(R)-5-(Benzyloxy)-3-((tert-butyldimethylsilyl)oxy)pentan-1-ol (1-90) 
 
To a solution of alcohol 1-89 (5.61 g, 17.5 mmol) in methanol (74 mL, 0.15M), 2-3 drops of 
Sudan-ΙΙΙ (1% in methanol) were added as an indicator resulting in a pink colored solution. The 
mixture was cooled to −80 °C and ozone gas was bubbled through the solution until it turned 
pink to colorless (about 50 min). Residual O3 was removed by passing nitrogen through the 
reaction (about 5 min). Thereafter, NaBH4 (6.62 g, 175 mmol) was added and the reaction 
mixture was slowly allowed to reach room temperature, with the flask kept in the cooling bath. 
Water (30 mL) was added and the mixture was concentrated to ~50 mL on a rotary evaporator 
before it was extracted with ethyl acetate (3 × 120 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (petroleum ether/EtOAc, 5:1) to provide alcohol 1-90 (5.52 g, 97%) as colorless 
oil. Rf = 0.24 (petroleum ether/EtOAc, 5:1); []D
20
 = +3.2 (c 1, CHCl3); 
1
H NMR (400 MHz, 
CDCl3):  = 0.07 (s, 3H, Si(CH3)2), 0.09 (s, 3H, Si(CH3)2), 0.88 (s, 9H, SiC(CH3)3), 1.61–1.70 
(m, 1H, 4-H), 1.76–1.92 (m, 3H, 4-H, 2-H), 2.18 (br, s, 1H, OH), 3.52 (t, J = 6.3 Hz, 2H, 5-H), 
3.67–3.73 (ddd, J = 11.1, 5.5, 5.3 Hz, 1H, 1-H), 3.78–3.84 (dddd, J = 8.3, 6.6, 4.5, 3.8 Hz, 1H, 3-
H), 4.10 (ddd, J = 10.9, 5.8, 5.8 Hz, 2H, 1-H), 4.43 (d, J = 11.9 Hz, 1H, OCH2Ph), 4.49 (d, J = 
11.9 Hz, 1H, OCH2Ph); 7.26–7.36 (m, 5H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = −4.7 
(Si(CH3)2), 17.9 (SiC(CH3)3), 25.8 (SiC(CH3)3), 36.7 (C-4), 38.3 (C-2), 60.0 (C-1), 66.8 (C-5), 
69.0 (C-3), 73.0 (PhCH2O), 127.6 (CH, phenyl), 127.7 (2CH, phenyl); 128.4 (2CH, phenyl), 
138.3 (C, phenyl); HRMS (ESI): [M+Na]
+
 calcd for C18H32O3SiNa 347.20129, found 
347.201340. 
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(4R,6S)-8-(Benzyloxy)-6-((tert-butyldimethylsilyl)oxy)oct-1-en-4-ol (1-91) 
 
An oven dried screw cap glass bottle was charged under nitrogen with alcohol 1-90 (5.90 g, 18.2 
mmol), [Ir(cod)Cl]2 (305 mg, 0.46 mmol), (R)-(+)-Cl,MeO-BIPHEP (592 mg, 0.9 mmol), 
Cs2CO3 (1.18 g, 1.2 mmol) and 4-Cl-3-NO2-benzoic acid (366 mg, 1.8 mmol) in THF (100 mL) 
to which allyl acetate (3.64 g, 36.4 mmol) was added. The mixture was heated at 100 °C for 40 
h. The mixture was cooled and then adsorbed on silica gel (about 40 g) and purified by flash 
chromatography (petroleum ether/EtOAc, 6:1) to afford homoallyl alcohol 1-91 (5.26 g, 93%) as 
colorless oil. Rf = 0.38 (petroleum ether/EtOAc, 6:1); []D
20
 = +14.2 (c 1, CHCl3); 
1
H NMR 
(400 MHz, CDCl3):  = 0.08 (s, 3H, Si(CH3)2), 0.10 (s, 3H, Si(CH3)2), 0.88 (s, 9H, SiC(CH3)3), 
1.55 (ddd, J = 14.4, 8.6, 8.3 Hz, 1H, 5-H), 1.65 (ddd, J = 14.4, 5.1, 2.8 Hz, 1H, 5-H), 1.76–1.91 
(m, 2H, 7-H), 2.18–2.22 (m, 2H, 3-H), 3.51 (dd, J = 6.6, 6.3 Hz, 2H, 8-H), 3.77–3.80 (dddd, J = 
11.6, 6.1, 3.3, 2.8 Hz, 1H, 4-H), 4.04–4.10 (dddd, J = 11.6, 6.3, 3.5, 1.5 Hz, 1H, 6-H), 4.44 (d, J 
= 11.9 Hz, 1H, OCH2Ph), 4.48 (d, J = 11.9 Hz, 1H, OCH2Ph), 5.05–5.13 (m, 2H, 1-H), 5.80 
(dddd, J =16.9, 10.6, 7.3, 7.1 Hz, 1H, 2-H), 7.26–7.35 (m, 5H, Ar-H); 13C NMR (100 MHz, 
CDCl3):  = −4.6 (Si(CH3)2), −4.3 (Si(CH3)2), 17.9 (SiC(CH3)3), 25.8 (SiC(CH3)3), 37.7 (C-7), 
42.2 (C-5), 42.8 (C-3), 66.6 (C-4), 69.7 (C-8), 70.2 (C-6), 73.0 (OCH2Ph), 117.5 (C-1), 127.6 
(CH, Ar), 127.6 (2CH, Ar), 128.4 (2CH, Ar), 134.8 (C-2), 138.3 (C, Ar); HRMS (ESI): 
[M+Na]
+
 calcd for C21H37O3SiNa 387.23259, found 387.232566. 
 
(4R,6S)-4-Allyl-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxane (1-92) 
 
A mixture of p-toluenesulphonic acid monohydrate (268 mg, 1.51 mmol) and alcohol 1-91 (5.49 
g, 15.1 mmol) in methanol (150 mL) was stirred at room temperature for 1 h to complete the 
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deprotection (TLC control). The reaction mixture was concentrated on the rotary evaporator to 
about 50 mL before it was diluted with 2,2-dimethoxypropane (150 mL, 602 mmol) and stirred 
for further 30 min at room temperature. The reaction mixture was concentrated in vacuo, the 
residue diluted with CH2Cl2 (500 mL), then washed with saturated NaHCO3 solution (150 mL) 
and saturated NaCl solution (150 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography (petroleum 
ether/EtOAc, 19:1) to yield acetal 1-92 (3.51 g, 80%) as colorless oil. Rf = 0.48 (petroleum 
ether/ethyl acetate, 17:3); []D
20
 = −9.0 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.15 
(ddd, J = 12.9, 11.6, 11.6 Hz, 1H, 5-H), 1.37 (s, 3H, 2-CH3), 1.42 (s, 3H, 2-CH3), 1.50 (ddd, J = 
12.9, 2.5, 2.5 Hz, 1H, 5-H), 1.66–1.82 (m, 2H, BnOCH2CH2), 2.09–2.18 (m, 1H, CH2CH=CH2), 
2.25–2.34 (m, 1H, CH2CH=CH2), 3.48–3.62 (m, 2H, BnOCH2CH2), 3.86 (dddd, J = 13.9, 6.3, 
3.8, 2.5 Hz, 1H, 6-H), 4.02 (dddd, J = 11.6, 7.3, 5.1, 2.5 Hz, 1H, 4-H), 4.48 (d, J = 12.1 Hz, 1H, 
PhCH2O), 4.52 (d, J = 12.1 Hz, 1H, PhCH2O), 5.01–5.11 (m, 2H, CH2CH=CH2), 5.79 (dddd, J = 
17.8, 10.4, 7.3, 6.6 Hz, 1H, CH2CH=CH2), 7.23–7.37 (m, 5H, Ar-H); 
13
C NMR (100 MHz, 
CDCl3):  = 19.8 (2-CH3), 30.2 (2-CH3), 36.5 (BnOCH2CH2), 36.6 (C-5), 40.8 (CH2CH=CH2), 
66.0 (C-4), 66.2 (BnOCH2CH2), 68.6 (C-6), 73.0 (OCH2Ph), 98.5 (C-2), 117.2 (CH2CH=CH2), 
127.5 (CH, phenyl), 127.6 (2CH, phenyl), 128.3 (2CH, phenyl), 134.2 (CH2CH=CH2), 138.5 (C, 
phenyl); HRMS (ESI): [M+Na]
+
 calcd for C18H26O3Na 313.17742, found 313.177541. 
 
2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethanol (1-93) 
 
A solution of alkene 1-92 (2.69 g, 9.3 mmol) in methanol/CH2Cl2 (7:3, 100 mL), containing 4-5 
drops of Sudan ΙΙΙ (1% in methanol) was cooled to −80 °C followed by bubbling ozone through 
the solution for 1 h until it became colorless. Residual O3 was removed by bubbling nitrogen 
through the solution. Thereafter, NaBH4 (3.50 g, 92.6 mmol) was added and the reaction mixture 
allowed to reach room temperature with the flask kept in the cooling bath. Now, H2O (40 mL) 
was added and the mixture concentrated to ~50 mL before it was extracted with ethyl acetate (3 
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× 60 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash chromatography (petroleum ether/EtOAc, 1:1) to 
furnish primary alcohol 1-93 (2.60 g, 97%) as colorless oil. Rf = 0.2 (petroleum ether/ethyl 
acetate, 1:1); []D
20
 = −10.0 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.28 (ddd, J = 12.9, 
11.6, 11.6 Hz, 1H, 5-H), 1.36 (s, 3H, 2-CH3), 1.44 (s, 3H, 2-CH3), 1.45 (ddd, J = 12.9, 2.5, 2.5 
Hz, 1H, 5-H), 1.64–1.80 (m, 4H, OBnCH2CH2, CH2CH2OH), 2.16 (s, 1H, OH), 3.49–3.67 (m, 
2H, BnOCH2CH2), 3.71–3.84 (m, 2H, CH2CH2OH), 4.02–4.18 (m, 2H, 4-H, 6-H), 4.48 (d, J = 
12.1 Hz, 1H, OCH2Ph), 4.52 (d, J = 12.1 Hz, 1H, OCH2Ph), 7.27–736 (m, 5H, Ar-H); 
13
C NMR 
(100 MHz, CDCl3):  = 19.9 (2-CH3), 30.2 (2-CH3), 36.4 (BnOCH2CH2), 36.7 (C-5), 38.0 
(CH2CH2OH), 60.9 (OBnCH2CH2), 65.9 (C-4), 66.0 (CH2CH2OH), 69.4 (C-6), 73.0 (OCH2Ph), 
98.6 (C-2), 127.5 (CH, Ar), 127.6 (2CH, Ar), 128.3 (2CH, Ar), 138.5 (C, Ar); HRMS (ESI): 
[M+Na]
+
 calcd for C17H26O4Na 317.17233, found 317.172357. 
 
2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl 4-
methylbenzenesulfonate (1-94)
163
 
 
To a mixture of alcohol 1-93 (2.60 g, 8.8 mmol), Et3N (3.69 mL, 26.5 mmol), DMAP (323 mg, 
2.7 mmol) in CH2Cl2 (50 mL), p-toluenesulphonyl chloride (3.37 g, 17.7 mmol) was added in 
one portion at 0 °C. The reaction mixture was allowed to stir overnight at room temperature 
before it was diluted with CH2Cl2 (70 mL), washed with saturated NaHCO3 solution (50 mL) and 
saturated NaCl solution (50 mL) then dried over Na2SO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography (petroleum ether/EtOAc, 4:1) to afford tosylate 1-
94 (3.42 g, 86%) as colorless oil. Rf = 0.28 (petroleum ether/EtOAc, 4:1); []D
20
 = −2.6 (c 1, 
CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.09 (ddd, J = 12.6, 11.6, 11.6 Hz, 1H, 5-H), 1.27 (s, 
3H, 2-CH3), 1.31 (s, 3H, 2-CH3), 1.39 (ddd, J = 12.6, 2.5, 2.5 Hz, 1H, 5-H), 1.63–1.81 (m, 4H, 
OBnCH2CH2, CH2CH2OTs), 2.43 (s, 3H, CH3, tosyl), 3.46–3.59 (m, 2H, OBnCH2CH2), 3.90 
(dddd, J = 11.4, 7.6, 4.8, 3.0 Hz, 1H, 4-H), 3.98 (dddd, J = 11.4, 7.6, 5.0, 2.8 Hz, 1H, 6-H), 4.07 
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(ddd, J = 9.8, 5.3, 4.5 Hz, 1H, CH2CH2OTs), 4.11–4.20 (m, 1H, CH2CH2OTs), 4.44 (d, J = 12.1 
Hz, 1H, OCH2Ph), 4.47 (d, J = 12.1 Hz, 1H, OCH2Ph), 7.23–7.37 (m, 7H, Ar-H), 7.78 (d, J = 8.3 
Hz, 2H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 19.7 (2-CH3), 21.6 (CH3, tosyl), 30.0 (2-CH3), 
35.5 (CH2CH2OTs), 36.5 (C-5), 36.8 (OBnCH2CH2), 64.9 (C-4), 65.9 (C-6), 66.1 
(OBnCH2CH2), 66.8 (CH2CH2OTs), 73.0 (OCH2Ph), 98.6 (C-2), 127.6 (CH, phenyl), 127.6 
(2CH, phenyl), 127.9 (2CH, tosyl), 128.4 (2CH, phenyl), 129.8 (2CH, tosyl), 133.1 (C, tosyl), 
138.5 (C, phenyl), 144.7 (C, tosyl); HRMS (ESI): [M+Na]
+
 calcd for C24H32O6SNa 471.18118, 
found 471.181152. 
 
(4R,6S)-4-(2-Azidoethyl)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxane (1-95)
163
 
 
A mixture of tosylate 1-94 (3.41 g, 7.6 mmol) and NaN3 (1.05 g, 15.2 mmol) in DMF (40 mL) 
was stirred for 12 h at room temperature. The reaction mixture was diluted with water (20 mL) 
and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude azide was purified by a simple filtration 
column (flash silica gel, petroleum ether/EtOAc, 4:1) yielding pure azide 1-95 (2.35 g, 97%) as 
colorless oil. Rf = 0.53 (petroleum ether/EtOAc, 4:1); []D
20
 = −3.0 (c 1, CHCl3); 
1
H NMR (400 
MHz, CDCl3):  = 1.17 (ddd, J = 12.6, 11.6, 11.6 Hz, 1H, 5-H), 1.36 (s, 3H, 2-CH3), 1.42 (s, 3H, 
2-CH3), 1.46 (ddd, J = 12.9, 2.5, 2.5 Hz, 1H, 5-H), 1.64–1.82 (m, 4H, BnOCH2CH2, 
CH2CH2N3), 3.30–3.45 (m, 2H, CH2CH2N3), 3.49–3.61 (m, 2H, BnOCH2CH2), 3.95 (dddd, J = 
11.6, 7.3, 4.8, 2.8 Hz, 1H, 4-H), 4.01 (dddd, J = 11.4, 7.6, 5.0, 2.5 Hz 1H, 6-H), 4.46 (d, J = 12.1 
Hz, 1H, OCH2Ph), 4.49 (d, J = 12.1 Hz, 1H, OCH2Ph), 7.24–7.38 (m, 5H, Ar-H); 
13
C NMR (100 
MHz, CDCl3):  = 17.8 (2-CH3), 28.1 (2-CH3), 33.6 (CH2CH2N3), 34.5 (BnOCH2CH2), 35.0 (C-
6’), 45.5 (CH2CH2N3), 63.9 (C-6), 64.0 (C-4), 64.1 (BnOCH2CH2), 73.0 (PhCH2O), 98.7 (C-2), 
127.6 (CH, phenyl), 127.6 (2CH, phenyl), 128.3 (2CH, phenyl), 138.5 (C, phenyl); HRMS 
(ESI): [M+Na]
+
 calcd for C17H25N3O3Na 342.17881, found 342.178839. 
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2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethanamine (1-96)
163
 
 
To a solution of azide 1-95 (2.55 g, 8.0 mmol) in a mixture of THF (50 mL) and H2O (5 mL), 
PPh3 (4.19 g, 16.0 mmol) was added and the mixture was stirred at room temperature for 10–12 
h. The reaction mixture was concentrated to remove most of the THF. Benzene (100 mL) was 
added and the reaction mixture was concentrated to remove water as azeotrope. This 
manipulation was repeated once. The crude residue was purified by flash chromatography 
(CH2Cl2/MeOH/Et3N, 9.5:0.4:0.1) to furnish amine 1-96 (2.2 g, 94%) as colorless oil. Rf = 0.29 
(CH2Cl2/MeOH/Et3N, 9.5:0.4:0.1); []D
20
 = −10.0 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  
= 1.19 (ddd, J = 12.6, 11.6, 11.6 Hz, 1H, 5-H), 1.35 (s, 3H, 2-CH3), 1.41 (s, 3H, 2-CH3), 1.44 
(ddd, J = 12.6, 2.5, 2.3 Hz, 1H, 5-H), 1.53–1.80 (m, 4H, BnOCH2CH2, CH2CH2NH2), 1.97 (br, s, 
2H, NH2), 2.80, (d, J = 6.8, 6.6 Hz, 2H, CH2CH2NH2), 3.51 (ddd, J = 9.3, 5.8, 5.8 Hz, 1H, 
BnOCH2CH2), 3.54–3.61 (m, 1H, BnOCH2CH2), 3.94 (dddd, J = 11.4, 7.3, 4.8, 2.8 Hz, 1H, 4-
H), 4.02 (dddd, J = 11.4, 7.6, 5.0, 2.5 Hz, 1H, 6-H), 4.45 (d, J = 11.9 Hz, 1H, OCH2Ph), 4.49 (d, 
J = 11.9 Hz, 1H, OCH2Ph), 7.26–7.35 (m, 5H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 19.9 (2-
CH3), 30.2 (2-CH3), 36.5 (BnOCH2CH2), 37.0 (C-5), 38.5 (CH2CH2NH2), 39.4 (CH2CH2NH2), 
66.0 (C-4), 66.1 (BnOCH2CH2), 67.7 (C-6), 73.0 (OCH2Ph), 127.5 (CH, phenyl), 127.6 (2CH, 
phenyl), 128.34 (2CH, phenyl), 138.49 (C, phenyl); HRMS (ESI): [M+Na]
+
 calcd for 
C17H27NO3Na 294.20637, found 294.206401. 
 
(Z)-tert-Butyl((1-methoxybuta-1,3-dien-1-yl)oxy)dimethylsilane (1-98)
49
 
 
To a cooled (0 

C) solution of diisopropylamine (8.81 mL, 62.4 mmol) in THF (100 mL) was 
added dropwise n-BuLi (24.0 mL, 60 mmol, 2.5M in hexane) followed by stirring the mixture for 
15 min. The mixture was cooled to −78 C and subjected to the successive addition of DMPU 
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(9.06 mL, 74.9 mmol), trans-methylcrotonate 1-97 (5.0 g, 49.9 mmol) and a solution of tert-
butyldimethylsilyl chloride (9.41 g, 62.4 mmol) in THF (10 mL) after a 15 min interval each. 
The reaction mixture was stirred for additional 45 min and allowed to stir for 2 h at room 
temperature, treated with saturated NaHCO3 solution (50 mL) and extracted with n-hexane (3 × 
100 mL). The combined organic layers were washed with saturated NaHCO3 solution (4 × 50 
mL) and saturated NaCl solution, dried over MgSO4, filtered and concentrated on a rotary 
evaporator. The residue was distilled out under high vacuum (1 mbar, distillate temp. 60–70 C) 
to yield ketene acetal 1-98 (9.2 g, 86%). 
1
H NMR (400 MHz, CDCl3):  = 0.17 (s, 6H, 
Si(CH3)2), 0.94 (s, 9H, SiC(CH3)3), 3.56 (s, 3H, OCH3), 4.46 (d, J = 10.4 Hz, 1H, 2-H), 4.59 (dd, 
J = 10.4, 2.0 Hz, 1H, 4-H), 4.83 (dd, J = 17.2, 2.0 Hz, 1H, 4-H), 6.51 (ddd, J = 17.2, 10.4, 10.4 
Hz, 1H, 3-H); 
13
C NMR (100 MHz, CDCl3):  = −4.3 (2CH3, Si(CH3)2), 18.1 (SiC(CH3)3), 25.6 
(SiC(CH3)3), 54.8 (OCH3), 80.2 (C-2), 106.7 (C-4), 132.4 (C-3), 158.7 (C-1). 
 
N-((4-Methylphenyl)sulfonyl)-(L)-tryptophan (1-100)
49
 
 
(L)-Tryptophan 1-99 (5.0 g, 24.5 mmol) was dissolved in a mixture of THF/water (1:9, 30 mL) 
to which triethylamine (6.82 mL, 49.0 mmol) and p-toluenesulphonyl chloride (4.67g, 24.5 
mmol) in THF (10 mL) were added subsequently using a dropping funnel. The mixture was 
stirred for 3 h and then extracted with diethyl ether (2 × 20 mL). The ether layers were discarded. 
Then 1N HCl was added to the aqueous phase which was extracted with ethyl acetate (3 ×30 
mL). The combined organic layers were dried over MgSO4, filtered, concentrated and the crude 
brownish residue was purified by flash chromatography (methanol/toluene, 1:8) to afford N-Ts-
L-tryptophan 1-100 (7.01 g, 80%) as brownish solid. Rf = 0.2 (methanol/toluene, 1:8); [α]D
22
 = 
−39.5 (c 1, ethanol); 1H NMR (400 MHz, CD3OD):  = 2.29 (s, 3H, CH3), 2.97 (dd, J = 14.4, 8.3 
Hz, 1H, CH2), 3.18 (dd, J = 14.4, 5.3 Hz, 1H, CH2), 4.04 (dd, J = 8.3, 5.3 Hz, 1H, CH), 6.9 (ddd, 
J = 8.1, 7.1, 1.0 Hz, 1H, Ar-H, tryp), 6.98 (s, 1H, Ar-H, tryp), 7.02 (d, J = 7.83 Hz, 2H, Ar-H, 
tosyl), 7.04 (ddd, J = 7.8, 7.1, 1.0 Hz, Ar-H, tryp), 7.08–7.22 (m, 1H), 7.26 (d, J = 8.1 Hz, 1H, 
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Ar-H, tryp), 7.36 (d, J = 7.8 Hz, 1H, Ar-H, tryp), 7.39 (d, J = 8.3 Hz, 2H, Ar-H, tosyl); 13C 
NMR (100 MHz, CD3OD):  = 21.5 (CH3), 30.0 (CH2), 57.9 (CH), 110.2 (C, Ar), 112.2 (CH, 
Ar), 119.6 (CH, Ar), 119.7 (CH, Ar), 122.2 (CH, Ar), 124.8 (CH, Ar), 127.7 (2CH, Ar), 128.4 
(C, Ar), 130.2 (2CH, Ar), 138.0 (C, Ar), 138.6 (C, Ar), 144.2 (C, Ar), 175.3 (C=O). 
 
3-(Benzyloxy)propanal (1-101)
164
 
 
To a cooled solution (−78 C) of oxalyl chloride (6.06 mL, 70.7 mmol) in CH2Cl2 (200 mL) in a 
three neck flask fitted with thermometer, rubber septum and pressure equalizer with N2 inlet, was 
added DMSO (10.04 mL, 141.4 mmol) dropwise very slowly to maintain the temperature below 
−75 C. After 40 min a solution of alcohol 1-87 (9.79 g, 58.9 mmol) in CH2Cl2 (50 mL) was 
added dropwise using a syringe pump over 20 min followed by addition of triethylamine (41.05 
mL, 294.5 mmol) after 30 min. The reaction mixture was allowed to warm slowly to room 
temperature and stirred for 30 min before it was quenched with saturated NH4Cl solution. The 
organic layer was separated and aqueous layer was extracted with CH2Cl2 (2 × 50 mL) and the 
combined organic layers were washed with saturated NaHCO3 solution (100 mL) and saturated 
NaCl solution. The organic layer was dried over Na2SO4, filtered, concentrated and purified by 
flash chromatography (EtOAc/petroleum ether, 1:3) to give aldehyde 1-101 (9.23 g, 95%) as 
colorless oil. Rf = 0.46 (EtOAc/petroleum ether, 1:3); 
1
H NMR (400 MHz, CDCl3):  = 2.69 
(dt, J = 6.3, 2.0 Hz, 2H, 2-H), 3.81 (t, J = 6.1 Hz, 3H, 3-H), 4.53 (s, 2H, OCH2Ph), 7.24-7.39 
(5H, Ar-H), 9.79 (t, J = 1.8 Hz, 1-H); 13C NMR (100 MHz, CDCl3):  = 43.9 (C-2), 63.8 (C-3), 
73.2 (OCH2Ph), 127.7 (2CH, phenyl), 127.8 (CH, phenyl), 128.4 (2CH, phenyl), 137.8 (C,  
phenyl), 201.1 (C-1). 
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(R,E)-Methyl 7-(benzyloxy)-5-hydroxyhept-2-enoate (1-103)
49
 
 
Dichlorophenylborane (1.61 g, 12.2 mmol) was added to a mixture of N-Ts-(L)-tryptophan 1-100 
(4.39 g, 12.2 mmol) in CH2Cl2 (100 mL) dropwise at room temperature which led to persistent 
HCl gas evolution immediately. The resulting dark brown solution was stirred at room 
temperature for 1 h. The solvent was evaporated under reduced pressure and the dark brown 
foamy solid was dissolved in n-butyronitrile (44 mL). The solution was cooled to −78 C and a 
mixture of aldehyde 1-101 (2.01 g, 12.2 mmol), 2-propanol (1.14 mL, 14.7 mmol) and ketene 
acetal 1-98 (3.15 g, 14.7 mmol) in n-butyronitrile (10 mL) was added dropwise using a syringe 
pump over 40 min. The reaction mixture was stirred for 4 h, quenched with saturated NaHCO3 
solution (30 mL), brought to the room temperature and extracted with diethyl ether (3 × 60 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated under vacuum. 
Purification of the crude residue by flash chromatography (EtOAc/petroleum ether, 3:7) afforded 
δ-hydroxy-α,β-unsaturated ester 1-103 (1.95 g, 60%, 88% ee by Mosher ester method) as 
colorless oil. Rf = 0.4 (EtOAc/petroleum ether, 2:3); [α]D
22
 = +10.1 (c 1, CHCl3); 
1
H NMR (400 
MHz, CDCl3):  = 1.68–1.83 (m, 2H, 6-H), 2.30–2.44 (m, 2H, 4-H), 3.64 (ddd, J = 9.3, 7.6, 5.0 
Hz, 1H, 7-H), 3.68–3.74 (m, 1H, 7-H), 3.71 (s, 3H, OCH3), 3.92–4.01 (m, 1H, 5-H), 4.51 (s, 2H, 
CH2Ph), 5.88 (ddd, J = 15.7, 1.5, 1.3 Hz, 1H, 2-H), 6.98 (ddd, J = 15.7, 7.6, 7.3 Hz, 1H, 3-H), 
7.25–7.37 (m, 5H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 35.9 (C-6), 40.5 (C-4), 51.4 
(OCH3), 68.9 (C-7), 70.2 (C-5), 73.4 (CH2Ph), 123.2 (C-2), 127.7 (2CH, phenyl), 127.8 (CH, 
phenyl), 128.5 (2CH, phenyl), 137.7 (C, phenyl), 145.5 (C-3), 166.7 (C-1); HRMS (ESI): 
[M+Na]
+
 calcd for C18H26O5Na 287.12538, found 287.125232. 
 
Methyl 2-((2S,4S,6S)-6-(2-(benzyloxy)ethyl)-2-phenyl-1,3-dioxan-4-yl)acetate (1-104)
165
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To a cooled (salt-ice bath) solution of enoate 1-103 (2.02 g, 7.6 mmol) in THF (40 mL) under N2 
atmosphere was added freshly distilled benzaldehyde (0.86 mL, 8.4 mmol), and potassium tert-
butoxide (86 mg, 0.76 mmol). This manipulation was repeated three times in 15 min intervals. 
After additional 30 min of stirring, the reaction mixture was quenched by addition of pH 7 
phosphate buffer solution (30 mL). The mixture was extracted using diethyl ether (3 × 70 mL), 
the combined organic layers were washed with saturated NaCl solution, dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified by flash chromatography 
(EtOAc/petroleum ether, 1:9 then 1:4) to yield acetal 1-104 (1.86 g, 66%) as colorless thick oil. 
Rf = 0.37 (EtOAc/petroleum ether, 2:3); [α]D
21
 = −27.3 (c 1, CHCl3); 
1
H NMR (400 MHz, 
CDCl3):  = 1.46 (ddd, J = 12.9, 11.4, 11.1 Hz, 1H, 5-H), 1.73 (ddd, J = 12.9, 2.3, 2.3 Hz, 1H, 5-
H), 1.81–1.99 (m, 2H, BnOCH2CH2), 2.52 (dd, J = 15.7, 6.1 Hz, 1H, CH2CO2Me), 2.74 (dd, J = 
15.7, 7.1 Hz, 1H, CH2CO2Me), 3.60 (ddd, J = 9.3, 5.6, 5.6 Hz, 1H, BnOCH2CH2), 3.66–3.76 (m, 
1H, BnOCH2CH2), 3.70 (m, 3H, OCH3), 4.08 (dddd, J = 10.6, 8.3, 4.5, 2.5 Hz, 1H, 6-H), 4.32 
(dddd, J = 11.1, 8.8, 6.3, 2.3 Hz, 1H, 4-H), 4.50 (d, J = 11.9 Hz, 1H, OCH2Ph), 4.54 (d, J = 11.9 
Hz, 1H, OCH2Ph), 5.56 (s, 1H, CHPh), 7.23–7.38 (m, 8H, Ar-H), 7.42–7.47 (m, 2H, Ar-H); 
13
C 
NMR (100 MHz, CDCl3):  = 36.0 (BnOCH2CH2), 36.6 (C-5), 40.3 (CH2CO2Me), 51.7 
(OCH3), 65.9 (BnOCH2CH2), 73.0 (OCH2Ph), 73.1 (C-4), 73.6 (C-6), 100.5 (CHPh), 126.0 
(2CH, Ar), 127.6 (CH, Ar), 127.6 (2CH, Ar), 128.1 (2CH, Ar), 128.4 (2CH, Ar), 128.6 (CH, Ar), 
138.4 (2CH, Ar), 171.1 (CO2Me); HRMS (ESI): [M+Na]
+
 calcd for C22H26O5Na 393.16725, 
found 393.167621. 
 
Methyl 2-((4S,6S)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate (1-105) 
 
Acetal 1-104 (3.04 g, 8.2 mmol) was dissolved in CH2Cl2 (30 mL) to which 2,2-
dimethoxypropane (30 mL) and p-toluenesulphonic acid monohydrate (312 mg, 0.16 mmol) 
were added. The mixture was heated to reflux for 24 h and brought to room temperature. The 
volatiles were evaporated under vacuum and the residual mixture was diluted with CH2Cl2 (100 
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mL), washed with saturated NaHCO3 solution (50 mL), saturated NaCl solution, dried over 
Na2SO4, filtered and concentrated in vacuo. Flash chromatography (EtOAc/petroleum ether, 1:9) 
furnished acetonide ester 1-105 (2.51 g, 95%) as colorless oil. Rf = 0.52 (EtOAc/petroleum ether, 
1:4); [α]D
20
 = −18.34 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.18 (ddd, J = 12.6, 12.6, 
11.6 Hz, 1H, 5-H), 1.34 (s, 3H, 2-CH3), 1.43 (m, 3H, 2-CH3), 1.57 (ddd, J = 12.6, 2.5, 2.3 Hz, 
1H, 5-H), 1.67–1.81 (m, 2H, BnOCH2CH2), 2.36 (dd, J = 15.4, 6.1 Hz, 1H, CH2CO2Me), 2.53 
(dd, J = 15.4, 6.8 Hz, 1H, CH2CO2Me), 3.48–3.62 (m, 2H, BnOCH2CH2), 3.67 (s, 3H, OCH3), 
4.05 (dddd, J = 11.4, 6.8, 5.0, 2.8 Hz, 1H, 6-H), 4.29 (dddd, J = 11.4, 8.6, 4.8, 2.3 Hz, 1H, 4-H), 
4.46 (d, J = 12.1 Hz, 1H, OCH2Ph), 4.50 (d, J = 12.1 Hz, 1H, OCH2Ph), 7.24–7.36 (m, 5H, Ar-
H); 
13
C NMR (100 MHz, CDCl3):  = 20.2 (2-CH3), 30.5 (2-CH3), 36.9 (BnOCH2CH2), 37.0 (C-
5), 41.7 (CH2CO2Me), 52.0 (OCH3), 66.3 (C-4), 66.3 (C-6), 66.5 (BnOCH2CH2), 73.4 
(OCH2Ph), 99.2 (C-2), 128.0 (CH, phenyl), 128.0 (2CH, phenyl), 128.8 (2CH, phenyl), 138.9 (C, 
phenyl), 171.8 (CO2Me); HRMS (ESI): [M+Na]
+
 calcd for C18H26O5Na 345.16725, found 
345.167000. 
 
2-((4S,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetamide (1-106)
166
 
 
Ester 1-105 (450 mg, 1.4 mmol) was heated in a screw cap bottle in a mixture of 25% aq NH4OH 
solution (5 mL) and methanol (10 mL) for 48 h. The mixture was cooled to room temperature 
and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with 
saturated NaCl solution (5 mL), dried over anhydrous MgSO4 and filtered. The filtrate was 
concentrated and purified by flash chromatography (methanol/CH2Cl2, 1:20) to yield amide 1-
106 (327 mg, 76%) as yellow colored thick oil. Rf = 0.31 (methanol/CH2Cl2, 1:20); [α]D
20
 = 
−5.34 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.24 (ddd, J = 12.6, 11.6, 11.6 Hz, 1H, 5-
H), 1.37 (s, 3H, 2-CH3), 1.43 (s, 3H, 2-CH3), 1.52 (ddd, J = 12.9, 2.5, 2.3 Hz, 1H, 5-H), 1.65–
1.80 (m, 2H, BnOCH2CH2), 2.32 (dd, J = 15.4, 4.0 Hz, 1H, CH2CONH2), 2.39 (dd, J = 15.1, 7.6 
Hz, 1H, CH2CONH2), 3.46–3.62 (m, 2H, BnOCH2CH2), 4.05 (dddd, J = 11.9, 7.6, 5.0, 2.3 Hz, 
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1H, 4-H), 4.21 (dddd, J = 11.4, 7.3, 4.3, 2.8 Hz, 1H, 6-H), 4.45 (d, J = 12.1 Hz, 1H, OCH2Ph), 
4.49 (d, J = 11.9 Hz, 1H, OCH2Ph), 5.74 (s, 1H, CONH2), 6.31 (s, 1H, CONH2), 7.23–7.38 (m, 
5H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 19.8 (2-CH3), 30.1 (2-CH3), 36.2 (C-5), 36.3 
(BnOCH2CH2), 42.8 (CH2CO2Me), 65.9 (BnOCH2CH2), 65.9 (C-4), 66.2 (C-6), 73.0 (OCH2Ph), 
98.9 (C-2), 127.5 (CH, phenyl), 127.6 (2CH, phenyl), 128.3 (2CH, phenyl), 138.4 (C, phenyl), 
173.2 (C=O, amide); HRMS (ESI): [M+Na]
+
 calcd for C17H25NO4Na 330.16758, found 
330.167335. 
 
2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethanamine (1-96) 
 
Amide 1-106 (350 mg, 0.14 mmol) in THF (1.5 mL) was added to a cooled (0 °C) solution of 
LiAlH4 in THF (2 mL) dropwise under nitrogen atmosphere. The reaction mixture was heated to 
reflux for overnight (~12 h), cooled to room temperature and 3N KOH (2 mL) was added to the 
mixture. After 2 h of stirring, the mixture was extracted with ethyl acetate (3 × 10 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification 
by flash chromatography (MeOH/CH2Cl2/25% NH4OH, 1:9:0.005) afforded amine 1-96 (240 
mg, 72%) as colorless oil. []D
20
 = −9.1 (c 1, CHCl3). All spectral information is mentioned 
above. 
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1-(2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2-(4-
fluorophenyl)-5-isopropyl-3-phenyl-1H-pyrrole (1-108) 
 
A mixture of 1,4-diketone 1-27 (500 mg, 1.7 mmol), amine 1-96 (516 mg, 1.8 mmol), and p-
TSA•H2O (64 mg, 0.33 mmol) in xylene (20 mL) was refluxed for 7 days using a Dean-Stark 
trap to remove water as an azeotropic mixture. The completion of the reaction was checked by 
TLC. The reaction mixture was diluted with diethyl ether (30 mL), washed with saturated 
NaHCO3 (30 mL) and saturated NaCl solution (30 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (petroleum ether/diethyl ether, 9:1) to afford pyrrole 1-108 (520 mg, 68%) as 
colorless sticky solid. Rf = 0.25 (petroleum ether/diethyl ether, 9:1); []
20
D = +4.0 (c 1.0, 
CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 0.95 (ddd, J = 12.6, 11.6, 11.6 Hz, 1H, 5’-H), 1.15 
(ddd, J = 12.6, 2.3, 2.3 Hz, 1H, 5’-H), 1.28–1.38 (m, 12H, 2’-CH3, CH(CH3)2), 1.44–1.75 (m, 
4H, NCH2CH2, CH2CH2OBn), 3.01 (ap. sept, J = 6.8 Hz, 1H, CH(CH3)2), 3.44–3.59 (m, 3H, 4’-
H, CH2CH2OBn), 3.75–3.85 (m, 1H, NCH2CH2), 3.88–3.99 (m, 2H, NCH2CH2, 6’-H), 4.44 (d, J 
= 12.1 Hz, 1H, OCH2Ph), 4.47 (d, J = 12.1 Hz, 1H, OCH2Ph), 6.18 (s, 1H, 4-H, pyrrole), 7.00–
7.17 (m, 7H, Ar-H), 7.23–7.37 (m, 7H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.8 (2’-CH3), 
23.3 (CH(CH3)2), 23.7 (CH(CH3)2), 25.5 (CH(CH3)2), 30.1 (2’-CH3), 36.4 (NCH2CH2), 36.5 (C-
5’), 37.9 (CH2CH2OBn), 39.8 (NCH2CH2), 65.7 (C-6’), 66.0 (CH2CH2OBn), 66.3 (C-4’), 72.9 
(OCH2Ph), 98.4 (C-2’), 103.4 (C-4, pyrrole), 115.6 (d, JCF = 21.2 Hz, CH, Ar), 122.0 (C, Ar), 
124.8 (CH, Ar), 127.5 (CH, Ar), 127.5 (CH, Ar), 127.6 (CH, Ar), 127.8 (C, Ar), 128.0 (CH, Ar), 
128.3 (CH, Ar), 129.8 (d, JCF = 3.7 Hz, C, Ar), 132.9 (d, JCF = 8.1 Hz, CH, Ar), 136.5 (C, Ar), 
138.5 (C, Ar), 140.4 (C, Ar), 162.2 (d, JCF = 246.6 Hz, C, Ar); HRMS (ESI): [M+Na]
+
 calcd for 
C36H42FNO3Na 578.30409, found 578.304437. 
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1-(2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2-(4-
fluorophenyl)-4-iodo-5-isopropyl-3-phenyl-1H-pyrrole (1-109) 
 
To a solution of pyrrole 1-108 (206 mg, 0.37 mmol) in DMF (5 mL), N-iodosuccinimide (100 
mg, 0.45 mmol) was added in one portion and the reaction mixture was stirred for 30 min at 
room temperature. The reaction mixture was diluted with diethyl ether (15 mL), washed with 
10% Na2S2O3 solution (5 mL), saturated NaHCO3 solution (10 mL) and saturated NaCl solution 
(10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The 
crude product was purified by flash chromatography (petroleum ether/EtOAc, 9:1) to give 
iodopyrrole 1-109 (230 mg, 91%) as colorless oil. Rf = 0.3 (petroleum ether/EtOAc, 9:1); []D
20
 
= −2.0 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 0.98 (ddd, J = 12.4, 11.6, 11.6 Hz, 1H, 
5’-H), 1.20 (ddd, J = 12.9, 2.5, 2.3 Hz, 1H, 5’-H), 1.29 (s, 3H, 2’-CH3), 1.32 (s, 3H, 2’-CH3), 
1.49 (d, J = 7.1 Hz, 3H, CH(CH3)2), 1.51 (d, J = 7.1 Hz, 3H, CH(CH3)2), 1.56–1.75 (m, 4H, 
NCH2CH2, CH2CH2OBn), 3.32 (ap. sept, J = 7.1 Hz, 1H, CH(CH3)2), 3.44–3.58 (m, 2H, 
CH2CH2OBn), 3.61 (dddd J = 11.1, 7.1, 4.3, 3.0 Hz, 1H, 4’-H), 3.80 (ddd, J = 15.7, 10.4, 5.6 Hz, 
1H, NCH2CH2), 3.92 (dddd, J = 11.4, 7.3, 5.1, 2.5 Hz, 1H, 6’-H), 4.04 (ddd, J = 15.4, 10.3, 4.5 
Hz, 1H, NCH2CH2), 4.44 (d, J = 12.1 Hz, 1H, OCH2Ph), 4.48 (d, J = 12.1 Hz, 1H, OCH2Ph), 
6.89–7.00 (m, 2H, Ar-H), 7.06–7.38 (m, 7H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.8 (2’-
CH3), 21.4 (CH(CH3)2), 21.5 (CH(CH3)2), 27.2 (CH(CH3)2), 30.0 (2’-CH3), 36.4 (CH2CH2OBn), 
36.5 (C-5’), 38.3 (NCH2CH2), 41.2 (NCH2CH2), 65.7 (C-6’), 66.0 (CH2CH2OBn), 66.5 (C-4’), 
72.9 (OCH2Ph), 98.5 (C-2’), 117.2 (d, JCF = 21.2 Hz, 2CH, aryl), 126.0 (CH, aryl), 126.5 (C, 
aryl), 127.4 (CH, aryl), 127.5 (CH, aryl), 127.6 (CH, aryl), 128.3 (CH, aryl), 129.8 (d, JCF = 3.7 
Hz, C, aryl), 128.7 (C, aryl), 129.7 (C, aryl), 130.9 (2CH, aryl), 132.9 (C-1, JCF = 8.1 Hz, 2CH, 
aryl), 135.9 (C, aryl), 137.1 (C, aryl), 138.5 (C, aryl), 162.1 (d, JCF = 247.4 Hz, C, aryl); HRMS 
(ESI): [M+Na]
+
 calcd for C36H41FINO3Na 704.20074, found 704.200369. 
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1-(2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-5-(4-
fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid (1-110) 
 
A solution of iodopyrrole 1-109 (201 mg, 0.29 mmol) in THF (10 mL) was cooled to −80 °C, 
then t-BuLi (0.387 mL, 0.62 mmol, 2.5M in hexane) was added dropwise. After 10 min, excess 
of CO2 gas was bubbled through the reaction mixture with stirring for 15 min. Thereafter, the 
mixture was allowed to reach room temperature within 1 h. The progress of the reaction was 
checked by TLC. Saturated NH4Cl solution (2 mL) was added and the mixture was extracted 
with ethyl acetate (3 × 30 mL). The combined organic layers were washed with saturated NaCl 
solution, dried over Na2SO4, filtered and concentrated. The residue was purified by flash 
chromatography (petroleum ether/EtOAc, 8:2) to furnish acid 1-110 (144 mg, 81%) as white 
solid, m.p. 73–78 °C. Rf = 0.3 (petroleum ether/EtOAc, 7:3); []D
20
 = −1.7 (c 1, CHCl3); 
1
H 
NMR (400 MHz, CDCl3):  = 0.97 (ddd, J = 12.4, 11.9, 11.6 Hz, 1H, 5’-H), 1.19 (ddd, J = 13.1, 
2.3, 2.3 Hz, 1H, 5’-H), 1.28 (s, 3H, 2’-CH3), 1.31 (s, 3H, 2’-CH3), 1.46 (d, J = 7.1 Hz, 3H, 
CH(CH3)2), 1.47 (d, J = 7.3 Hz, 3H, CH(CH3)2), 1.54–1.75 (m, 4H, NCH2CH2, CH2CH2OBn), 
3.43–3.66 (m, 4H, 4’-H, CH2CH2OBn, CH(CH3)2), 3.77 (ddd, J = 14.9, 10.6, 5.8 Hz, 1H, 
NCH2CH2), 3.92 (dddd, J = 11.8, 7.3, 4.8, 2.3 Hz, 1H, 6’-H), 4.04 (ddd, J = 14.9, 9.3, 4.5 Hz 1H, 
NCH2CH2), 4.44 (d, J = 12.1 Hz, 1H, OCH2Ph), 4.48 (d, J = 12.1 Hz, 1H, OCH2Ph), 6.90–6.97 
(m, 2H, Ar-H), 7.02–7.16 (m, 7H, Ar-H), 7.25–7.36 (m, 5H, Ar-H); 13C NMR (100 MHz, 
CDCl3):  = 19.8 (2’-CH3), 20.8 (CH(CH3)2), 26.0 (CH(CH3)2), 30.0 (2’-CH3), 36.4 
(CH2CH2OBn), 36.4 (C-5’), 37.9 (NCH2CH2), 41.1 (NCH2CH2), 65.7 (C-6’), 66.0 
(CH2CH2OBn), 66.5 (C-4’), 72.9 (OCH2Ph), 98.5 (C-2’), 109.4 (C, aryl), 115.2 (d, JCF = 21.2 
Hz, CH, aryl), 125.8 (CH, aryl), 127.2 (CH, aryl), 127.6 (CH, aryl), 127.6 (CH, aryl), 128.1 (d, 
JCF = 2.9 Hz, C, aryl), 128.3 (CH, aryl), 130.0 (C, aryl), 130.5 (CH, aryl), 133.2 (d, JCF = 8.1 Hz, 
CH, aryl), 135.4 (C, aryl), 138.4 (C, aryl), 144.9 (C, aryl), 162.2 (d, JCF = 248.1 Hz, C, aryl), 
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170.7 (C, aryl), 177.3 (COOH); HRMS (ESI): [M+Na]
+
 calcd for C37H42FNO5Na 622.29392, 
found 622.293491. 
 
1-(2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-5-(4-
fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (1-111) 
 
To a solution of acid 1-110 (73 mg, 0.12 mmol) and aniline (13 μL, 0.15 mmol) in CH2Cl2 (5 
mL), DIPEA (63 μL, 0.36 mmol) was added and the reaction mixture was cooled to 0 °C. 
PyBrOP (85 mg, 0.18 mmol) was then added and the mixture allowed to stir at room temperature 
for 4 h. Completion of the reaction was checked by TLC. The reaction mixture was diluted with 
CH2Cl2 (5 mL), washed with water (3 × 5 mL) and saturated NaCl solution. The organic layer 
was dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by 
flash chromatography (petroleum ether/EtOAc, 4:1) to afford amide 1-111 (65 mg, 82%) as 
white solid, m.p. 75–82 °C. Rf = 0.29 (petroleum ether/EtOAc, 4:1); []D
20
 = −1.5 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.00 (ddd, J = 12.4, 11.6, 11.6 Hz, 1H, 5’-H), 1.14–1.26 (m, 
1H, 5’-H), 1.29 (s, 3H, 2’-CH3), 1.33 (s, 3H, 2’-CH3), 1.52 (d, J = 7.1 Hz, 6H, CH(CH3)2), 1.58–
1.77 (m, 4H, NCH2CH2, CH2CH2OBn), 3.42–3.70 (m, 4H, 4’-H, CH2CH2OBn, CH(CH3)2), 3.80 
(ddd, J = 14.6, 9.8, 6.3 Hz, 1H, NCH2CH2), 3.89–3.99 (m, 1H, 6’-H), 4.06 (ddd, J = 14.9, 9.1, 
4.5 Hz, 1H, NCH2CH2), 4.35 (d, J = 12.4 Hz, 1H, OCH2Ph), 4.48 (d, J = 12.4 Hz, 1H, OCH2Ph), 
6.85 (s, 1H, NH), 6.92–7.02 (m, 3H, Ar-H), 7.03–7.10 (m, 2H, Ar-H), 7.11–7.23 (m, 9H, Ar-H), 
7.24–7.40 (m, 5H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.8 (2’-CH3), 21.5 (CH(CH3)2), 
21.7 (CH(CH3)2), 26.1 (CH(CH3)2), 30.0 (2’-CH3), 36.4 (CH2CH2OBn), 36.4 (C-5’), 38.1 
(NCH2CH2), 40.9 (NCH2CH2), 65.7 (C-6’), 66 0 (CH2CH2OBn), 66.5 (C-4’), 72.9 (OCH2Ph), 
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98.5 (C-2’), 115.2 (C, aryl), 115.3 (d, JCF = 21.2 Hz, CH, aryl), 119.5 (CH, aryl), 121.7 (C, aryl), 
123.5 (CH, aryl), 126.5 (CH, aryl), 127.6 (CH, aryl), 127.6 (CH, aryl), 128.2 (C, aryl), 128.3 
(CH, aryl), 128.6 (CH, aryl), 128.7 (C, aryl), 130.5 (CH, aryl), 133.2 (d, JCF = 8.1 Hz, C, aryl), 
134.6 (C, aryl), 138.4 (d, JCF = 7.3 Hz, CH, aryl), 141.5 (C, aryl), 149.9 (C, aryl), 141.5 (C, aryl), 
162.2 (d, JCF = 248.1 Hz, C, aryl), 164.8 (CONH); HRMS (ESI): [M+Na]
+
 calcd for 
C43H47FO4Na 697.34121, found 697.341636. 
 
5-(4-Fluorophenyl)-1-(2-((4R,6S)-6-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2-
isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (1-76) 
 
A solution of benzyl ether 1-108 (20 mg, 0.03 mmol) containing 20% Pd(OH)2 on carbon (5 mg, 
25 wt%), cyclohexene (1 mL) and ethanol (2 mL) was stirred for 4 h at 80 °C. After cooling, the 
catalyst was filtered off, and the filtrate concentrated in vacuo. The crude product was purified 
by flash chromatography (petroleum ether/EtOAc, 3:2) to afford alcohol 1-76 (15 mg, 86%) as 
white solid, m.p. 75–85 °C. Rf = 0.11 (petroleum ether/EtOAc, 6:4); []D
20
 = −6.0 (c 1, CHCl3). 
Spectral details are reported above. 
 
1-Nitro-4-vinylbenzene (1-114)
79
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In a well stirred mixture of zinc powder (19.57 g, 0.30 mol) in THF (300 mL) in an ice bath, 
CH2I2 (13.43 mL, 0.17 mol) was added dropwise carefully (sudden exotherm is possible after 
addition) using dropping funnel. The mixture was stirred for 30 min at room temperature, then 
Ti(OiPr)4 (9.96 mL, 0.033 mol) was added over 20 min and stirring was continued for 30 min 
before 4-nitro benzaldehyde 1-117 (5.0 g, 0.033 mol) in THF (50 mL) was added to the reaction 
mixture. After being stirred for 3 h at room temperature excess of zinc was removed by filtration 
through celite and the filtrate was diluted with diethyl ether (100 mL). 1N HCl was added to the 
solution until a clear orange red color persisted. The organic layer was separated and the aqueous 
layer extracted with diethyl ether (3 × 40 mL). The combined organic layers were washed with 
saturated NaHCO3 solution, saturated NaCl solution, dried over MgSO4, and concentrated in 
vacuo. Purification by flash chromatography (petroleum ether/diethyl ether, 25:1) afforded 
styrene 1-114 (4.69 g, 94%) as yellow colored liquid which solidified at low temperature. Rf = 
0.36 (petroleum ether/diethyl ether, 25:1); 
1
H NMR (400 MHz, CDCl3):  = 5.48 (d, J = 10.9 
Hz, 1H, CH=CH2), 5.92 (d, J = 17.4 Hz, 1H, CH=CH2), 6.77 (dd, J = 10.9, 17.4 Hz, 1H, 
CH=CH2), 7.52 (d, J = 8.6 Hz, 2H, Ar-H), 8.17 (d, J = 8.8 Hz, 2H, Ar-H); 
13
C NMR (100 MHz, 
CDCl3):  = 118.6 (CH=CH2), 123.9 (2CH, aryl), 126.8 (2CH, aryl), 135.0 (CH=CH2), 143.8 (C, 
aryl). 
 
2-(2-(2-(tert-Butyl-dimethyl-silanyloxy)-ethoxy)-ethoxy)-ethanol (1-118)
167
 
 
A solution of triethylene glycol 1-116 (3.0 g, 20.0 mmol) in THF (60 mL) was cooled in ice bath. 
NaH (0.8 g, 20.0 mmol) was added portionwise to the reaction mixture which was stirred at 
room temperature for 45 min before tert-butyldimethylsilyl chloride (3.01 g, 20.0 mmol) in THF 
(10 mL) was added dropwise at the same temperature and the resulting milky solution was 
allowed to stir at room temperature. After 2 h, the mixture was diluted with diethyl ether (50 
mL), washed with 10% aq K2CO3 solution (30 mL) and saturated NaCl solution. The separated 
organic layer was dried over anhydrous MgSO4, filtered and concentrated under vacuum. The 
crude oil was purified by flash chromatography (petroleum ether/EtOAc, 3:7) to isolate 
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monoprotected alcohol 1-118 (4.10 g, 78%) as colorless oil. Rf = (petroleum ether/EtOAc, 3:7) 
0.19; 
1
H NMR (400 MHz, CDCl3):  = 0.05 (s, 6H, Si(CH3)2), 0.87 (s, 9H, SiC(CH3)3), 2.38 (s, 
1H, OH), 3.55 (d, J = 5.6, 5.0 Hz, 2H, OCH2), 3.58−3.61 (m, 2H, OCH2), 3.65 (s, 4H, OCH2), 
3.69–3.73 (m, 2H, OCH2), 3.73–3.77 (dd, J = 5.6, 5.0 Hz, 2H, OCH2); 
13
C NMR (100 MHz, 
CDCl3):  = −5.3 (Si(CH3)2), 18.3 (C(CH3)3), 25.9 (C(CH3)3), 61.8 (OCH2), 62.7 (OCH2), 70.4 
(OCH2), 70.7 (OCH2), 72.5 (OCH2), 72.7 (OCH2). 
 
2,2,3,3-Tetramethyl-4,7,10,13-tetraoxa-3-silahexadec-15-ene (1-119)
80 
 
A solution of NaOH (1.40 g, 34.0 mmol), tetra n-butyl ammonium hydrogen sulphate (148 mg, 
0.44 mmol) and alcohol 1-118 (2.31 g, 8.7 mmol) in a mixture of benzene (18 mL) and water  
(3 mL) was cooled to ~0 °C (ice bath). Allyl bromide (2.11 g, 17.4 mmol) was added dropwise to 
the mixture which was stirred vigorously at room temperature for 40 h (TLC). The reaction 
mixture was diluted with diethyl ether (30 mL) and washed with 10% HCl solution (20 ml) and 
saturated NaHCO3 solution (20 mL). The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The crude ether was purified by flash chromatography (petroleum 
ether/EtOAc, 1:4) to furnish O-allyl TEG 1-119 (2.01 g, 76%) as colorless liquid. Rf = 0.5 
(petroleum ether/EtOAc, 1:4); 
1
H NMR (400 MHz, CDCl3):  = 0.05 (s, 6H, Si(CH3)2), 0.88 (s, 
9H, SiC(CH3)3), 3.54 (dd, J = 5.5, 5.3 Hz, 2H, OCH2), 3.57–3.61 (m, 2H, OCH2), 3.63–3.66 (m, 
6H, OCH2), 3.75 (dd, J = 5.6 Hz, 2H, OCH2), 4.01 (ddd, J = 5.6, 1.5, 1.3 Hz, 2H, 
OCH2CH=CH2), 5.16–5.18 (m, 1H, CH=CH2), 5.25 (dddd, J = 17.2, 1.8, 1.5, 1.5 Hz, 1H, 
CH=CH2), 5.90 (dddd, J = 17.2, 10.4, 5.8, 5.6 Hz, 1H, CH=CH2); 
13
C NMR (100 MHz, CDCl3): 
 = −5.3 (Si(CH3)2), 18.3 (SiC(CH3)3), 25.9 (C(CH3)3), 62.7 (OCH2), 69.4 (OCH2), 70.6 (OCH2), 
70.7 (2 OCH2), 72.2 (OCH2), 72.6 (OCH2), 117.1 (CH=CH2), 134.8 (CH=CH2); HRMS (ESI): 
[M + Na]
+
 calcd for C15H32O4SiNa 327.196188, found 327.19621. 
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2,2,3,3-Tetramethyl-16-(4-nitrophenyl)-4,7,10,13-tetraoxa-3-silahexadec-15-ene (1-120) 
 
To a solution of O-allyl TEG 1-119 (100 mg, 0.3 mmol) and p-nitro styrene 1-114 (195 mg, 1.3 
mmol) in dry, degassed toluene (2 mL) Grubb´s 2
nd
 catalyst (14 mg) in toluene (0.2 mL) was 
added dropwise and the reaction mixture was heated to 70 °C for 24 h. The reaction mixture was 
cooled to room temperature. The solvent was evaporated under vacuum and the crude compound 
was purified by flash chromatography (petroleum ether/EtOAc, 4:1) to afford an isomeric 
mixture of isomers (trans/vinlylic trans/vinylic cis) of metathesis products 1-120 (75 mg, 53%) 
as red yellow colored oil. Rf = (petroleum ether/EtOAc, 4:1) 0.11 (trans), 0.24 (vinylic trans), 
0.29 (vinylic cis); 
1
H NMR (400 MHz, CDCl3) (vinylic cis):  = 0.04 (s, 6H, Si(CH3)2), 0.87 (s, 
9H, SiC(CH3)3), 3.50 (d, J = 7.6 Hz, 2H, OCH2), 3.55 (dd, J = 5.5, 5.3 Hz, 2H, OCH2), 3.65 (s, 
4H, OCH2), 3.68−3.70 (m, 2H, OCH2), 3.75 (dd, J = 5.6, 5.3 Hz, 2H, OCH2), 3.93–395 (m, 2H, 
OCH2), 4.53 (ddd, J = 7.6, 7.6, 6.1 Hz, 1H, OCH=CHCH2), 6.16 (ddd, J = 6.3, 1.5, 1.3 Hz, 1H, 
OCH=CHCH2), 7.36 (d, J = 8.6 Hz, 2H, Ar), 8.11 (d, J = 8.6 Hz, 2H, Ar); (vinylic trans):  = 
0.04 (s, 6H, Si(CH3)2), 0.87 (s, 9H, SiC(CH3)3), 3.34 (d, J = 7.6 Hz, 2H, OCH=CHCH2), 3.54 
(dd, J = 5.5, 5.3 Hz, 2H, OCH2), 3.65 (s, 4H, OCH2), 3.71−3.76 (m, 4H, OCH2), 3.83−3.85 (m, 
2H, OCH2), 4.87 (ddd, J = 12.6, 7.3, 5.3 Hz, 1H, OCH=CHCH2Ar), 6.42 (d, J = 12.6 Hz, 1H, 
OCH=CHCH2Ar), 7.34 (d, J = 8.8 Hz, 2H, Ar-H), 8.12 (d, J = 8.8 Hz, 2H, Ar-H); (trans 
isomer):  = 0.05 (s, 6H, Si(CH3)2), 0.87 (s, 9H, SiC(CH3)3), 3.55 (dd, J = 5.6, 5.3 Hz, 2H, 
OCH2), 3.64–3.71 (m, 8H, OCH2), 3.75 (dd, J = 5.6, 5.3 Hz, 2H, OCH2), 4.23 (dd, J = 5.3, 1.5 
Hz, 2H, OCH2CH=CHAr), 6.46 (ddd, J = 15.9, 5.6, 5.6 Hz, 1H, OCH2CH=CHAr), 6.68 (d, J = 
16.2 Hz, 1H, OCH2CH=CHAr), 7.49 (d, J = 8.8 Hz, 2H, Ar-H), 8.16 (d, J = 8.8 Hz, 2H, Ar-H); 
13
C NMR (100 MHz, CDCl3): (vinylic cis)  = −5.3 (Si(CH3)2), 18.3 (SiC(CH3)3), 25.9 
(SiC(CH3)3), 30.1 (ArCH2CH=CH), 62.7 (OCH2), 70.4 (OCH2), 70.8 (2 × OCH2), 71.6 (OCH2), 
72.7 (OCH2), 103.4 (CH2CH=CHO), 123.5 (2CH, Ar), 129.1 (2CH, Ar), 146.2 (C, Ar), 146.8 
(CH2CH=CHO), 149.8 (C, Ar); (vinylic trans)  = −5.3 (Si(CH3)2), 18.3 (SiC(CH3)3), 25.9 
(SiC(CH3)3), 33.9 (OCH=CHCH2Ar), 62.7 (OCH2), 68.6 (OCH2), 69.8 (OCH2), 70.7 (OCH2), 
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70.8 (OCH2), 72.7 (OCH2), 101.2 (OCH=CHCH2Ar), 123.6 (2CH, Ar), 129.0 (2CH, Ar), 146.4 
(C, Ar), 148.3 (OCH=CHCH2), 149.3 (C, Ar); (trans isomer)  = −5.3 (Si(CH3)2), 18.3 
(SiC(CH3)3), 25.9 (SiC(CH3)3), 62.7 (OCH2), 70.0 (OCH2), 70.7 (OCH2), 70.8 (2 × OCH2), 71.2 
(OCH2), 72.7 (OCH2), 124.0 (2CH, Ar), 126.9 (2CH, Ar), 129.5 (OCH2CH=CH), 131.3 
(OCH2CH=CH), 143.4 (C, Ar), 146.9 (C, Ar); HRMS (ESI): [M + Na]
+
 calcd for 
C21H35NO6SiNa 448.21259, found 450.22824. 
 
4-(2,2,3,3-Tetramethyl-4,7,10,13-tetraoxa-3-silahexadecan-16-yl)aniline (1-121) 
 
A solution of p-nitro styrene derivative 1-120 (570 mg, 1.3 mmol) in methanol (10 mL) was 
hydrogenated in presence of a catalytic amount of 10% Pd/C under hydrogen balloon pressure 
for 3 h. The catalyst was filtered off through a pad of celite and the filtrate was concentrated in 
vacuo. Residual oil was purified by flash chromatography (petroleum ether/EtOAc, 7:3) which 
furnished TEG coupled aniline 1-121 (400 mg, 75%) as reddish brown colored oil. Rf = 0.26 
(petroleum ether/EtOAc, 7:3); 
1
H NMR (400 MHz, CDCl3):  = 0.05 (s, 6H, Si(CH3)2), 0.88 (s, 
9H, SiC(CH3)3), 1.80–1.87 (m, 2H, OCH2CH2CH2Ar), 2.57 (dd, J = 7.8, 7.6 Hz, 2H, 
OCH2CH2CH2Ar), 3.44 (dd, J = 6.6, 6.6 Hz, 2H, OCH2), 3.53–3.58 (m, 4H, OCH2), 3.63–3.66 
(m, 6H, OCH2), 3.75 (dd, J = 5.6, 5.3 Hz, 2H, OCH2), 6.68 (d, J = 8.3 Hz, 2H, Ar-H), 6.98 (d, J 
= 8.1 Hz, 2H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = −5.3 (Si(CH3)2), 18.4 (SiC(CH3)3), 25.9 
(SiC(CH3)3), 31.4 (CH2), 31.4 (CH2Ar), 62.7 (OCH2), 70.1 (OCH2), 70.5 (OCH2), 70.6 (OCH2), 
70.7 (OCH2), 70.8 (OCH2), 72.7 (OCH2), 115.9 (2CH, Ar), 129.3 (2CH, Ar), 133.0 (C, Ar), 
142.7 (C, Ar); HRMS (ESI): [M+H]
+
 calcd for C21H39NO4SiNa 398.27211, found 398.27244. 
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2-(2-(2-(tert-Butyl-diphenyl-silanyloxy)-ethoxy)-ethoxy)-ethanol (1-122)
168 
 
Imidazole (4.53 g, 66.6 mmol) and DMAP (813 mg, 6.7 mmol) were added to a solution of 
triethylene glycol 1-116 (5.02 g, 33.3 mmol) in dry CH2Cl2 (100 mL) and the mixture was stirred 
at room temperature for 10 min. Then tert-butyldiphenylsilyl chloride (4.12 g, 15.0 mmol) in 
CH2Cl2 (25 mL) was added and stirring was continued for 14 h at room temperature. The 
reaction mixture was washed with saturated NaHCO3 solution (30 mL), water (30 mL) and 
saturated NaCl (30 mL) solution. The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. The crude oil was purified by flash chromatography (petroleum 
ether/EtOAc, 3:7) to give alcohol 1-122 (4.59 g, 79%) as colorless oil. Rf = 0.36 (petroleum 
ether/EtOAc, 3:7); 
1
H NMR (400 MHz, CDCl3):  = 1.04 (s, 9H, SiC(CH3)3), 2.09 (s, 1H, OH), 
3.59–3.62 (m, 4H, OCH2), 3.63–3.67 (m, 4H, OCH2), 3.70–3.72 (m, 2H, OCH2), 3.81 (dd, J = 
5.3, 5.3 Hz, 2H, OCH2), 7.35–7.43 (m, 6H, Ar-H), 7.66–7.69 (m, 4H, Ar-H); 
13
C NMR (100 
MHz, CDCl3):  = 19.2 (SiC(CH3)3), 26.8 (SiC(CH3)3), 61.8 (OCH2), 63.4 (OCH2), 70.5 
(OCH2), 70.8 (OCH2), 72.4 (OCH2), 72.5 (OCH2), 127.6 (4CH, Ar), 129.6 (2CH, Ar), 133.6 (2C, 
Ar), 135.6 (4CH, Ar).  
 
2,2-Dimethyl-3,3-diphenyl-4,7,10-trioxa-3-siladodecan-12-ol (1-123)
80 
 
A biphasic mixture of alcohol 1-122 (3.01 g, 7.7 mmol), NaOH pellets (1.23 g, 30.9 mmol) and 
tetra n-butyl ammonium hydrogen sulphate (131 mg, 0.3 mmol) in benzene (36 mL) and water (6 
mL) was cooled in an ice bath. Allyl bromide (1.87 g, 15.4 mmol) was added to the reaction 
mixture which was allowed to stir at room temperature for 24 h. The reaction was found to be 
incomplete (TLC control), therefore excess of reagents NaOH (1 equiv) and allyl bromide (0.5 
equiv) was added and the mixture was stirred for 24 h. The reaction mixture was diluted with 
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diethyl ether (20 mL) and water (20 mL). The organic layer was washed with 5% HCl solution 
(20 mL), water (2 × 20 mL), dried over Na2SO4, filtered and concentrated under vacuum. The 
crude oil was purified by flash chromatography (petroleum ether/EtOAc, 4:1) to furnish mono 
allyl TEG 1-123 (2.82 g, 85%) as colorless oil. Rf = 0.3 (petroleum ether/EtOAc, 5:1); 
1
H NMR 
(400 MHz, CDCl3):  = 1.04 (s, 9H, SiC(CH3)3), 3.57–3.67 (m, 10H, OCH2), 3.80 (dd, J = 5.6, 
5.3 Hz, 2H, CH2OTBDPS), 4.01 (d, J = 5.8 Hz, 2H, OCH2CH=CH2), 5.15–5.18 (m, 1H, 
CH=CH2), 5.24–5.28 (m, 1H, CH=CH2), 5.86–5.95 (m, 1H, CH=CH2), 7.35–7.43 (m, 6H, Ar-H), 
7.67–7.69 (m, 4H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.2 (SiC(CH3)3), 26.8 
(SiC(CH3)3), 63.4 (OCH2), 69.4 (OCH2), 70.7 (2 × OCH2), 70.8 (OCH2), 72.2 (OCH2), 72.4 
(OCH2), 117.1 (CH=CH2), 127.6 (4CH, Ar), 129.6 (2CH, Ar), 133.7 (2C, Ar), 134.8 (CH=CH2), 
135.6 (4CH, Ar); HRMS (ESI): [M + Na]
+
 calcd for C25H36O4SiNa 451.22751, found 
451.227742. 
 
2,2-Dimethyl-16-(4-nitrophenyl)-3,3-diphenyl-4,7,10,13-tetraoxa-3-silahexadec-15-ene  
(1-124) 
 
A solution of Grubb´s 2
nd
 gen catalyst (198 mg, 5 mol%) in toluene (3 mL) was added at room 
temperature to a mixture of mono allyl TEG 1-123 (2.01 g, 4.7 mmol) and 4-nitro styrene 1-114 
(2.1 g, 14.0 mmol) in dry and degassed toluene (20 mL). The reaction mixture was heated to 70 
°C for 5 h before it was concentrated under vacuum. The crude product was purified by flash 
chromatography (petroleum ether/EtOAc, 17:3) to afford a mixture of isomers (trans/vinlylic 
trans/vinylic cis) of cross metathesis product 1-124 (1.67 g, 65 %) as yellow red oil. Rf = 
(petroleum ether/EtOAc, 4:1) 0.16 (trans), 0.29 (vinylic trans), 0.33 (vinylic cis); 
1
H NMR (400 
MHz, CDCl3): (vinylic cis)  = 1.04 (s, 9H, SiC(CH3)3), 3.49 (d, J = 7.6 Hz, 2H, 
CH=CHCH2Ar), 3.59–3.70 (m, 8H, OCH2), 3.80 (dd, J = 5.6, 5.0 Hz, 2H, CH2OTBDPS), 3.91–
3.94 (m, 2H, CH2), 4.51 (ddd, J = 7.6, 7.3, 6.3, Hz, 1H, OCH=CHCH2), 6.15 (ddd, J = 6.1, 1.3, 
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1.3 Hz, 1H, OCH=CHCH2), 7.33–7.42 (m, 8H, Ar-H), 7.66–7.68 (m, 4H, Ar-H), 8.10 (d, J = 8.6 
Hz, 2H, Ar-H); (vinylic trans)  = 1.03 (s, 9H, SiC(CH3)3), 3.33 (d, J = 7.3 Hz, 2H, 
CH=CHCH2Ar), 3.60 (dd, J = 5.6, 5.0 Hz, 3H, OCH2), 3.62–3.68 (m, 4H, OCH2), 3.71–3.73 (m, 
2H, OCH2), 3.79–3.83 (m, 4H, OCH2), 4.86 (ddd, J = 12.6, 7.6, 5.0 Hz, 1H, OCH=CHCH2), 6.41 
(d, J = 12.6 Hz, 1H, OCH=CH), 7.32–7.42 (m, 8H, Ar-H), 7.66–7.68 (m, 4H, Ar-H), 8.12 (d, J = 
8.6 Hz, 2H, Ar-H); (allylic trans)  = 1.03 (s, 9H, SiC(CH3)3), 3.58–3.71 (m, 10H, OCH2), 3.80 
(dd, J = 5.3, 5.3 Hz, 2H, OCH2), 4.22 (dd, J = 5.6, 1.5 Hz, 2H, OCH2CH=CH), 6.45 (ddd, J = 
16.2, 5.6, 5.3 Hz, 1H, OCH2CH=CH), 6.67 (d, J = 16.2 Hz, 1H, OCH2CH=CH), 7.33–7.42 (m, 
6H, Ar-H), 7.47 (d, J = 8.8 Hz, 2H, Ar-H), 7.66–7.68 (m, 4H, Ar-H), 8.15 (d, J = 8.8 Hz, 2H, Ar-
H); 
13
C NMR (100 MHz, CDCl3): (vinylic cis)  = 19.2 (SiC(CH3)3), 26.8 (SiC(CH3)3), 30.1 
(CH2Ar), 63.4 (OCH2), 70.4 (OCH2), 70.8 (OCH2), 70.9 (OCH2), 71.6 (OCH2), 72.5 (OCH2), 
103.4 (OCH=CH), 123.5 (2CH, Ar), 127.6 (4CH, Ar), 129.0 (2CH, Ar), 129.6 (2CH, Ar), 133.6 
(2C, Ar), 135.6 (4CH, Ar), 146.2 (C, Ar), 146.8 (OCH=CH), 149.8 (C, Ar); (vinylic trans)  = 
19.2 (SiC(CH3)3), 26.8 (SiC(CH3)3), 33.9 (CH2Ar), 63.4 (OCH2), 68.6 (OCH2), 69.8 (OCH2), 
70.8 (2 × OCH2), 72.5 (OCH2), 101.1 (CH=CHCH2), 123.6 (2CH, Ar), 127.6 (4CH, Ar), 129.0 
(2CH, Ar), 129.6 (2CH, Ar), 133.7 (2C, Ar), 135.6 (4CH, Ar), 146.5 (C, Ar), 148.3 
(CH=CHCH2), 149.4 (C, Ar); (allylic trans)  = 19.2 (SiC(CH3)3), 26.8 (SiC(CH3)3), 63.4 
(OCH2), 70.0 (OCH2), 70.7 (OCH2), 70.8 (2 × OCH2), 71.2 (OCH2), 72.5 (OCH2), 124.0 
(OCH2CH=CH), 126.9 (2CH, Ar), 127.6 (4CH, Ar), 129.5 (C, Ar), 129.6 (2CH, Ar), 133.7 (2C, 
Ar), 135.6 (4CH, Ar), 143.3 (OCH2CH=CH), 146.9 (C, Ar); HRMS (ESI): [M+Na]
+
 calcd for 
C31H39NO6SiNa 572.24389, found 572.243999. 
 
4-(2,2-Dimethyl-3,3-diphenyl-4,7,10,13-tetraoxa-3-silahexadecan-16-yl)aniline (1-125) 
 
A mixture of metathesis products 1-124 (1.52 g, 2.8 mmol) in methanol (15 mL) was 
hydrogenated in presence of a catalytic amount of 10% Pd/C at room temperature under 
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hydrogen balloon pressure. After 24 h (TLC control), the reaction mixture was filtered through a 
pad of celite to remove the catalyst and the filtrate was concentrated under vacuum. The residue 
was purified by flash chromatography (petroleum ether/EtOAc, 3:2) to afford aniline 1-125 (1.14 
g, 79%) as yellow red oil. Rf = 0.37 (petroleum ether/EtOAc, 3:2); 
1
H NMR (400 MHz, CDCl3): 
 = 1.04 (s, 9H, SiC(CH3)3), 1.78–1.88 (m, 2H, OCH2CH2CH2Ar), 2.56 (dd, J = 7.8, 7.3 Hz, 2H, 
OCH2CH2CH2Ar), 3.43 (dd, J = 6.6, 6.3 Hz, 2H, OCH2CH2CH2Ar), 3.54–3.65 (m, 10H, OCH2), 
3.80 (dd, J = 5.6, 5.0 Hz, 2H, OCH2), 6.68 (d, J = 8.3 Hz, 2H, Ar-H), 6.98 (d, J = 8.3 Hz, 2H, 
Ar-H), 7.34–7.43 (m, 6H, Ar-H), 7.66–7.69 (m, 4H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 
19.2 (SiC(CH3)3), 26.8 (SiC(CH3)3), 31.3 (2 × CH2), 63.4 (OCH2), 70.1 (OCH2), 70.5 (OCH2), 
70.6 (OCH2), 70.7 (OCH2), 70.8 (OCH2), 72.4 (OCH2), 116.0 (2CH, Ar), 127.6 (4CH, Ar), 129.3 
(2CH, Ar), 129.6 (2CH, Ar), 133.1 (C, Ar), 133.7 (2C, Ar), 135.6 (4CH, Ar), 142.5 (C, Ar); 
HRMS (ESI): [M + Na]
+
 calcd for C31H43NO4SiNa 544.28536, found 544.285897. 
 
2-(2-(2-(Allyloxy)ethoxy)ethoxy)ethanol (1-126)
169
 
 
To a solution of triethylene glycol 1-116 (22.34 g, 149 mmol) in dry THF (50 mL) under 
nitrogen, NaH (3.2 g, 79 mmol, 60% in mineral oil) was added portionwise at room temperature. 
The mixture was stirred for 15 min before allyl bromide (6.0 g, 50.0 mmol) was added. The 
reaction mixture was stirred further for 1 h at room temperature before the solvent was removed 
under vacuum. The residue was diluted with ethyl acetate (50 mL) and washed with saturated 
NaCl solution. The aqueous layer was extracted with EtOAc (2 × 15 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (EtOAc) to yield mono allyl TEG 1-126 (6.78 g, 
89%) as colorless oil. Rf = 0.24 (EtOAc); 
1
H NMR (400 MHz, CDCl3):  = 2.58 (s, 1H, OH), 
3.57–3.60 (m, 4 H, OCH2), 3.63–3.65 (m, 6H, OCH2), 3.69–3.71 (m, 2H, CH2OH), 4.00 (ddd, J 
= 5.8, 1.5, 1.3 Hz, 2H, CH2CH=CH2), 5.16 (dddd, J = 10.4, 1.5, 1.3, 1.3 Hz, 1H, CH2CH=CH2), 
5.23–5.30 (m, 1H, CH2CH=CH2), 5.85–5.94 (m, 1H, CH2CH=CH2); 
13
H NMR (100 MHz, 
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CDCl3):  = 61.7 (CH2OH), 69.3 (OCH2), 70.3 (OCH2), 70.5 (OCH2), 70.6 (OCH2), 72.2 
(OCH2), 72.5 (OCH2), 117.2 (CH=CH2), 134.6 (CH=CH2). 
 
tert-Butyl 3,6,9,12-tetraoxapentadec-14-en-1-oate (1-127)
170 
 
To a mixture of alcohol 1-126 (4.5 g, 23.6 mmol), tert-butyl bromoacetate (11.2 mL, 70.9 mmol) 
and tetra n-butyl ammonium hydrogen sulphate (2.0 g, 5.9 mmol) in benzene (23 mL) a 50% aq 
solution of NaOH (25 mL) was added slowly at room temperature. The reaction mixture was 
stirred at room temperature for 5 h (TLC control) before it was neutralized with a 1N HCl 
solution to pH ~5 and extracted with ethyl acetate (3 × 100 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated under vacuum. The crude concentrate was 
purified by flash chromatography (petroleum ether/EtOAc, 1:1) to give O-alkylated compound 1-
127 (6.95 g, 96%) as colorless oil. Rf = 0.3 (petroleum ether/EtOAc, 3:2); 
1
H NMR (400 MHz, 
CDCl3):  = 1.45 (s, 9H, C(CH3)3), 3.56–3.59 (m, 2H, OCH2), 3.62–3.71 (m, 10H, OCH2), 3.99–
4.01 (m, 4H, OCH2CH=CH2, OCH2CO), 5.14–5.17 (m, 1H, CH=CH2), 5.25 (dddd, J = 17.2, 1.8, 
1.5, 1.5 Hz, 1H, CH=CH2), 5.84–5.94 (m, 1H, CH=CH2); 
13
C NMR (100 MHz, CDCl3):  = 
28.1 (C(CH3)3), 69.0 (OCH2CO), 69.4 (OCH2), 70.6 (4 OCH2), 70.7 (OCH2), 72.2 
(OCH2CH=CH2), 81.5 (C(CH3)3), 117.0 (CH=CH2), 134.7 (CH=CH2), 169.6 (CO2tBu); HRMS 
(ESI): [M+Na]+ calcd for C15H28O6Na 327.17781, found 327.17765. 
 
(E)-tert-Butyl 15-(4-nitrophenyl)-3,6,9,12-tetraoxapentadec-14-en-1-oate (1-128) 
 
Experimental Section  139 
 
To a solution of O-allyl TEG 1-127 (2.2 g, 7.2 mmol) and 4-nitrostyrene 1-114 (3.23 g, 21.7 
mmol) in CH2Cl2 (55 mL, dry and degassed) Grubb’s 2
nd
 catalyst (307 mg, 5 mol%) in CH2Cl2 
(5 mL) was added dropwise over 10 min at room temperature and the reaction mixture was 
heated to reflux for 6 h. After complete conversion, the reaction mixture was concentrated under 
vacuum and the residue was purified by flash chromatography (petroleum ether/EtOAc, 1:1) to 
furnish trans isomer of metathesis product 1-128 (2.43 g, 80%) as reddish brown oil. Rf = 0.2 
(petroleum ether/EtOAc, 1:1); 
1
H NMR (400 MHz, CDCl3):  = 1.43 (s, 9H, C(CH3)3), 3.63–
3.69 (m, 12H, OCH2), 3.98 (s, 2H, OCH2CO2tBu), 4.21 (dd, J = 5.6, 1.5 Hz, 2H, 
ArCH=CHCH2), 6.44 (ddd, J = 15.9, 5.6, 5.5 Hz, 1H, ArCH=CHCH2), 6.66 (d, J = 16.2 Hz, 1H, 
ArCH=CHCH2), 7.47 (d, J = 8.6 Hz, 2H, Ar-H), 8.13 (d, J = 8.6 Hz, 2H, Ar-H); 
13
C NMR (100 
MHz, CDCl3):  = 28.0 (C(CH3)3), 68.9 (OCH2CO2tBu), 69.9 (OCH2), 70.5 (2 × OCH2), 70.6 (2 
× OCH2), 71.1 (OCH2), 81.4 (C(CH3)3), 123.9 (CH, Ar), 126.8 (CH, Ar), 129.4 
(ArCH=CHCH2), 131.3 (ArCH=CHCH2), 143.2 (C, Ar), 146.8 (C, Ar), 169.5 (CH2COO); 
HRMS (ESI): [M + Na]
+
 calcd for C21H31NO8Na 448.19419, found 448.194519. 
 
tert-Butyl-15-(4-aminophenyl)-3,6,9,12-tetraoxapentadecan-1-oate (1-129) 
 
A solution of nitro compound 1-128 (2.55 g, 5.5 mmol) in dry EtOAc (40 mL) was hydrogenated 
under balloon pressure in presence of a catalytic amount of 10% Pd/C overnight (~14 h). The 
catalyst was filtered through a pad of celite and the filtrate was concentrated in vacuo. The crude 
oil was purified by flash chromatography (petroleum ether/EtOAc, 2:3) to furnish amine 1-129 
(2.3 g, 96%) as slightly green oil. Rf = 0.2 (petroleum ether/EtOAc, 2:3); 
1
H NMR (400 MHz, 
CDCl3):  = 1.46 (s, 9H, C(CH3)3), 1.79–1.86 (m, 2H, CH2CH2Ar), 2.55 (dd, J = 7.8, 7.3 Hz, 2H, 
CH2CH2Ar), 3.43 (dd, J = 6.6, 6.6 Hz, 2H, OCH2CH2CH2Ar), 3.55–3.58 (m, 4H, NH2, OCH2), 
3.61–3.71 (m, 10H, OCH2), 4.00 (m, 2H, OCH2CO2tBu), 6.60 (d, J = 8.3 Hz, 2H, Ar-H), 6.95 (d, 
J = 8.3 Hz, 2H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 28.1 (C(CH3)3), 31.3 (CH2), 31.4 
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(CH2), 69.0 (OCH2CO2tBu), 70.1 (OCH2), 70.5 (OCH2), 70.6 (4 × OCH2), 70.7 (OCH2), 81.5 
(C(CH3)3), 115.2 (2CH, Ar), 129.2 (2CH, Ar), 131.9 (C, Ar), 144.2 (C, Ar), 169.7 
(OCH2CO2tBu); HRMS (ESI): [M + Na]
+
 calcd for C15H35NO6Na 420.23566 found 420.235325. 
 
1-(2-((4R,6S)-6-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-N-(4-(2,2-
dimethyl-3,3-diphenyl-4,7,10,13-tetraoxa-3-silahexadecan-16-yl)phenyl)-5-(4-fluorophenyl)-
2-isopropyl-4-phenyl-1H-pyrrole-3-carboxamide (1-130) 
 
To a cooled solution of acid 1-110 (440 mg, 0.73 mmol) and amine 1-125 (382 mg, 0.73 mmol) 
in CH2Cl2 (10 mL) at 0 

C were added diisopropylethylamine (376 µL, 2.2 mmol) and PyBrOP 
(410 mg, 0.88 mmol) successively. The mixture was stirred at room temperature for 12 h then 
diluted with CH2Cl2 (10 mL), washed with saturated NaHCO3 solution (10 mL) and saturated 
NaCl solution. The organic layer was dried over Na2SO4, filtered and concentrated. The residue 
was purified by flash chromatography to afford amide 1-130 (540 mg 73%) as yellow colored 
sticky oil. Rf = 0.32 (EtOAc/petroleum ether, 3:7); [α]D
20
 = −0.6 (c 1, CHCl3); 
1
H NMR (400 
MHz, CDCl3):  = 0.95–1.07 (m, 1H, 5’-H), 1.04 (s, 9H, SiC(CH3)3), 1.22 (ddd, J = 12.9, 2.5, 
2.3 Hz, 1H, 5’-H), 1.29 (s, 3H, 2’-CH3), 1.33 (s, 3H, 2’-CH3), 1.52 (d, J = 7.1 Hz, 6H, 
CH(CH3)2), 1.60–1.74 (m, 4H, CH2, NCH2CH2, CH2CH2OBn), 1.77–1.87 (m, 2H, 
OCH2CH2CH2Ar), 2.56 (dd, J = 8.1, 7.3 Hz, 2H, OCH2CH2CH2Ar), 3.41 (dd, J = 6.6, 6.3 Hz, 
2H, OCH2CH2CH2Ar), 3.44–3.68 (m, 14H, 4’-H, CH(CH3)2, OCH2), 3.75–3.85 (m, 1H, 
NCH2CH2), 3.80 (dd, J = 5.6, 5.3 Hz, 2H, CH2CH2OBn), 3.93 (dddd, J = 11.6, 7.3, 5.0, 2.3 Hz, 
1H, 6’-H), 3.99–4.11 (m, 1H, NCH2CH2), 4.45 (d, J = 12.1 Hz, 1H, OCH2Ph), 4.48 (d, J = 12.1 
Hz, 1H, OCH2Ph), 6.80 (br, s, 1H, NH), 6.92–7.03 (m, 6H, Ar-H), 7.09–7.21 (m, 7H, Ar-H), 
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7.26–7.43 (m, 11H, Ar-H), 7.64–7.71 (m, 4H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.2 
(SiC(CH3)3), 19.8 (2’-CH3), 21.6 (CH(CH3)2), 21.7 (CH(CH3)2), 26.1 (CH(CH3)2), 26.8 
(SiC(CH3)3), 30.0 (2’-CH3), 31.2 (OCH2CH2CH2Ar), 31.6 (OCH2CH2CH2Ar), 36.4 (C-5’), 36.5 
(NCH2CH2), 38.1 (CH2CH2OBn), 40.8 (NCH2CH2), 63.4 (CH2CH2OBn), 65.7 (C-6’), 66.0 
(OCH2), 66.5 (C-4’), 70.1 (OCH2), 70.4 (OCH2), 70.6 (OCH2), 70.7 (OCH2), 70.8 (OCH2), 72.4 
(OCH2), 72.9 (OCH2Ph), 98.5 (C-2’), 115.3 (d, JCF = 22.0 Hz, 2CH, Ar), 115.4 (C, Ar), 119.7 
(2CH, Ar), 121.7 (C, Ar), 126.5 (CH, Ar), 127.6 (7CH, Ar), 128.3 (C, Ar), 128.3 (4CH, Ar), 
128.6 (2CH, Ar), 128.7 (C, Ar), 129.6 (2CH, Ar), 130.5 (2CH, Ar), 133.2 (d, JCF = 8.0 Hz, 2CH, 
Ar), 133.7 (C, Ar), 134.7 (C, Ar), 135.6 (4CH, Ar), 136.1 (C, Ar), 137.2 (C, Ar), 138.5 (2C, Ar), 
141.3 (C, Ar), 162.9 (d, JCF = 377.6 Hz, C, Ar), 163.5 (C=O, amide); HRMS (ESI): [M+Na]
+
 
calcd for C68H83FN2O8SiNa 1125.579493, found 1125.579667. 
 
N-(4-(2,2-Dimethyl-3,3-diphenyl-4,7,10,13-tetraoxa-3-silahexadecan-16-yl)phenyl)-5-(4-
fluorophenyl)-1-(2-((4R,6S)-6-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxan-4-yl)ethyl)-2-
isopropyl-4-phenyl-1H-pyrrole-3-carboxamide (1-131) 
 
A solution of benzyl ether 1-130 (550 mg, 0.50 mmol) in dry ethyl acetate (15 mL) was 
hydrogenated under balloon pressure in presence of 20% Pd(OH)2 on carbon (110 mg, 20 wt%) 
for 8 h. The mixture was filtered through a pad of celite, the filtrate was concentrated under 
reduced pressure and purified by short filtration column (EtOAc/petroleum ether, 1:1) to afford 
alcohol 1-131 (438 mg, 87%) as yellow colored thick oil. Rf = 0.27 (EtOAc/petroleum ether, 
1:1); [α]D
20
 = −0.6 (c 1, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.03 (s, 9H, SiC(CH3)3), 1.12 
(ddd, J = 12.9, 11.4, 11.1 Hz, 1H, 5’-H), 1.21 (ddd, J = 12.9, 2.8, 2.5 Hz, 1H, 5’-H), 1.25 (s, 1H, 
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OH), 1.31 (s, 3H, 2’-CH3), 1.36 (s, 3H, 2’-CH3), 1.52 (d, J = 7.1 Hz, 6H, CH(CH3)2), 1.58–1.71 
(m, 4H, NCH2CH2, CH2CH2OH), 1.76–1.87 (m, 2H, OCH2CH2CH2Ar), 2.56 (dd, J = 8.1, 7.3 
Hz, 2H, OCH2CH2CH2Ar), 3.41 (dd, J = 6.6, 6.3 Hz, 2H, OCH2CH2CH2Ar), 3.51–3.76 (m, 14H, 
4’-H, CH2CH2OH, CH(CH3)2, OCH2), 3.79 (dd, J = 5.5, 5.3 Hz, 2H, OCH2), 3.78–3.87 (m, 1H, 
NCH2CH2), 3.95–4.12 (m, 2H, NCH2CH2, 6’-H), 6.81 (s, 1H, CONH), 5.92–7.04 (m, 6H, Ar-H), 
7.10–7.21 (m, 7H, Ar-H), 7.32–7.44 (m, 6H, Ar-H), 7.64–7.70 (m, 4H, Ar-H); 13C NMR (100 
MHz, CDCl3):  = 19.2 (SiC(CH3)3), 19.8(2’-CH3), 21.6 (CH(CH3)2), 21.8 (CH(CH3)2), 26.1 
(CH(CH3)2), 26.8 (SiC(CH3)3), 30.0 (2’-CH3), 31.2 (OCH2CH2CH2Ar), 31.6 (OCH2CH2CH2Ar), 
36.1 (C-5’), 38.0 (NCH2CH2), 38.0 (CH2CH2OH), 40.8 (NCH2CH2), 60.6 (CH2CH2OH), 63.4 
(OCH2), 66.5 (C-4’), 68.8 (C-6’), 70.1 (OCH2), 70.4 (OCH2), 70.6 (OCH2), 70.7 (2OCH2), 72.4 
(OCH2), 98.6 (C-2’), 115.3 (d, JCF = 21.2 Hz, 2CH, Ar), 119.7 (2CH, Ar), 121.7 (C, Ar), 126.5 
(CH, Ar), 127.6 (4CH, Ar), 128.4 (d, JCF = 3.7 Hz, C, Ar), 128.3 (C, Ar), 128.3 (2CH, Ar), 128.6 
(2CH, Ar), 128.7 (C, Ar), 129.6 (2CH, Ar), 130.4 (2CH, Ar), 133.2 (d, JCF = 8.0 Hz, 2CH, Ar), 
133.7 (C, Ar), 134.6 (C, Ar), 135.6 (4CH, Ar), 136.1 (C, Ar), 137.2 (C, Ar), 141.2 (C, Ar), 162.9 
(d, JCF = 376.9 Hz, C, Ar), 163.5 (CONH); HRMS (ESI): [M+Na]
+
 calcd for C51H77FN2O8SiNa 
1035.53254, found 1035.532117. 
 
2-((4R,6R)-6-(2-(3-((4-(2,2-Dimethyl-3,3-diphenyl-4,7,10,13-tetraoxa-3-silahexadecan-16-
yl)phenyl)carbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-
dimethyl-1,3-dioxan-4-yl)acetic acid (1-132) 
 
Dess-Martin periodinane (69 mg, 0.16 mmol) was added in one portion to a solution of alcohol 
1-131 (138 mg, 0.14 mmol) in CH2Cl2 (3 mL) at 0 

C. The mixture was stirred for 1 h at room 
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temperature, diluted with CH2Cl2 (5 mL), washed successively with saturated NaHCO3 (5 mL), 
1M Na2S2O3 (5 mL), and saturated NaCl solution. The organic layer was filtered, dried over 
Na2SO4, filtered and purified through a short silica plug by flash chromatography to yield pure 
aldehyde (105 mg, 0.10 mmol) which was dissolved in t-butanol (6 mL) and 2-methyl-2-butene 
(0.6 mL) was added. Then a mixture of NaClO2 (19 mg, 0.21 mmol) and NaH2PO4•2H2O (97 
mg, 0.62 mmol) in water (6 mL) was added dropwise to the reaction mixture at room 
temperature and the resultant biphasic reaction mixture was stirred for 6 h. The organic layer was 
separated and the aqueous layer extracted with ethyl acetate (3 × 10 mL), dried over MgSO4, 
filtered, and concentrated under vacuum. The residue on purification by flash chromatography 
(EtOAc/petroleum ether/AcOH, 1:1:0.001) provided acid 1-132 (104 mg, 74%, two steps) as 
yellowish sticky solid. Rf = (EtOAc/petroleum ether/AcOH, 1:1:0.001) 0.29; [α]D
20
 = +1.8 (c 1, 
CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.00–1.11 (m, 1H, 5’-H), 1.03 (s, 9H, SiC(CH3)3), 
1.29–1.39 (m, 1H, 5’-H), 1.31 (s, 3H, 2’-CH3), 1.36 (s, 3H, 2’-CH3), 1.51 (d, J = 7.1 Hz, 6H, 
CH(CH3)2), 1.59–1.73 (m, 2H, NCH2CH2), 1.76–1.86 (m, 2H, OCH2CH2CH2Ar), 2.38 (dd, J = 
15.9, 5.8 Hz, 1H, CH2COOH), 2.52 (dd, J = 15.9, 6.8 Hz, 1H, CH2COOH), 2.56 (dd, J = 8.1, 7.3 
Hz, 2H, OCH2CH2CH2Ar), 3.41 (dd, J = 6.6, 6.6 Hz, 2H, OCH2CH2CH2Ar), 3.48–3.73 (m, 12H, 
4’-H, CH(CH3)2, OCH2), 3.79 (dd, J = 5.6, 5.0 Hz, 2H, OCH2), 3.83 (ddd, J = 15.9, 9.6, 6.3 Hz, 
1H, NCH2CH2), 4.07 (ddd, J = 14.9, 9.8, 5.6 Hz, 1H, NCH2CH2), 4.14–4.24 (m, 1H, 6’-H), 6.81 
(s, 1H, CONH), 6.92–7.04 (m, 6H, Ar-H), 7.10–7.21 (m, 7H, Ar-H), 7.31–7.43 (m, 6H, Ar-H), 
7.62–7.71 (m, 4H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.2 (SiC(CH3)3), 19.6 (2’-CH3), 
21.6 (CH(CH3)2), 21.8 (CH(CH3)2), 26.1 (CH(CH3)2), 26.8 (SiC(CH3)3), 29.8 (2’-CH3), 31.2 
(OCH2CH2CH2Ar), 31.6 (OCH2CH2CH2Ar), 35.7 (NCH2CH2), 37.8 (C-5’) 40.7 (NCH2CH2, 
CH2COOH), 63.4 (OCH2), 65.5 (C-6’), 66.4 (C-4’), 70.1 (OCH2), 70.4 (OCH2), 70.6 (OCH2), 
70.7 (2 × OCH2), 70.7 (OCH2), 72.4 (OCH2), 99.0 (C-2’), 115.4 (d, JCF = 21.2 Hz, 2CH, Ar), 
115.5 (C, Ar), 119.8 (2CH, Ar), 121.8 (C, Ar), 126.5 (CH, Ar), 127.6 (4CH, Ar), 128.1 (d, JCF = 
3.7 Hz, C, Ar), 128.3 (C, Ar), 128.3 (2CH, Ar), 128.6 (2CH, Ar), 128.7 (C, Ar), 129.6 (2CH, 
Ar), 130.4 (2CH, Ar), 133.1 (d, JCF = 8.0 Hz, 2CH, Ar), 133.7 (C, Ar), 134.5 (C, Ar), 135.6 
(4CH, Ar), 136.0 (C, Ar), 137.3 (C, Ar), 141.1 (C, Ar), 163.0 (d, JCF = 393.0 Hz, C, Ar), 163.5 
(CONH); HRMS (ESI): [M+Na]
+
 calcd for C61H75FN2O9Na 1049.51181, found 1049.511774. 
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N-(4-(2,2-Dimethyl-3,3-diphenyl-4,7,10,13-tetraoxa-3-silahexadecan-16-yl)phenyl)-5-(4-
fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-
4-phenyl-1H-pyrrole-3-carboxamide (1-133) 
 
A mixture of acetonide acid 1-132 (126 mg, 0.12 mmol) and camphorsulphonic acid (57 mg, 
0.24 mmol) in CH2Cl2 (4 mL) was stirred at room temperature for 3 h. The mixture was diluted 
with CH2Cl2 (10 mL), washed with water (3 × 10 mL), saturated NaCl solution (10 mL), dried 
over Na2SO4, filtered and concentrated. The crude residue was purified by flash chromatography 
to afford pure lactone 1-133 (105 mg, 90%) as yellow colored sticky solid. Rf = 0.22 
(EtOAc/petroleum ether, 7:3); [α]D
20
 = +13.2 (c 1, CHCl3);
 1
H NMR (400 MHz, CDCl3):  = 
1.03 (s, 9H, SiC(CH3)3), 1.50 (d, J = 6.6 Hz, 3H, CH(CH3)2), 1.52 (d, J = 6.8 Hz, 3H, 
CH(CH3)2), 1.55–1.61 (m, 1H, 3’-H), 1.67–1.92 (m, 6H, NCH2CH2, 3’-H, OCH2CH2CH2Ar, 
OH), 2.48–2.60 (m, 3H, 5’-H, OCH2CH2CH2Ar), 2.64 (dd, J = 17.7, 4.8 Hz, 1H, 5’-H), 3.40 (dd, 
J = 6.6, 6.6 Hz, 2H, OCH2CH2CH2Ar), 3.46–3.68 (m, 11H, CH(CH3)2, OCH2), 3.79 (dd, J = 5.3, 
5.3 Hz, 2H, OCH2), 4.01 (ddd, J = 14.9, 9.1, 4.8 Hz, 1H, 1-H), 4.20 (ddd, J = 14.9, 9.8, 4.5 Hz, 
1H, 1-H), 4.26–4.32 (m, 1H, 4’-H), 4.51 (dddd, J = 11.4, 8.6, 3.3, 3.0 Hz, 1H, 2’-H), 6.82 (s, 1H, 
CONH), 6.92–7.04 (m, 6H, Ar-H), 7.09–7.22 (m, 7H, Ar-H), 7.31–7.43 (m, 6H, Ar-H), 7.62–
7.70 (m, 4H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 19.2 (SiC(CH3)3), 21.7 (CH(CH3)2), 22.0 
(CH(CH3)2), 26.2 (CH(CH3)2), 26.8 (SiC(CH3)3), 31.2 (OCH2CH2CH2Ar), 31.6 
(OCH2CH2CH2Ar), 35.6 (C-3’), 37.1 (NCH2CH2), 38.5 (C-5’), 40.7 (NCH2CH2), 62.5 (C-4’), 
63.4 (OCH2), 70.1 (OCH2), 70.4 (OCH2), 70.6 (OCH2), 70.7 (2 × OCH2), 72.4 (OCH2), 73.0 (C-
2’), 115.6 (d, JCF = 22.0 Hz, 2CH, Ar), 115.8 (C, Ar), 119.8 (2CH, Ar), 122.0 (C, Ar), 126.6 
(CH, Ar), 127.6 (4CH, Ar), 128.0 (d, JCF = 3.7 Hz, C, Ar), 128.3 (2CH, Ar), 128.6 (2CH, Ar), 
129.6 (2CH, Ar), 130.3 (2CH, Ar), 133.1 (d, JCF = 133.1 Hz, 2CH, Ar), 133.1 (2C, Ar), 134.4 (C, 
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Ar), 135.6 (4CH, Ar), 136.0 (C, Ar), 137.4 (C, Ar), 141.2 (C, Ar), 162.9 (d, JCF = 374.0 Hz, C, 
Ar), 163.5 (CONH), 169.4 (C=O, lactone); HRMS (ESI): [M+Na]
+
 calcd for C58H69FN2O8SiNa 
991.46994, found 991.469476. 
 
5-(4-Fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-N-(4-(3-
(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propyl)phenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-
carboxamide (1-134) 
 
HF•pyridine complex (53 L, 1.86 mmol, 70%) was added to a cooled (0 C) solution of silyl 
ether 1-133 (120 mg, 0.125 mmol) in THF (3 mL) in a plastic tube and the mixture was allowed 
to stir overnight. The mixture was diluted with ethyl acetate (10 mL), washed with the saturated 
NaHCO3 solution (5 mL), 10% CuSO4 solution (2 × 5 mL) followed by washing with saturated 
NaCl solution. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography (methanol/CH2Cl2, 1:20) to afford lactone 1-134 
(78 mg, 87%) as colorless sticky solid. Rf = 0.21 (methanol/CH2Cl2, 1:20); [α]D
20
 = +14.4 (c 1, 
CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.50 (d, J = 6.8 Hz, 3H, CH(CH3)2), 1.51 (d. J = 6.6 
Hz, 3H, CH(CH3)2), 1.54–1.61 (m, 1H, 3’-H), 1.64–1.96 (m, 6H, NCH2CH2, 3’-H, 
OCH2CH2CH2Ar, OH), 2.48–2.60 (m, 3H, 5’-H, OCH2CH2CH2Ar), 2.62 (dd, J = 17.9, 4.8 Hz, 
1H, 5’-H), 3.41 (dd, J = 6.6, 6.3 Hz, 2H, OCH2CH2CH2Ar), 3.46–3.74 (m, 13H, CH(CH3)2, 
OCH2), 4.00 (ddd, J = 15.2, 10.1, 5.8 Hz, 1H, NCH2CH2), 4.19 (ddd, J = 14.9, 10.4, 4.8 Hz, 1H, 
NCH2CH2), 4.27 (m, 1H, 4’-H), 4.50 (dddd, J = 11.4, 8.6, 3.3, 3.0 Hz, 1H, 2’-H), 6.84 (s, 1H, 
CONH), 6.92–7.05 (m, 6H, Ar-H), 7.07–7.22 (m, 7H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 
21.7 (CH(CH3)2), 22.0 (CH(CH3)2), 26.1 (CH(CH3)2), 31.1 (OCH2CH2CH2Ar), 31.5 
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(OCH2CH2CH2Ar), 35.6 (C-3’), 37.1 (NCH2CH2), 38.5 (C-5’), 40.7 (NCH2CH2), 61.7 (OCH2), 
62.4 (C-4’), 70.0 (OCH2), 70.3 (OCH2CH2CH2Ar), 70.4 (OCH2), 70.5 (OCH2), 70.6 (OCH2), 
72.5 (OCH2), 73.0 (C-3), 115.6 (d, JCF = 21.2 Hz, 2CH, Ar), 115.7 (C, Ar), 119.8 (2CH, Ar), 
122.0 (C, Ar), 126.6 (CH, Ar), 128.0 (d, JCF = 2.9 Hz, C, Ar), 128.3 (2CH, Ar), 128.6 (2CH, Ar), 
130.3 (2CH, Ar), 133.1 (d, JCF = 8.0 Hz, 2CH, Ar), 134.4 (C, Ar), 136.0 (C, Ar), 137.4 (C, Ar), 
141.1 (C, Ar), 162.9 (d. JCF = 378.4 Hz, C, Ar), 163.5 (CONH), 169.5 (C=O, lactone); HRMS 
(ESI): [M+Na]
+
 calcd for C42H51FN2O8Na 753.35217, found 753.352783. 
 
tert-Butyl 2-(2-(2-(3-(4-(1-(2-((4R,6S)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-
yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-
carboxamido)phenyl)propoxy)ethoxy)ethoxy)acetate (1-135) 
 
A mixture of acid 1-110 (520 mg, 0.87 mmol) and amine 1-129 (306 mg, 0.87 mmol) in CH2Cl2 
(15 mL) was cooled to 0 

C followed by the addition of DIPEA (0.44 mL, 2.6 mmol) and 
PyBrOP (606 mg, 1.3 mmol). The mixture was stirred at room temperature for overnight before 
it was diluted with CH2Cl2 (10 mL), washed with saturated NaHCO3 solution (10 mL), water (2 
× 10 mL) and saturated NaCl solution. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated under vacuum. Purification by flash chromatography 
(EtOAc/petroleum ether, 2:3) provided amide 1-135 (705 mg, 87%) as colorless sticky solid. Rf 
= 0.38 (EtOAc/petroleum ether, 3:2); [α]D
20
 = −0.6 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3): 
 = 0.99 (ddd, J = 12.4, 11.9, 11.6 Hz, 1H, 5’-H), 1.22 (ddd, J = 12.9, 2.5, 2.3 Hz, 1H. 5’-H), 
1.29 (s, 3H, 2’-CH3), 1.32 (s, 3H, 2’-CH3), 1.46 (s, 9H, C(CH3)3), 1.51 (d, J = 7.3 Hz, 6H, 
CH(CH3)2), 1.56–1.76 (m, 4H, NCH2CH2, CH2CH2OBn), 1.77–1.87 (m, 2H, OCH2CH2CH2Ar), 
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2.57 (dd, J = 8.1, 7.3 Hz, 2H, OCH2CH2CH2Ar), 3.41 (dd, J = 6.6, 6.6 Hz, 2H, 
OCH2CH2CH2Ar), 3.44–3.59 (m, 5H, CH2CH2OBn, CH(CH3)2, OCH2), 3.59–3.73 (m, 11H, 4’-
H, OCH2), 3.79 (ddd, J = 14.9, 10.1, 6.3 Hz, 1H, NCH2CH2), 3.93 (dddd, J = 11.6, 7.3, 4.8, 2.3 
Hz, 1H, 6’-H), 4.00 (s, 2H, OCH2CO2tBu), 4.05 (ddd, J = 14.9, 9.1, 4.8 Hz, 1H, NCH2CH2), 4.46 
(d, J = 12.1 Hz, 1H, OCH2Ph), 4.47 (d, J = 12.4 Hz, 1H, OCH2Ph), 6.80 (s, 1H, CONH), 6.93–
7.02 (m, 5H, Ar-H), 7.10–7.21 (m, 7H, Ar-H), 7.23–7.35 (m, 6H, Ar-H); 13C NMR (100 MHz, 
CDCl3):  = 19.8 (2’-CH3), 21.6 (CH(CH3)2), 21.7 (CH(CH3)2), 26.1 (CH(CH3)2), 28.1 
(C(CH3)3), 30.0 (2’-CH3), 31.1 (OCH2CH2CH2Ar), 31.6 (OCH2CH2CH2Ar), 36.4 (C-5’), 36.4 
(NCH2CH2), 38.1 (CH2CH2OBn), 40.8 (NCH2CH2), 65.7 (C-6’), 66.0 (OCH2), 66.5 (C-3), 69.0 
(C-7), 70.1 (OCH2CO2tBu), 70.4 (OCH2), 70.6 (OCH2), 70.6 (3 × OCH2), 70.7 (OCH2), 72.9 
(OCH2), 81.5 (C(CH3)3), 98.5 (C-2’), 115.3 (d, JCF = 21.2 Hz, 2CH, Ar), 115.4 (C, Ar), 119.7 
(2CH, Ar), 121.7 (C, Ar), 126.5 (CH, Ar), 127.6 (4CH, Ar), 128.2 (C, Ar), 128.3 (3CH, Ar), 
128.6 (2CH, Ar), 128.7 (C, Ar), 130.4 (2CH, Ar), 133.2 (d, JCF = 8.0 Hz, 2CH, Ar), 134.7 (C, 
Ar); 136.1 (C, Ar), 137.2 (C, Ar), 138.5 (C, Ar), 141.3 (C, Ar), 162.9 (d, JCF = 379.8 Hz, C, Ar), 
163.5 (CONH), 169.7 (CO2tBu); HRMS (ESI): [M+Na]
+
 calcd for C58H75FN2O10Na 
1001.52980, found 1001.530129. 
 
tert-Butyl 2-(2-(2-(3-(4-(5-(4-fluorophenyl)-1-(2-((4R,6S)-6-(2-hydroxyethyl)-2,2-dimethyl-
1,3-dioxan-4-yl)ethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-
carboxamido)phenyl)propoxy)ethoxy)ethoxy)acetate (1-136) 
 
A solution of benzyl ether 1-135 (650 mg, 0.07 mmol) in dry ethyl acetate (7 mL) was 
hydrogenated for 6 h under balloon pressure in presence of a catalytic amount of 20% Pd(OH)2 
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on carbon. The mixture was filtered through a pad of celite and the filtrate was concentrated in 
vacuo. The residue was purified by flash chromatography (ethyl acetate only) to afford alcohol 
1-136 (540 mg, 82%) as colorless oil. Rf = 0.25 (EtOAc/petroleum ether, 7:3); []D
20
 = −2.8 (c 
1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.12 (ddd,  J = 12.9, 11.9, 11.1 Hz, 1H, 5’-H), 
1.21 (ddd, J = 12.9, 2.8, 2.5 Hz, 1H, 5’-H), 1.30 (s, 3H, 2’-CH3), 1.35 (s, 3H, 2’-CH3), 1.45 (s, 
9H, C(CH3)3), 1.51 (d, J = 7.1 Hz, 6H, CH(CH3)2), 1.57–1.73 (m, 4H, NCH2CH2, CH2CH2OH), 
1.76–1.87 (m, 2H, OCH2CH2CH2Ar), 2.39 (s, br, 1H, OH), 2.56 (dd, J = 7.8, 7.3 Hz, 2H, 
OCH2CH2CH2Ar), 3.41 (dd, J = 6.6, 6.3 Hz, 2H, OCH2CH2CH2Ar), 3.49–3.58 (m, 3H, 
CH(CH3)2, CH2CH2OH), 3.59–3.76 (m, 11H, 4’-H, OCH2), 3.81 (ddd, J = 14.9, 10.1, 6.3 Hz, 
1H, NCH2CH2), 3.94–4.02 (m, 1H, 6’-H), 4.00 (s, 2H, OCH2CO2tBu), 4.06 (ddd, J = 14.9, 10.1, 
4.8 Hz, 1H, NCH2CH2), 6.81 (s, 1H, CONH), 6.92–7.02 (m, 6H, Ar-H), 7.09–7.22 (m, 7H, Ar-
H); 
13
C NMR (100 MHz, CDCl3):  = 19.7 (2’-CH3), 21.6 (CH(CH3)2), 21.7 (CH(CH3)2), 26.1 
(CH(CH3)2), 28.1 (C(CH3)3), 30.0 (2’-CH3), 31.1 (OCH2CH2CH2Ar), 31.6 (OCH2CH2CH2Ar), 
36.1 (C-5’), 38.0 (NCH2CH2), 38.0 (CH2CH2OH), 40.8 (NCH2CH2), 60.6 (OCH2), 66.5 (C-4’), 
68.8 (C-6’), 69.0 (OCH2CO2tBu), 70.1 (CH2CH2OH), 70.4 (OCH2CH2CH2Ar), 70.5 (2 × OCH2), 
70.6 (2 × OCH2), 70.7 (OCH2), 81.5 (C(CH3)3), 98.6 (C-2’), 115.3 (d, JCF = 21.2 Hz, 2CH, Ar). 
115.4 (C, Ar), 119.7 (2CH, Ar), 121.7 (C, Ar), 126.5 (CH, Ar), 128.3 (2CH, Ar), 128.3 (C, Ar), 
128.6 (2CH, Ar), 128.7 (C, Ar), 128.4 (d, JCF = 3.7 Hz, C, Ar), 130.4 (2CH, Ar), 133.1 (d, JCF = 
8.0 Hz, 2CH, Ar), 134.6 (C, Ar), 136.1 (C, Ar), 137.2 (C, Ar), 162.9 (d, JCF = 378.4 Hz, C, Ar), 
163.4 (CONH), 169.7 (CO2tBu); HRMS (ESI): [M+Na]
+
 calcd for C51H69FN2O10Na 911.48285, 
found 911.483546. 
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2-((4R,6R)-6-(2-(3-((4-(2,2-Dimethyl-4-oxo-3,6,9,12-tetraoxapentadecan-15-
yl)phenyl)carbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-
dimethyl-1,3-dioxan-4-yl)acetic acid (1-137) 
 
To a cooled solution (ice/water bath) of alcohol 1-136 (540 mg, 0.60 mmol) in CH2Cl2 (20 mL) 
was added Dess-Martin periodinane (335 mg, 0.78 mmol) in one portion. The mixture was 
stirred for 1 h at room temperature, washed with saturated NaHCO3 (10 mL), 1M Na2S2O3 (10 
mL), and saturated NaCl solution. The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated under vacuum. The residue was purified by passing it through a short silica gel 
column (EtOAc/petroleum ether, 3:2) to afford intermediate aldehyde (400 mg, 0.45 mmol) 
which was dissolved in t-butanol (15 mL). 2-Methyl-2-butene (2 mL) was added followed by the 
addition of an aqueous solution (15 mL) of NaH2PO4•2H2O (422 mg, 2.7 mmol) and NaClO2 (81 
mg, 0.90 mmol). The mixture was stirred for 6 h at room temperature and then extracted with 
ethyl acetate (3 × 15 mL). The combined organic layers were dried over anhydrous MgSO4, 
filtered and concentrated under vacuum. The residue was purified by flash chromatography 
(methanol/CH2Cl2/AcOH, 1:20:0.001) to furnish acid 1-137 (390 mg, 96%) as yellow colored 
sticky oil. Rf = 0.11 (methanol/CH2Cl2/AcOH, 1:20:0.001); []D
20
 = 3.8 (c 1.0, CHCl3); 
1
H 
NMR (400 MHz, CDCl3):  = 1.05 (dd, J = 12.4, 11.9 Hz, 1H, 5’-H), 1.30 (s, 3H, 2’-CH3), 1.30–
1.36 (m, 1H, 5’-H), 1.36 (s, 3H, 2’-CH3), 1.45 (s, 9H, C(CH3)3), 1.51 (d, J = 7.1 Hz, 6H, 
CH(CH3)2), 1.57–1.72 (m, 2H, NCH2CH2), 1.76–1.90 (m, 2H, OCH2CH2CH2Ar), 2.37 (dd, J = 
15.9, 5.8 Hz, 1H, CH2COOH), 2.52 (dd, J = 15.9, 6.8 Hz, 1H, CH2COOH), 2.57 (dd, J = 8.1, 7.3 
Hz, 2H, OCH2CH2CH2Ar), 3.41 (dd, J = 6.6, 6.6 Hz, 2H, OCH2CH2CH2Ar), 3.47–3.59 (m, 3H, 
CH(CH3)2, OCH2), 3.59–3.74 (m, 11H, 4’-H, OCH2), 3.82 (ddd, J = 14.9, 9.6, 6.1 Hz, 1H, 
NCH2CH2), 4.00 (s, 2H, OCH2CO2tBu), 4.07 (ddd, J = 14.9, 9.3, 5.0 Hz, 1H, NCH2CH2), 4.18 
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(dddd, J = 11.9, 9.6, 5.3, 3.3 Hz, 1H, 6’-H), 6.82 (s, 1H, CONH), 6.91–7.05 (m, 6H, Ar-H), 
7.09–7.21 (m, 7H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 19.6 (2’-CH3), 21.6 (CH(CH3)2), 
21.8 (CH(CH3)2), 26.1 (CH(CH3)2), 29.8 (2’-CH3), 31.1 (OCH2CH2CH2Ar), 31.6 
(OCH2CH2CH2Ar), 35.7 (C-5’), 37.8 (NCH2CH2), 40.8 (NCH2CH2), 40.8 (CH2COOH), 65.5 (C-
6’), 66.4 (C-4’), 69.0 (OCH2CO2tBu), 70.1 (OCH2), 70.4(OCH2), 70.5 (2 OCH2), 70.6 (2 OCH2), 
70.6 (OCH2CH2CH2Ar), 70.7 (OCH2), 81.5 (C(CH3)3), 99.0 (C-2’), 115.4 (d, JCF = 21.9 Hz, 
2CH, Ar), 115.5 (C, Ar), 119.8 (2CH, Ar), 121.8 (C, Ar), 126.5 (CH, Ar), 128.3 (C, Ar), 128.3 
(2CH, Ar), 128.6 (2CH, Ar), 128.7 (C, Ar), 130.4 (2CH, Ar), 133.1 (d, JCF = 8.0 Hz, 2CH, Ar), 
134.5 (C, Ar), 136.0 (C, Ar), 137.3 (C, Ar), 141.1 (C, Ar), 162.9 (d, JCF = 393.7 Hz, C, Ar), 
163.5 (CONH), 169.7 (CO2tBu); HRMS (ESI): [M+Na]
+
 calcd for C51H67FN2O11Na 925.46211, 
found 925.462059. 
 
tert-Butyl 2-(2-(2-(3-(4-(5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-
pyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-
carboxamido)phenyl)propoxy)ethoxy)ethoxy)acetate (1-138) 
 
Camphorsulphonic acid (195 mg, 0.84 mmol) was added to a solution of acetonide acid 1-137 
(380 mg, 0.42 mmol) in CH2Cl2 (5 mL). The reaction was completed within 3 h (TLC control). 
The solution was washed with saturated NaHCO3 solution (5 mL), water (5 mL), and saturated 
NaCl solution. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. Purification by flash chromatography (methanol/CH2Cl2/AcOH, 3:97: 0.001) provided 
lactone 1-138 (240 mg, 68%) as colorless sticky solid. Rf = 0.33 (methanol/CH2Cl2/AcOH, 3:97: 
0.001); []D
20
 = +17.5 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.45 (s, 9H, C(CH3)3), 
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1.50 (d, J = 6.8 Hz, 3H, CH(CH3)2), 1.51 (d, J = 6.6 Hz, 3H, CH(CH3)2), 1.54–1.61 (m, 1H, 3’-
H), 1.66–1.91 (m, 6H, NCH2CH2, 3’-H, OCH2CH2CH2Ar, OH), 2.50–2.59 (m, 3H, 5’-H, 
OCH2CH2CH2Ar), 2.62 (dd, J = 17.9, 4.8 Hz, 1H, 5’-H), 3.41 (dd, J = 6.6, 6.6 Hz, 
OCH2CH2CH2Ar), 3.47–3.57 (m, 3H, CH(CH3)2, OCH2), 3.59–3.72 (m, 10H, OCH2), 3.95–4.06 
(m, 1H, NCH2CH2), 4.00 (s, 2H, OCH2CO2tBu), 4.19 (ddd, J = 14.9, 10.1, 4.8 Hz, 1H, 
NCH2CH2), 4.24–4.31 (m, 1H, 4’-H), 4.50 (dddd, J = 11.4, 8.6, 3.3, 3.0 Hz, 1H, 2’-H), 6.83 (s, 
1H, CONH), 6.91–7.04 (m, 6H, Ar-H), 7.08–7.22 (m, 7H, Ar-H); 13C NMR (100 MHz, CDCl3): 
 = 21.7 (CH(CH3)2), 22.0 (CH(CH3)2), 26.1 (CH(CH3)2), 28.1 (C(CH3)3), 31.1 
(OCH2CH2CH2Ar), 31.6 (OCH2CH2CH2Ar), 35.6 (C-3’), 37.1 (NCH2CH2), 38.5 (C-5’), 40.7 
(NCH2CH2), 62.3 (C-4’), 69.0 (OCH2COtBu), 70.1 (OCH2), 70.4 (OCH2CH2CH2Ar), 70.5 (3 
OCH2), 70.6 (OCH2), 70.7 (OCH2), 73.0 (C-3), 81.5 (C(CH3)3), 115.6 (d, JCF = 21.9 Hz, 2CH, 
Ar), 115.7 (C, Ar), 119.8 (2CH, Ar), 122.0 (C, Ar), 126.6 (CH, Ar), 128.0 (d, JCF = 3.7 Hz, C, 
Ar), 128.3 (2CH, Ar), 128.6 (2CH, Ar), 130.3 (2CH, Ar), 133.0 (d, JCF = 8.0 Hz, 2CH, Ar), 
134.4 (C, Ar), 135.9 (C, Ar), 137.4 (C, Ar), 141.1 (C, Ar), 162.9 (d, JCF = 377.6 Hz, C, Ar), 
163.5 (CONH), 169.5 (C=O, lactone), 169.7 (C=O, ester); HRMS (ESI): [M+Na]
+
 calcd for 
C48H61FN2O10Na 867.42025, found 867.420241. 
 
2-(2-(2-(3-(4-(5-(4-Fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-
yl)ethyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-
carboxamido)phenyl)propoxy)ethoxy)ethoxy)acetic acid (1-139)
82
 
 
Aqueous phosphoric acid (58 L, 0.5 mmol, 85 wt%) was added to a solution of ester 1-138 (85 
mg, 0.1 mmol) in CH2Cl2 (2 mL). The reaction mixture was stirred about 7 h at room 
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temperature. After completion, the reaction mixture was diluted with water (2 mL) and extracted 
with CH2Cl2 (3 × 5 mL). The combined organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated under vacuum. The residue was purified by flash chromatography 
(acetone/CH2Cl2/AcOH, 1:1:0.01) to afford atorvastatin lactone TEG acid 1-139 (45 mg, 84%) 
as sticky oil. Rf = 0.40 (acetone/CH2Cl2/AcOH, 3:7:0.01); []D
20
 = 15.5 (c 0.5, CHCl3); 
1
H 
NMR (400 MHz, CDCl3):  = 1.50 (d, J = 6.8 Hz, 6H, CH(CH3)2), 1.53–1.62 (m, 1H, 3’-H), 
1.67–1.91 (m, 5H, NCH2CH2, 3’-H, OCH2CH2CH2Ar), 2.48–2.59 (m, 3H, 5’-H, 
OCH2CH2CH2Ar), 2.62 (dd, J = 17.7, 4.8 Hz, 1H, 5’-H), 3.42 (dd, J = 6.6, 6.6 Hz, 2H, 
OCH2CH2CH2Ar), 3.46–3.74 (m, 13H, CH(CH3)2, OCH2), 4.01 (ddd, J = 14.9, 8.8, 5.0 Hz, 1H, 
NCH2CH2), 4.10 (s, 2H, OCH2CO2tBu), 4.18 (ddd, J = 14.9, 9.9, 4.8 Hz, 1H, NCH2CH2), 4.24–
4.30 (m, 1H, 4’-H), 4.45–4.55 (m, 1H, 2’-H), 6.86 (s, 1H, CONH), 6.92–7.04 (m, 6H, Ar-H), 
7.07–7.23 (m, 8H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 21.7 (CH(CH3)2), 22.0 (CH(CH3)2), 
26.1 (CH(CH3)2), 30.8 (OCH2CH2CH2Ar), 31.4 (OCH2CH2CH2Ar), 35.6 (C-3’), 37.1 
(NCH2CH2), 38.4 (C-5’), 40.7 (NCH2CH2), 62.3 (C-4’), 69.2 (OCH2CO2tBu), 70.0 (OCH2), 70.2 
(2 OCH2), 70.3 (OCH2), 70.4 (OCH2), 70.5 (OCH2), 71.1 (OCH2), 73.0 (C-2’), 115.6 (d, JCF = 
22.0 Hz, 2CH, Ar), 115.7 (C, Ar), 120.0 (2CH, Ar), 122.0 (C, Ar), 126.6 (CH, Ar), 128.0 (d, JCF 
= 3.7 Hz, C, Ar), 128.3 (2CH, Ar), 128.7 (2CH, Ar), 128.7 (C, Ar), 130.3 (2CH, Ar), 133.1 (d, 
JCF = 8.0 Hz, 2CH, Ar), 134.4 (C, Ar), 135.9 (C, Ar), 137.3 (C, Ar), 141.0 (C, Ar), 163.0 (d, JCF 
= 395.9 Hz, C, Ar), 163.5 (C=O, amide), 163.8 (C=O, lactone), 169.6 (C=O, acid); HRMS 
(ESI): [M+Na]
+
 calcd for C44H53FN2O10Na 787.36115, found 787.361297. 
 
2-(4-Fluorophenyl)-5-isopropyl-1-phenethyl-3-phenyl-1H-pyrrole (1-140) 
 
A mixture of diketone 1-27 (0.502 g, 1.7 mmol) and 2-phenylethyl amine (0.317 mL, 2.5 mmol) 
was refluxed in toluene (10 mL) in presence of p-TSA•H2O (96 mg, 0.5 mmol) for 72 h. The 
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reaction mixture was cooled to the room temperature and diluted with diethyl ether (10 mL). The 
mixture was washed with saturated NaHCO3 solution (5 mL), water (5 mL) and saturated NaCl 
solution. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. 
Purification of the crude residue by flash chromatography (diethyl ether/petroleum ether, 1:50) 
afforded pyrrole 1-140 (0.620 g, 98%) as white solid, m.p. 99–101 °C. Rf = 0.43 
(EtOAc/petroleum ether, 1:25); 
1
H NMR (400 MHz, CDCl3):  = 1.33 (d, J = 6.6 Hz, 6H, 
CH(CH3)2), 2.67 (dd, J = 8.1, 7.8 Hz, 2H, NCH2CH2Ph), 2.91 (app septet, J = 6.6 Hz, 1H, 
CH(CH3)2), 3.98 (dd, J = 8.1, 7.8 Hz, 2H, NCH2CH2Ph), 6.22 (s, 1H, 4-H, pyrrole), 6.84 (d, J = 
7.1 Hz, 2H, Ar-H), 7.01–7.32 (m, 12H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 23.6 
(CH(CH3)2), 25.9 (CH(CH3)2), 37.9 (NCH2CH2Ph), 45.4 (NCH2CH2Ph), 103.5 (CH, Ar), 115.6 
(d, JCF = 21.2 Hz, 2CH, Ar), 122.2 (C, Ar), 124.8 (CH, Ar), 126.5 (CH, Ar), 127.5 (2CH, Ar), 
127.9 (C, Ar), 128.0 (2CH, Ar), 128.5 (4CH, Ar), 129.8 (d, JCF = 3.7 Hz, C, Ar), 133.8 (d, JCF = 
7.3 Hz, 2CH, Ar), 136.5 (C, Ar), 138.1 (C, Ar), 140.2 (C, Ar), 162.3 (d, JCF = 247.4 Hz, C, Ar); 
HRMS (ESI): [M+H]
+
 calcd for C27H27FN 384.212204, found 384.212478. 
 
3-Bromo-5-(4-fluorophenyl)-2-isopropyl-1-phenethyl-4-phenyl-1H-pyrrole (1-141) 
 
NBS (333 mg, 1.9 mmol) was added to a solution of pyrrole 1-140 (598 mg, 1.6 mmol) in DMF 
(12 mL) at room temperature and the mixture was stirred for 90 min (TLC control). The mixture 
was diluted with diethyl ether (15 mL), washed with saturated NaHCO3 solution (10 mL), water 
(10 mL) and saturated NaCl solution. The organic layer was dried over anhydrous MgSO4, 
filtered and concentrated under vacuum. Purification of the residue by passing it through a short 
plug of silica gel (EtOAc/petroleum ether, 1:20) yielded bromopyrrole 1-141 (629 mg, 87%) as 
pale yellow colored sticky oil. Rf = 0.33 (EtOAc/petroleum ether, 1:20); 
1
H NMR (400 MHz, 
CDCl3):  = 1.50 (d, J = 7.1 Hz, 6H, CH(CH3)2), 2.72 (dd, J = 7.8, 7.8 Hz, 2H, NCH2CH2Ph), 
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3.27 (app septet, J = 7.1 Hz, 1H, CH(CH3)2), 3.99 (dd, J = 7.8, 7.8 Hz, 2H, NCH2CH2Ph), 6.81 
(d, J = 7.3 Hz, 2H, Ar-H), 6.89–7.05 (m, 4H, Ar-H), 7.06–7.23 (m, 8H, Ar-H); 13C NMR (100 
MHz, CDCl3):  = 21.2 (CH(CH3)2), 26.5 (CH(CH3)2), 38.1 (NCH2CH2Ph), 46.2 (NCH2CH2Ph), 
94.7 (C, Ar), 115.2 (d, JCF = 21.2 Hz, 2CH, Ar), 123.1 (C, Ar), 125.9 (CH, Ar), 126.7 (CH, Ar), 
127.5 (C, Ar), 127.5 (2CH, Ar), 128.2 (C, Ar), 128.5 (2CH, Ar), 128.6 (2CH, Ar), 128.9 (C, Ar), 
130.5 (2CH, Ar), 133.0 (d, JCF = 8.0 Hz, 2CH, Ar), 134.1 (C, Ar), 134.3 (C, Ar), 137.7 (C, Ar), 
162.1 (d, JCF = 247.4 Hz, C, Ar). 
 
5-(4-Fluorophenyl)-2-isopropyl-1-phenethyl-4-phenyl-1H-pyrrole-3-carboxylic acid (1-142) 
 
To a cooled (−78 °C) solution of bromopyrrole 1-141 (199 mg, 0.43 mmol) in THF (5 mL) was 
added slowly n-BuLi (0.361 mL, 0.90 mmol, 2.5M in hexane). After 5 min, excess of solid CO2 
was added to the mixture; the flask was removed from the cooling bath and allowed to warm to 
room temperature. After evolution of excess of CO2 gas the mixture was quenched with saturated 
NH4Cl solution and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated. Purification by flash chromatography 
(EtOAc/petroleum ether, 1:4) of the solid residue provided acid 1-142 (171 mg, 93%) as white 
solid. Rf = 0.27 (EtOAc/petroleum ether, 1:4); 
1
H NMR (400 MHz, CDCl3):  = 1.50 (d, J = 7.3 
Hz, 6H, CH(CH3)2), 2.16 (acetone), 2.73 (dd, J = 8.3, 7.6 Hz, 2H, NCH2CH2Ph), 3.71 (app 
septet, J = 7.1 Hz, CH(CH3)2), 4.04 (dd, J = 8.1, 7.8 Hz, NCH2CH2Ph), 6.81 (d, J = 7.3 Hz, 2H, 
Ar-H), 6.93–7.30 (m, 12H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 21.1 (CH(CH3)2), 26.1 
(CH(CH3)2), 30.9 (CH(CH3)2), 37.7 (CH2Ph), 46.4 (NCH2), 115.2 (d, J = 21.2 Hz, 2CH, Ar), 
124.9 (d, JCF = 3.7 Hz, C, Ar), 125.9 (CH, Ar), 126.8 (CH, Ar), 127.3 (2CH, Ar), 128.5 (2CH, 
Ar), 128.7 (2CH, Ar), 130.1 (C, Ar), 130.5 (2CH, Ar), 133.3 (d, J = 8.0 Hz, 2CH, Ar), 135.3 (C, 
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Ar), 137.5 (C, Ar), 144.3 (C, Ar), 162.2 (d, JCF = 248.8 Hz, C, Ar), 169.0 (COOH); HRMS 
(ESI): [M+Na]
+
 calcd for C28H26FNO2Na 450.183978, found 450.183914. 
 
5-(4-Fluorophenyl)-N-(4-(3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propyl)phenyl)-2-
isopropyl-1-phenethyl-4-phenyl-1H-pyrrole-3-carboxamide (1-143) 
 
To a cooled (~ 0 °C) solution of acid 1-142 (255 mg, 0.64 mmol) and amine 1-121 (275 mg, 0.64 
mmol) in CH2Cl2 (10 mL) was added DIPEA (0.34 mL, 0.77 mmol) and PyBrOP (1.93 mmol). 
The mixture was allowed to stir at room temperature for completion (TLC control). After 24 h, 
the mixture was diluted with CH2Cl2 (10 mL), washed with water (5 × 20 mL) and saturated 
NaCl solution. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated 
under vacuum and the residue purified by flash chromatography (EtOAc/petroleum ether, 3:7) to 
yield amide 1-143 (350 mg, 67%) as reddish yellow oil. Rf = 0.34 (EtOAc/petroleum ether, 3:7); 
1
H NMR (400 MHz, CDCl3):  = 0.05 (s, 6H, Si(CH3)2), 0.88 (s, 9H, SiC(CH3)3), 1.56 (d, J = 
7.1 Hz, 6H, CH(CH3)2), 1.78–1.87 (m, 2H, OCH2CH2CH2Ar), 2.58 (dd, J = 7.8, 7.6 Hz, 2H, 
OCH2CH2CH2Ar), 2.74–2.80 (m, 2H, NCH2CH2Ph), 3.42 (dd, J = 6.6, 6.3 Hz, 2H, 
OCH2CH2CH2Ar), 3.52–3.58 (m, 4H, OCH2), 3.60–3.68 (m, 7H, CH(CH3)2, OCH2), 3.75 (dd, J 
= 5.6, 5.3 Hz, 2H, OCH2), 4.01–4.10 (m, 2H, NCH2CH2Ph), 6.95–7.07 (m, 6H, Ar-H), 7.08–7.27 
(m, 12H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = −5.28 (Si(CH3)2), 18.3 (SiC(CH3)3), 21.8 
(CH(CH3)2), 25.9 (SiC(CH3)3), 26.3 (CH(CH3)2), 31.2 (OCH2CH2CH2Ar), 31.6 
(OCH2CH2CH2Ar), 37.9 (NCH2CH2Ph), 46.2 (NCH2CH2Ph), 62.7 (CH2OTBS), 70.1 (OCH2), 
70.4 (OCH2), 70.6 (OCH2), 70.7 (2 × OCH2), 72.6 (OCH2), 115.3 (d, JCF = 21.1 Hz, 2CH, Ar), 
115.5 (C, Ar), 119.7 (2CH, Ar), 121.8 (C, Ar), 126.8 (CH, Ar), 128.3 (d, JCF = 3.7 Hz, C, Ar), 
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128.3 (2CH, Ar), 128.5 (2CH, Ar), 128.6 (2CH, Ar), 128.7 (2CH, Ar), 129.0 (C, Ar), 130.5 
(2CH, Ar), 131.5 (CH, Ar), 133.2 (d, J = 8.0 Hz, 2CH, Ar), 134.6 (C, Ar), 136.1 (C, Ar), 137.2 
(C, Ar), 137.6 (C, Ar), 141.2 (C, Ar), 162.3 (d, JCF = 248.1 Hz, C, Ar), 164.6 (CONH). 
 
5-(4-Fluorophenyl)-2-isopropyl-1-phenethyl-4-phenyl-N-(4-(14,14,15,15-tetramethyl-
4,7,10,13-tetraoxahexadecyl)phenyl)-1H-pyrrole-3-carboxamide (1-144) 
 
A solution of silyl ether 1-143 (250 mg, 0.31 mmol) in methanol (3 mL) containing a catalytic 
amount of p-TSA•H2O was stirred at room temperature. After 2 h, the reaction mixture was 
diluted with ethyl acetate (5 mL), washed with saturated NaHCO3 and saturated NaCl solution. 
The separated organic layer was dried over anhydrous MgSO4, filtered and concentrated under 
vacuum. The residue was purified by flash chromatography using pure ethyl acetate to afford 1-
144 (170 mg, 79%) as pale yellow colored thick oil. Rf = 0.24 (only EtOAc); 
1
H NMR (400 
MHz, CDCl3):  = 1.56 (d, J = 7.1 Hz, 6H, CH(CH3)2), 1.77–1.89 (m, 2H, OCH2CH2CH2Ar), 
2.31 (br, s, 1H, OH), 2.58 (dd, J = 7.6, 7.6 Hz, 2H, OCH2CH2CH2Ar), 2.77 (dd, J = 8.3, 7.6 Hz, 
2H, NCH2CH2Ph), 3.42 (dd, J = 6.6, 6.3 Hz, 2H, OCH2CH2CH2Ar), 3.51–3.75 (m, 12H, OCH2), 
4.05 (dd, J = 8.1, 8.1 Hz, 2H, NCH2CH2Ph), 6.81 (br, s, 1H, CONH), 6.84 (d, J = 6.3 Hz, 2H, 
Ar-H), 6.93–7.06 (m, 6H, Ar-H), 7.08–7.34 (m, 10H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 
21.8 (CH(CH3)2), 26.3 (CH(CH3)2), 31.1 (OCH2CH2CH2Ar), 31.6 (OCH2CH2CH2Ar), 37.9 
(NCH2CH2Ph), 46.2 (NCH2CH2Ph), 61.7 (CH2OH), 70.1 (OCH2), 70.4 (2 × OCH2), 70.6 (2 × 
OCH2), 72.5 (OCH2), 115.4 (d, JCF = 21.2 Hz, 2CH, Ar), 115.4 (C, Ar), 119.7 (2CH, Ar), 121.8 
(C, Ar), 126.6 (CH, Ar), 126.8 (CH, Ar), 128.3 (2CH, Ar), 128.5 (2CH, Ar), 128.6 (2CH, Ar), 
128.7 (2CH, Ar), 130.5 (2CH, Ar), 131.48, 133.2 (d, JCF = 8.0 Hz, 2CH, Ar), 134.6 (C, Ar), 
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136.1 (C, Ar), 137.2 (C, Ar), 137.6 (C, Ar), 141.2 (C, Ar), 162.3 (d, JCF = 247.4 Hz, C, Ar), 
163.5 (CONH); HRMS (ESI): [M+H]
+
 calcd for C43H50FN2O5 693.36983, found 693.36979. 
 
2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (2-5)
171
 
 
Tosyl chloride (10 g, 52.4 mmol) was added in a mixture of triethylene glycol 2-4 (31.5 g, 210 
mmol) and Et3N (105 mmol) in CH2Cl2 (250 mL) at room temperature. The reaction was 
completed in 1 h (TLC). Then the mixture was washed with 1M KHSO4 solution (150 mL), 5% 
NaHCO3 solution (150 mL) and saturated NaCl solution (100 mL). The organic layer was dried 
over anhydrous Na2SO4, filtered and concentrated under vacuum. The crude oil was purified by 
flash chromatography (MeOH/CH2Cl2, 1:19) to afford alcohol 2-5 (14.84 g, 93%) as colorless 
oil. Rf = 0.2 (EtOAc/petroleum ether, 1:4); 
1
H NMR (400 MHz, CDCl3)  = 2.26 (s, 1H, OH), 
2.42 (s, 3H, CH3), 3.55 (dd, J = 4.5, 4.5 Hz, 2H, OCH2), 3.59 (s, 4H, OCH2), 3.68 (dd, J = 9.6, 
4.8 Hz, 4H, OCH2), 4.14 (dd, J = 4.8, 4.8 Hz, 2H, OCH2), 7.32 (d, J = 8.1 Hz, 2H, Ar-H), 7.78 
(d, J = 8.1 Hz, 2H, Ar-H); 13C NMR (100 MHz, CDCl3)  = 21.6 (CH3), 61.7 (OCH2), 68.6 
(OCH2), 69.1 (OCH2), 70.7 (OCH2), 72.4 (OCH2), 127.9 (2CH, Ar), 129.8 (2CH, Ar), 132.9 (C, 
Ar), 144.8 (C, Ar). 
 
2-(2-(2-Azidoethoxy)ethoxy)ethanol (2-6)
172
 
 
A mixture of tosylate 2-5 (14.84g, 48.7 mmol) and NaN3 (6.34 g, 97.5 mmol) in DMF (75 mL) 
was stirred at 50 °C. After 14 h, the reaction mixture was quenched by addition of water (50 mL) 
and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with 
saturated NaCl solution (100 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by flash chromatography (MeOH/CH2Cl2, 1:20) to afford 
azide 2-6 (7.89 g, 92%) as colorless oil. Rf = 0.17 (MeOH/CH2Cl2, 1:4); 
1
H NMR (400 MHz, 
CDCl3):  = 2.31 (s, 1H, OH), 3.38 (dd, J = 4.9, 4.9 Hz, 2H, OCH2), 3.58–3.60 (dd, J = 4.5, 4.5 
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Hz, 2H, OCH2), 3.65–3.68 (m, 6H, OCH2), 3.70–3.73 (dd, J = 4.4, 4.4 Hz, 2H, OCH2); 
13
C 
NMR (100 MHz, CDCl3):  = 50.6 (CH2N3), 61.7 (CH2OH), 70.0 (OCH2), 70.3 (OCH2), 70.6 
(OCH2), 72.4 (OCH2). 
 
tert-Butyl 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)acetate (2-7)
172
 
 
NaH (2.67 g, 66.8 mmol, 60 % suspension in oil) was added to a solution of alcohol 2-6 (7.8 g, 
44.5 mmol) in DMF (150 mL) at room temperature. The reaction mixture was allowed to stir for 
30 min before tert-butyl bromoacetate (13.2 mL, 89.0 mmol) was added to the reaction mixture 
and stirring was continued for 3 h. The reaction mixture was quenched by addition of a small 
amount of water and then extracted with ethyl acetate (3 × 100 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under vacuum. Purification by flash 
chromatography of the residual material afforded ester 2-7 (9.78g, 76%) as colorless oil. Rf = 
0.46 (petroleum ether/EtOAc, 1:1); 
1
H NMR (400 MHz, CDCl3)  = 1.46 (s, 9H, C(CH3)3), 3.37 
(dd, J = 5.1, 5.1 Hz, 2H, CH2N2), 3.64–3.73 (m, 10H, OCH2), 4.01 (s, 2H, OCH2CO); 
13
C NMR 
(100 MHz, CDCl3)  = 28.1 (C(CH3)3), 50.7 (CH2N3), 69.0 (OCH2), 70.0 (OCH2), 70.6 (OCH2), 
70.7 (3 × OCH2), 81.5 (C(CH3)3), 169.6 (CO2tBu). 
 
tert-Butyl 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)acetate (2-8)
163
 
 
Azide 2-7 (2.31 g, 7.9 mmol) was dissolved in a mixture of THF (23 mL) and H2O (2.3 mL) and 
PPh3 (4.19 g, 16.0 mmol) was added to the mixture which was stirred for 8 h at room 
temperature. The reaction volume was reduced to ~10 mL on a rotary evaporator, diluted with 
toluene (10 mL) and concentrated to remove water as azeotropic mixture. This manipulation was 
repeated once and then the crude residue was purified by flash chromatography 
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(MeOH/CH2Cl2/NH4OH, 1:9:0.005) which afforded amine 2-8 (1.68 g, 92%) as colorless oil. Rf 
= 0.17 (MeOH/CH2Cl2/NH4OH, 1:9:0.005); 
1
H NMR (400 MHz, CDCl3)  = 1.44 (s, 9H, 
C(CH3)3), 2.01 (s, 2H, NH2), 2.86 (dd, J = 5.2, 5.2 Hz, 2H, CH2NH2), 3.51 (dd, 2H, J = 5.2, 5.2 
Hz, OCH2), 3.59–3.71 (m, 8H, OCH2), 4.00 (s, 2H, OCH2CO2tBu); 
13
C NMR (100 MHz, 
CDCl3):  = 28.1 (C(CH3)3), 41.6 (CH2NH2), 69.0 (OCH2), 70.2 (OCH2), 70.5 (2 × OCH2), 70.6 
(OCH2), 73.0 (OCH2CO), 81.6 (C(CH3)3), 169.7 (CO2tBu). 
 
2,2,2-Trifluoro-1-piperidin-1-yl-ethanone (2-10)
98a
 
 
To a solution of piperidine (12.4 mL, 126 mmol) and triethylamine (14.6 mL, 105 mmol) in 
diethyl ether (6 mL) was added TFAA (14.8 mL, 105 mmol) via dropping funnel at room 
temperature over 3 h. The reaction mixture was cooled to 0 °C and stirred vigorously for 1 h at 
room temperature. The mixture was washed with 1N HCl solution (50 mL) and the separated 
organic layer was dried over Na2SO4, filtered and concentrated under vacuum. The residue was 
purified by high vacuum distillation (40 °C, 0.3 mbar) to furnish 2-10 (17.15 g, 90%) as 
colorless liquid. 
1
H NMR (400 MHz, CDCl3):  = 1.53–1.71 (m, 6H, CH2), 3.46–3.53 (t, J = 5.0 
Hz, 2H, NCH2), 3.54–3.62 (t, J = 5.6 Hz, 2H, NCH2); 
13
C NMR (100 MHz, CDCl3):  = 23.9 
(CH2), 25.3 (CH2), 26.2 (CH2), 44.7 (NCH2), 46.9 (q, JCF = 3.7 Hz, NCH2), 114.7 (q, JCF = 286.2 
Hz, CF3, minor), 116.5 (q, JCF = 287.6 Hz, CF3, major), 155.5 (q, JCF = 35.7 Hz, C=O, major), 
157.9 (q, JCF = 41.0 Hz, C=O, minor). 
 
2,2,2-Trifluoro-1-(4-tolyl)ethanone (2-11)
98a
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A three neck round bottom flask equipped with a reflux condenser, addition funnel and a 
pressure equalizing bubbler was charged with magnesium turnings (2.47 g, 101.5 mmol) and 
THF (100 mL) under nitrogen atmosphere. Preparation of Grignard reagent was initiated by 
addition of a small amount (~1 mL) of 4-bromotoluene 2-9 (12.42 mL, 100.1 mmol) and 
thereafter the rest of 2-9 in THF (30 mL) was added dropwise using a dropping funnel 
maintaining gentle refluxing. The mixture was heated to reflux for 1 h and then added to a flask 
containing a precooled (−78 °C) solution of amide 2-10 in THF (120 mL). The reaction mixture 
was allowed to stir at room temperature (14 h) overnight, and then quenched by addition of 
saturated NH4Cl solution (50 mL). The organic layer was separated and the aqueous layer was 
extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed successively 
with 1N HCl (2 × 60 mL), water (2 × 100 mL) and saturated NaCl solution (100 mL). The 
separated organic layer was dried over MgSO4, filtered and concentrated to afford sufficiently 
pure ketone 2-11 (18.23 g, 96%) as yellow colored oil. Rf = 0.58 (diethyl ether/petroleum ether, 
2:3); 
1
H NMR (400 MHz, CDCl3):  = 2.45 (s, 3H, CH3), 7.33 (d, J = 8.1 Hz, 2H, Ar-H), 7.06 
(d, J = 7.8 Hz, 2H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 21.9 (CH3), 116.7 (d, JCF = 291.3 
Hz, CF3), 127.4 (C, Ar), 129.8 (2CH, Ar), 130.2 (2CH, Ar), 147.0 (C, Ar), 180.1 (d, JCF = 34.4 
Hz, C, Ar). 
 
2,2,2-Trifluoro-1-(4-methylphenyl)-1-ethanone oxime (2-12)
98c
 
 
Ketone 2-11
98a
 (18.9 g, 100 mmol) was dissolved in a mixture of pyridine (200 mL) and ethanol 
(100 mL) wherein hydroxylamine hydrochloride (9.07 g, 130 mmol) was added. The reaction 
mixture was heated to reflux for 18 h then cooled to the room temperature and ethanol was 
removed under vacuum. The residual mixture was partitioned between diethyl ether (200 mL) 
and water (200 mL). The organic layer was separated, washed with 1N HCl (3 × 50 mL) and 
water (100 mL). The organic layer was dried over MgSO4, filtered and concentrated to afford 
oxime 2-12 (18.52 g, 91%) as colorless semisolid, pure enough for the next step. Rf = 0.57 
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(diethyl ether/petroleum ether, 1:4); 
1
H NMR (400 MHz, CDCl3):  = 2.41 (s, 3H, CH3), 7.29 (d, 
J = 7.8 Hz, 2H, Ar-H), 7.46 (d, J = 8.1 Hz, 2H, Ar-H), 9.62 (s, 1H, OH); 13C NMR (100 MHz, 
CDCl3):  = 21.4 (CH3), 120.7 (q, JCF = 275.2 Hz, CF3), 123.1 (C, Ar), 128.6 (2CH, Ar), 129.2 
(2CH, Ar), 147.3 (q, JCF = 32.2 Hz, C=N−OH). 
 
2,2,2-Trifluoro-1-(p-tolyl)ethanone O-tosyl oxime (2-13)
98a
 
 
To a solution of oxime 2-12
98a
 (18.52 g, 91.2 mmol) in pyridine (250 mL), tosyl chloride (26.1 g, 
136.7 mmol) was added in one portion and the mixture was refluxed for 3 h. The reaction 
mixture was cooled to the room temperature and the solvent was evaporated under vacuum. The 
residue was dissolved in diethyl ether (200 mL) and washed successively with 1N HCl (3 × 50 
mL) and water (3 × 100 mL). The organic layer was dried over MgSO4, filtered and concentrated 
in vacuo. The crude material was recrystallized from diethyl ether/hexane to provide tosylate 2-
13 (30.14 g, 92%) as white crystalline solid. Rf = 0.26 (toluene); 
1
H NMR (400 MHz, CDCl3):  
= 2.39 (s, 3H, CH3, tosyl), 2.46 (s, 3H, CH3, toluyl), 7.24–7.34 (m, 4H, Ar-H), 7.37 and 7.88 
(4H, AA' and BB' system, tosyl, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 21.5 (CH3), 21.7 
(CH3), 119.7 (q, JCF = 277.4 Hz, CF3), 121.6 (C, Ar), 127.0, 128.4 (2CH, Ar), 129.2 (2CH, Ar), 
129.4 (2CH, Ar), 129.8 (2CH, Ar), 130.2, 131.2 (C, Ar), 142.3 (C, Ar), 146.0 (C, Ar), 154.0 (q, 
JCF = 33.7 Hz, C=N). 
 
3-(p-Tolyl)-3-(trifluoromethyl)diaziridine (2-14)
98a
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In screw cap bottle (Duran Glass) containing diethyl ether (100 mL) under N2 atmosphere, 
ammonia (50 mL) was condensed at −78 °C to which a solution of tosylate 2-1398a (13.1 g, 64.6 
mmol) in diethyl ether (100 mL) was added and the bottle was closed with a screw cap under N2 
flow and the mixture stirred at room temperature. After 20 h, the reaction mixture was cooled 
(−30 °C) and excess of ammonia was evaporated slowly by opening the bottle carefully. The 
residual solution was washed with water (100 mL). The organic layer was dried over anhydrous 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (diethyl ether/petroleum ether, 1:4) to yield diaziridine 2-14 (12.10 g, 93%) as 
colorless solid. Rf = 0.32 (diethyl ether/petroleum ether, 1:4); 
1
H NMR (400 MHz, CDCl3):  = 
2.18 (d, J = 8.3 Hz, 1H, NH-NH), 2.37 (s, 3H, CH3), 2.75 (d, J = 8.1 Hz, 1H, NH-NH), 7.22 (d, J 
= 7.8 Hz, 2H, AA’ and BB’ system, Ar-H), 7.49 (d, J = 8.1 Hz, 2H, AA’BB’ system, Ar-H); 13C 
NMR (100 MHz, CDCl3):  = 21.3 (CH3), 57.9 (q, JCF = 35.9 Hz, ArC(NH-NH)CF3), 123.6 (q, 
JCF = 278.1 Hz, CF3), 128.0 (2CH, Ar), 128.7 (C, Ar), 129.4 (2CH, Ar), 140.2 (C, Ar). 
 
3-(p-Tolyl)-3-(trifluoromethyl)-3H-diazirine (2-15)
98c
 
 
A mixture of diaziridine 2-14
98a
 (5.01 g, 24.7 mmol) and freshly prepared Ag2O
98c
 (22.92 g, 98.9 
mmol) in diethyl ether (150 mL) was stirred at room temperature for 3 h. The mixture was 
filtered through a pad of celite and the filtrate was concentrated under vacuum to afford pure 
diazirine 2-15 (4.74 g, 95%) as colorless oil which upon storage under −20 °C crystallized as 
colorless solid. Rf = 0.7 (diethyl ether/petroleum ether, 1:4); 
1
H NMR (400 MHz, CDCl3):  = 
2.36 (s, 3H, CH3), 7.09 and 7.20 (d, J = 8.2 Hz, 4H, AA’ and BB’ system, Ar-H); 
13
C NMR (100 
MHz, CDCl3):  = 21.1 (CH3), 28.4 (q, JCF = 28.4 Hz, ArC(N=N)CF3), 122.2 (q, JCF = 275.2 Hz, 
CF3), 126.1 (C, Ar), 126.4 (2CH, Ar), 129.5 (2CH, Ar), 139.8 (C, Ar). 
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4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)benzoic acid (2-16)
98a
 
 
Toluene derivative 2-15
98a
 (4.18 g, 20.9 mmol) was dissolved in pyridine (80 mL) and water (80 
mL) to which KMnO4 (13.19 g, 83.5 mmol) in one portion was added and the mixture was 
heated at 60 °C for 20 h before it was diluted with water (500 mL). Afterwards, the mixture was 
acidified to pH ~ 3 using 1N H2SO4 resulting in a suspension of MnO2. Then 20% aq NaHSO3 
solution was added to dissolve the precipitated MnO2. The colorless aqueous solution was 
extracted with diethyl ether (3 × 100 mL). The combined organic layers were washed with water 
followed by 0.1N KOH solution (2 × 50 mL). The combined KOH solution was acidified back to 
pH ~ 3, and extracted with diethyl ether (3 × 70 mL). The combined organic layers were washed 
with saturated NaCl solution, dried over MgSO4, filtered and concentrated to furnish crude acid 
which was recrystallized from methanol/water to yield acid 2-16 (2.71 g, 56%) as white solid. Rf 
= 0.36 (EtOAc/petroleum ether/AcOH, 1:4:0.001); 
1
H NMR (400 MHz, CD3OD):  = 7.33 and 
8.08 (d, J = 8.3 and 8.1 Hz, 4H, AA’ and BB’ system, Ar-H); 13C NMR (100 MHz, CD3OD):  
= 29.5 (q, JCF = 41.0 Hz, C(N=N)CF3), 123.4 (q, JCF = 274.4 Hz, CF3), 127.5 (2CH, Ar), 131.3 
(2CH, Ar), 133.5 (C, Ar), 134.4 (C, Ar), 168.5 (COOH). 
 
tert-Butyl 1-oxo-1-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)-5,8,11-trioxa-2-
azatridecan-13-oate (2-17) 
 
To a cooled solution (0 °C) of acid 2-16 (500 mg, 2.2 mmol) and amine 2-8 (572 mg, 2.2 mmol) 
in CH2Cl2 (20 mL) was added DIPEA (757 mL, 4.3 mmol) followed by addition of PyBrOP 
(1.21 g, 2.6 mmol). The mixture was stirred overnight at room temperature then diluted with 
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CH2Cl2, washed with 1N HCl (20 mL), saturated NaHCO3 (20 mL) and saturated NaCl solution. 
The separated organic layer was dried over Na2SO4, filtered and concentrated under vacuum. 
The residue was purified by flash chromatography (methanol/CH2Cl2, 1:25) to furnish amide 2-
17 (760 mg, 73%) as colorless oil. Rf = 0.37 (methanol/CH2Cl2, 1:25); 
1
H NMR (400 MHz, 
CDCl3):  = 1.45 (s, 9H, C(CH3)3), 3.61–3.69 (m, 12H, OCH2), 3.96 (s, 2H, OCH2CO), 7.03 (1H 
NH), 7.21 and 7.85 (d, J = 8.6 and 8.1 Hz, 2H, AA’ and BB’ system, Ar-H); 13C NMR (100 
MHz, CDCl3):  = 28.0 (C(CH3)3), 28.3 (q, JCF = 40.2 Hz, C(N=N)CF3), 39.9 (CH2NHCO), 68.8 
(OCH2), 69.8 (OCH2), 70.1 (OCH2), 70.4 (OCH2), 70.5 (2C, OCH2), 81.8 (C(CH3)3), 121.9 (q, 
JCF = 274.4 Hz, CF3), 126.4 (2CH, Ar), 127.7 (2CH, Ar), 131.9 (C, Ar), 135.7 (C, Ar), 166.3 
(CONH), 169.6 (COOtBu); HRMS (ESI): [M+Na]+ calcd for C21H28N3F3O6Na  498.18224, 
found 498.182063. 
 
1-Oxo-1-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)-5,8,11-trioxa-2-azatridecan-13-oic 
acid (2-18) 
 
A solution of t-butyl ester 2-17 (100 mg, 2.1 mmol) in a mixture of TFA (0.5 mL) and CH2Cl2 
(1.5 mL) was stirred at room temperature for 14 h. The reaction mixture was concentrated under 
vacuum to remove volatiles, then the residue was purified by flash chromatography 
(methanol/CH2Cl2/AcOH, 1:9:0.01) to yield acid 2-18 (73 mg, 83%) as colorless oil. Rf = 0.56 
(methanol/CH2Cl2/AcOH, 1:9:0.01); 
1
H NMR (400 MHz, CDCl3):  = 3.55–3.75 (m, 12H, 
OCH2), 4.09 (s, 2H, OCH2CO), 7.19 (s, 1H, NH), 7.20 and 7.87 (d, J = 8.6 and 8.1 Hz, 4H, AA’ 
and BB’ system, Ar-H); 13C NMR (100 MHz, CDCl3):  = 28.3 (q, JCF = 40.3 Hz, C(N=N)CF3), 
39.9 (CH2NHCO), 68.7 (OCH2), 69.8 (2 OCH2), 70.0 (OCH2), 70.4 (OCH2), 71.2 (OCH2), 121.7 
(q, JCF = 274.4 Hz, CF3), 126.4 (2CH, Ar), 127.7 (2CH, Ar), 132.1 (C, Ar), 135.3 (C, Ar), 166.6 
(CONH), 172.2 (COOH); HRMS (ESI): [M+Na]+ calcd for C17H20N3F3O6Na 442.11964, found 
442.120007. 
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Immobilization of the diazirine containing linker 2-18 on Toyopearl AF amino 650 beads 
Toyopearl AF 650 amino beads (1.45 mL, 0.145 mmol, 20% aq ethanol suspensions) were 
filtered under vacuum on a sintered glass funnel (G-4 type). The beads were washed three times 
using DMF (3 mL each) and transferred into a Falcon tube to which DMF (3 mL), DIC (337 L) 
and linker 2-18 (200 mg, 0.48 mmol) were added. The tube was covered with aluminium foil to 
protect them from light and shaken at room temperature. After 72 h, the bead suspension was 
transferred into a sintered glass funnel, filtered and washed with DMF (3 × 5 mL), followed by 
50% aq dioxane (3 × 5 mL) and transferred into a new Falcon tube. 50% aq dioxane (5 mL), 
10% aq AcOH (135 L) and DIC (337 L) were added and the mixture was shaken for 4 h at 
room temperature in absence of light. The resulting suspension was washed with 50% aq dioxane 
(3 × 5 mL), which was followed by alternative washing with acetate buffer of pH ~4 (3 × 5 mL) 
and Tris buffer of pH ~8 (3 × 5 mL). Finally the beads were washed with dd H2O (3 × 5 mL) and 
20% aq ethanol (3 × 5 mL) successively. The obtained dry beads 2-19 were stored in 20% aq 
ethanol (0.725 mL) as bead suspension (total volume 1.3 mL). 
 
General procedure for the preparation of small molecule immobilized affinity beads. 
Affinity linker immobilized beads 2-19 (250 L, 27.5 mol) were washed with dd H2O (3 × 400 
L) followed by 2-propanol (3 × 400 L) to remove water from the swollen beads and then the 
beads were transferred into a glass sample vial. A solution of small molecule (1 equiv, 27.5 
mol, according to concentration of beads 2-19 in 20% aq ethanol) in ethanol (250 L) was 
added to the dry beads. The solvent was removed by putting the bead suspension under vacuum. 
The resulting homogenous mixture was exposed to UV light (365 nm, 4 Jcm
-2
) for 2 h while 
taking care for irradiation of complete sample. Then the vial was turned occasionally to expose 
all the beads to the UV light. The resulting beads were washed with 50% aq ethanol, ethanol, 
DMSO and ethanol (each 3 × 500 L). These dried beads were then transferred into an 
Eppendorf tube and stored as suspensions in 20% aq ethanol (200 L) before they were used for 
fishing experiment. At this point we assumed that roughly 10 mol% of the small molecule was 
successfully immobilized on the beads. 
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SILAC protocol for cells carried by colleague (In German) 
1. Reagenzien und Materialien: 
- DMEM Silac High Glucose (4,5 mg/ml) ohne Arginin, ohne Lysin, ohne L-Glutamin 
- Dialysiertes FBS 
- L-Glutamin 100x bzw. 200mM 
- Aminosäuren Arginin (light, medium, heavy), Lysin (light, medium, heavy) 
- Zur Herstellung einer Stock-Lösung werden die lyophilisierten AS in 1 ml PBS   
aufgenommen. 
                  Stock-Lösung: c(Lys) = 146 mg/ml                      c(Arg)= 84 mg/ml 
                       Lysin         light (L): Lys 0                           Arginin           light: Arg 0 
                                  medium (M): Lys 4                                             medium: Arg 6 
                                      heavy (H): Lys 8                                                 heavy: Arg 10 
- Penicillin/ Streptomycin mit c(Pen)=10000 U/ml, c(Strep)=10000 µg/ml 
- EDTA stock 0,5M pH=8, (verdünnt für Zellen: 170 µl EDTA-Stock auf 50 ml PBS) PBS  
- Corning Filter systems (Polyethersulfon PES, 0,22µm) 
- Mikroskop 
- Zellschalen mit Durchmesser 6 cm 
- Brutschrank: Bedingungen 37°C, 5% CO2, wasserdampfgesättigt. 
2. Herstellen des Silac Zell-Mediums für Einsatz Zellkultur: 
(Angabe allgemein, und in Klammer unsere eingesetzten Volumina, 190 mL pro Silac Medium 
L, M, H) Unter der Sterilbank arbeiten! Das DMEM Silac vorlegen (500ml). Dann gibt man L-
Glutamin 100x (5 ml) hinzu, damit die Endkonzentration 1% ist. Dann gibt man 
Experimental Section  167 
 
Penicillin/Streptomycin 100x (5ml) hinzu, damit die Endkonzentration 1% ist. (insgesamt nun 
510 ml Gesamtvolumen). Diese Mischung wird zu 3 gleichen Teilen (jeweils 170 ml) in neue 
sterile Gefäße überführt. Nun gibt man jeweils die Aminosäure-Stocks hinzu (Light, medium, 
heavy), so daß die Aminosäuren Arginin und Lysin im Medium nun 1:2000 vorliegen. (95 µl 
AS-stock auf insgesamt 190 ml Medium). Die Medien werden nun mittels Corning Sterilfiltern 
(Unterdruck) sterilfiltriert. Nun gibt man jeweils dialysiertes FBS dazu (20 ml), damit die 
Endkonzentration 10% ist und mischt das Medium gut durch. Das Silac Medium kann bei 4°C 
gelagert werden. 
3. SILAC Zellkultur führen: 
Die Silac-Kultur kann in Kulturschalen (Durchmesser 6 cm) mit 4 ml Kulturmedium geführt 
werden. Für die Durchführung von Versuchen kann die Zellkultur auf 10 cm Schalen expandiert 
werden mit 10 mL Kulturmedium. Bei einer Zellyse einer konfluenten 10 cm Schale ist die 
Proteinausbeute ca. 1,5 mg. 
4. Zellen splitten (6 cm Schale): 
Beispielsweise 3x die Woche 1:4, oder 2x die Woche 1:6. Dies ist abhängig Von der Zellart und 
der Wachstumsgeschwindigkeit. Das verbrauchte Kulturmedium wird abgezogen. Es wird 2x mit 
je 2 ml PBS gewaschen. (schwenken und vollständig abziehen d. Flüssigkeit). Nun wird 0,5 ml 
verdünntes EDTA dazugegeben, auf der Schale verteilt und ca. 10 min bei 37°C inkubiert. 
Danach wird mittels Mikroskop geprüft, ob sich die Zellen abgelöst haben, ggf. die Schale 
schwenken und abklopfen. Nun werden jeweils 1,5 ml neues Zellmedium (L,M,H) auf die 
Schalen gegeben und geschwenkt. (also insgesamt jetzt 2ml). Nun werden die Zellen in der 
Zellsuspension durch mehrmaliges auf- und abpipettieren vereinzelt. Bei einem Split von 1:4 
werden nun 0,5 ml davon in eine neue Kulturschale gegeben, in welcher zuvor schon 3,5 ml des 
entsprechenden Silac-Mediums vorgelegt wurden. Auch diese Schale wird kurz geschwenkt, 
damit sich die Zellen gleichmäßig verteilen. Die Zellen werden im Brutschrank bei 37°C 
inkubiert. 
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tert-Butyl (3S)-3-(acetyloxy)pent-4-enoate (S)-3-22
173,174
 
 
To a suspension of hydroxy ester rac-3-20173 (10.0 g, 58.1 mmol), molecular sieves (9.85 g) and 
amano PS lipase (5.83 g) in pentane (300 mL) was added vinyl acetate (5.36 mL, 58.1 mmol) 
and the reaction mixture was stirred at 30 °C for 16 h. The reaction mixture was filtered through 
a pad of celite. The filtrate was concentrated, and the residue purified by flash chromatography 
(Et2O/petroleum ether, 1:4) to give (S)-acetate 3-22 (5.53 g, 44%) and unreacted alcohol (R)-3-
20 (5.35 g, 53%). Rf = 0.24 (alcohol 3-20) and 0.56 (acetate 3-22) (Et2O/petroleum ether, 1:4); 
1
H NMR (400 MHz, CDCl3):  = 1.42 (s, 9H, C(CH3)3), 2.03 (s, 3H, OCOCH3), 2.50 (dd, J = 
15.2, 5.8 Hz, 1H, 2-H), 2.58 (dd, J = 15.4, 8.1 Hz, 1H, 2-H), 5.18 (ddd, J = 10.4, 1.0, 1.0 Hz, 1H, 
5-H), 5.28 (ddd, J = 17.2, 1.3, 1.0 Hz, 1H, 5-H), 5.54–5.62 (m, 1H, 3-H), 5.80 (ddd, J = 16.9, 
10.3, 6.1 Hz, 1H, 4-H); 
13
C NMR (100 MHz, CDCl3):  = 21.0 (OCOCH3), 28.0 (C(CH3)3), 40.6 
(C-2), 71.0 (C-3), 81.0 (C(CH3)3), 117.3 (C-5), 135.1 (C-4); 168.9 (CO2tBu), 169.8 (OCOCH3). 
 
tert-Butyl (3S)-3-hydroxypent-4-enoate (S)-3-20 
 
K2CO3 (4.01 g, 18.7 mmol) was added to a cooled solution of acetate (S)-3-22 (2.71 g, 19.6 
mmol) in methanol (40 mL) at −15 °C. The mixture was stirred for 45 min, before it was filtered 
through a pad of celite and the filtrate carefully concentrated to a volume of ~10 mL. This 
solution was diluted with Et2O (20 mL), washed with water, and saturated NaCl solution. The 
organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The crude 
hydroxyester was purified by flash chromatography (diethyl ether/petroleum ether, 3:7) to 
furnish (S)-alcohol (S)-3-20 (2.64 g, 82%) as colorless oil. Rf = 0.24 (diethyl ether/petroleum 
ether,1:4); []D
20
 = −6.6 (c 1.0, CHCl3); {ref
173
 ent-3-20 []D
25
 = + 7.7 (c 3.58, CHCl3)}; 
1
H 
NMR (400 MHz, CDCl3):  = 1.44 (s, 9H, C(CH3)3), 2.41 (dd, J = 16.2, 8.3, Hz, 1H, 2-H), 2,49 
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(dd, J = 4.0, 16.2 Hz, 1H, 2-H), 3.13 (d, J = 4.5 Hz, 1H, OH), 4.44−4.50 (m, 1H, 3-H), 5.13 (ddd, 
J = 10.4, 1.5, 1.3 Hz, 1H, 5-H), 5.28 (ddd, J = 17.2, 1.5, 1.5, Hz, 1H, 5-H), 5.85 (ddd, J = 17.2, 
10.6, 5.6 Hz, 1H, 4-H); 
13
C NMR (100 MHz, CDCl3):  = 27.8 (C(CH3)3), 41.7 (C-2), 68.7 (C-
3), 81.1 (C(CH3)3), 114.8 (C-5), 138.5 (C-4), 171.4 (C-1). 
The ee of (S)-3-20 after resolution was determined to be 98.5% by chiral GC. 
 
(S)-tert-Butyl-3-((tert-butyldimethylsilyl)oxy)pent-4-enoate (3-23) 
 
A mixture of alcohol (S)-3-20 (2.95 g, 17.1 mmol), imidazole (1.75 g, 25.7 mmol), and tert-
butyldimethylsilyl chloride (2.83 g, 18.8 mmol) in DMF (60 mL) was stirred at 50 °C for 3 h. 
The reaction was quenched by adding water (10 mL), and the mixture extracted with EtOAc (3 × 
25 mL). The combined organic layers were washed with saturated NaCl solution, dried over 
MgSO4, filtered, and concentrated in vaccuo. Flash chromatography (Et2O/petroleum ether, 1:50) 
provided silyl ether 3-23 (4.59 g, 93%) as a colorless oil. Rf = 0.17 (Et2O/petroleum ether, 1:50); 
[]D
21
 = −3.56 (c 1.0, CHCl3) {ref
173
 ent-3-23 []D
25
 +3.5 (c 1.94, CHCl3)}; 
1
H NMR (400 
MHz, CDCl3):  = 0.03 (s, 3H, Si(CH3)2), 0.05 (s, 3H, Si(CH3)2), 0.87 (s, 9H, SiC(CH3)3), 1.43 
(s, 9H, CO2tBu), 2.33 (dd, J = 14.6, 5.8 Hz, 1H, 2-H), 2.33 (dd, J = 14.6, 7.3 Hz, 1H, 2-H), 
4.49−4.56 (m, 1H, 3-H), 5.04 (ddd, J = 10.4, 1.5, 1.3 Hz, 1H, 5-H), 5.19 (ddd, J = 17.2, 1.5, 1.3 
Hz, 1H, 5-H), 5.82 (ddd, J = 16.9, 10.4, 6.3 Hz, 1H, 4-H); 13C NMR (100 MHz, CDCl3):  = 
−5.0 (Si(CH3)2), −4.4 (Si(CH3)2), 18.1 (SiC(CH3)3), 25.8 (SiC(CH3)3), 28.1 (OC(CH3)3), 44.8 (C-
2), 70.9 (C-3), 80.4 (OC(CH3)3), 114.4 (C-5), 140.5 (C-4), 170.3 (C-1); HRMS (ESI): 
[M+Na]
+
calcd for C15H30O3Na 309.18564, found 309.185479. 
 
(S)-3-((tert-Butyldimethylsilyl)oxy)pent-4-en-1-ol (3-24) 
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To a cooled (−78 °C) solution of ester 3-23 in CH2Cl2 (100 mL) was added dropwise a solution 
of DIBAL-H (61.1 mL, 61.1 mmol, 1M in hexane) using a syringe pump within 40 min. After 
complete addition, the mixture was allowed to warm to 0 °C over 2 h and then stirred for 
additional 2 h. The reaction was quenched by slow addition of methanol (3 mL) and saturated 
NH4Cl solution (15 mL). After 3 h of vigorous stirring at room temperature, the organic layer 
was separated and the aqueous layer extracted with CH2Cl2 (3 × 20 mL). The combined organic 
layers were washed with saturated NaCl solution (50 mL), dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude oil was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:9) to afford alcohol 3-24 (2.21 g, 84%) as colorless oil. Rf = 0.25 
(EtOAc/petroleum ether, 1:9); []D
21
 = −4.99 (c 1.0, CHCl3) {ref
175
 3-24 []D
29
 −5.65 (c 0.5, 
MeOH), ref
176
 ent-3-24 []D
25
 + 1.9 (c 1.2, CHCl3), ref
177
 ent-3-24 []D
20
 + 3.3 (c 0.94, CHCl3), 
ref
178 ent-3-24 []D
20
 +7.5 (c 0.75, CHCl3)}; 
1
H NMR (400 MHz, CDCl3):  = 0.05 (s, 3H, 
Si(CH3)2), 0.08 (s, 3H, Si(CH3)2), 0.89 (s, 9H, C(CH3)3), 1.70 (dddd, J = 14.1, 10.1, 6.3, 6.1 Hz, 
1H, 2-H), 1.84 (dddd, J = 14.1, 8.1, 4.3, 4.5 Hz, 1H, 2-H), 2.28 (s, 1H, OH), 3.70 (ddd, J = 10.6, 
6.1, 4.3 Hz, 1H, 1-H), 3.80 (ddd, J = 11.8, 8.1, 4.0 Hz 1H, 1-H), 4.36–4.44 (m, 1H, 3-H), 5.09 
(ddd, J = 10.6, 1.5, 1.3 Hz, 1H, 5-H), 5.20 (ddd, J = 17.2, 1.5, 1.3 Hz, 1H, 5-H), 5.84 (ddd, J = 
5.8, 10.6, 17.2 Hz, 1H, 5-H); 
13
C NMR (100 MHz, CDCl3):  = −5.1 (Si(CH3)2), −4.4 
(Si(CH3)2), 18.1 (SiC(CH3)3), 25.8 (SiC(CH3)3), 39.1 (C-2), 60.1 (C-1), 73.2 (C-3), 114.4 (C-5), 
140.6 (C-4); HRMS (ESI): [M+Na]
+ 
calcd for C11H24O2SiNa 239.14378, found 239.143772. 
 
(S)-3-((tert-butyldimethylsilyl)oxy)pent-4-en-1-yl pivalate (3-25) 
 
Et3N (1.67 mL, 12.0 mmol), pivaloyl chloride (1.08 mL, 9.0 mmol), and DMAP (73 mg, 0.6 
mmol) were added successively to a cooled (ice/water bath) solution of alcohol 3-24 (1.21 g, 6.0 
mmol) in CH2Cl2 (22 mL) and the reaction mixture was allowed to stir at room temperature for 1 
h (TLC control). The mixture was washed with saturated NaHCO3 solution (5 mL), water (5 mL) 
and saturated NaCl solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated on a rotary evaporator. Purification of the residue by flash chromatography 
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(Et2O/petroleum ether, 1:50) yielded pivaloyl ester 3-25 (1.85 g, 97%) as colorless liquid. Rf = 
0.23 (Et2O/petroleum ether, 1:50); []D
20
 = −5.35 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3): 
 = 0.02 (s, 3H, Si(CH3)2),  (s, 3H, Si(CH3)2), 0.88 (s, 9H, SiC(CH3)3), 1.19 (s, 9H, C(CH3)3, 
pivaloyl), 1.73–1.84 (m, 2H, 3-H), 4.08 (dddd, J = 17.4, 10.7, 6.6, 5.8 Hz, 2H, 1-H), 4.13 (dddd, 
J = 16.9, 10.9, 5.8, 5.8 Hz, 1-H) 4.19–4.27 (m, 1H, 3-H), 5.04 (ddd, J = 10.4, 1.0, 1.0 Hz, 1H, 5-
H), 5.15 (ddd, J = 17.2, 1.5, 1.3 Hz, 1H, 5-H), 5.79 (ddd, J = 17.2, 10.4, 6.3 Hz, 1H, 4-H); 13C 
NMR (100 MHz, CDCl3):  = −5.0 (Si(CH3)2), −4.4 (Si(CH3)2), 18.2, (SiC(CH3)3), 25.8 
(SiC(CH3)3), 27.2 (C(CH3)3, pivaloyl), 37.0 (C-2), 38.7 (C(CH3)3, pivaloyl), 61.0 (C-1), 70.7 (C-
3), 114.2 (C-5), 141.1 (C-4), 17.4 (C=O); HRMS (ESI): [M+Na]
+
 calcd for C16H32O3SiNa 
323.20129, found 323.201168. 
 
(R)-4-Isopropyl-5,5-diphenyl-3-propionyloxazolidin-2-one (3-27)
179
 
 
(4R)-4-Isopropyl-5,5-diphenyl-1,3-oxazolidin-2-one 3-26143b (26.01 g, 92.5 mmol) was dissolved 
in THF (330 mL) and cooled to 0 °C in an ice bath. n-BuLi (42.51 mL, 106.3 mmol, 2.5M in 
hexane) was added dropwise over 30 min and the mixture was stirred for 20 min. Propionyl 
chloride (10.48 mL, 92.5 mmol) was added within 15 min and the reaction mixture was allowed 
to stir at room temperature for 1 h. The mixture was diluted with ether (100 mL), excess of 
propionyl chloride was quenched with saturated NH4OH solution. The organic layer was 
separated and the aqueous layer was extracted with diethyl ether (3 × 30 mL). The combined 
organic layers were washed with aqueous 1M NaOH solution (50 mL), saturated NaCl solution 
(50 mL), dried over MgSO4, filtered and concentrated under vacuum. The crude solid was 
purified by flash chromatography (EtOAc/petroleum ether, 1:9) to yield 3-27 (30.1 g, 96%) as a 
white solid. Rf = 0.3 (EtOAc/petroleum ether, 1:4); [α]D
24
 = +223.15 (c 1, CHCl3); 
1
H NMR 
(400 MHz, CDCl3):  = 0.75 (d, J = 6.8 Hz, 3H, CHCH(CH3)2), 0.87 (d, J = 7.1 Hz, 3H, 
CHCH(CH3)2), 1.08 (t, J = 7.6 Hz, 3H, CH2CH3), 1.58 (s, H2O), 1.90–2.02 (m, 1H, 
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CHCH(CH3)2), 2.72 (ddd, J = 17.4, 14.6, 7.3 Hz, 1H, CH2CH3), 2.92 (ddd, J = 17.2, 14.6, 7.3 
Hz, 1H, CH2CH3), 5.36 (d, J = 3.5 Hz, 1H, CHCH(CH3)2), 7.23–7.41 (m, 8H, Ar-H), 7.44–7.49 
(m, 2H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 8.6 (CH2CH3), 16.3 (CHCH(CH3)2), 21.8 
(CHCH(CH3)2), 28.9 (CH2CH3), 29.9 (CHCH(CH3)2), 64.4 (CHCH(CH3)2), 89.3 (C(Ph)2OCO), 
125.6 (2CH, Ar), 125.9 (2CH, Ar), 127.9 (CH, Ar), 128.3 (2CH, Ar), 128.5 (CH, Ar), 128.9 
(2CH, Ar). 
 
(R)-4-Isopropyl-3-((S)-2-methylpent-4-ynoyl)-5,5-diphenyloxazolidin-2-one (3-28) 
 
NaHMDS (45 mL, 2M in THF, 90.0 mmol) was added to a solution of propionyl derivative 3-27 
(20.01 g, 59.3 mmol) in THF (60 mL) at −78 °C. The mixture was stirred for 2 h at this 
temperature followed by addition of propargyl bromide (15.1 mL, 178 mmol, 80% w/w in 
toluene). After complete addition, the mixture was allowed to warm to −15 °C and stirred at this 
temperature for 20 h. The reaction mixture was diluted with Et2O (50 mL) and treated with a 
saturated solution of NH4Cl (50 mL). The resulting white salt precipitated was dissolved by 
addition of a small amount of water. The organic layer was separated and the aqueous layer was 
extracted with Et2O (3 × 50 mL). The combined organic layers were washed with saturated NaCl 
solution (50 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude 
solid obtained was purified by flash chromatography (Et2O/petroleum ether, 1:4) to afford 
alkylated product 3-28 (21.15 g, 95%) as white solid, m.p. 166–169 °C; Rf = 0.36 (ethyl 
acetate/petroleum ether, 1:20); []D
22
 = +209.9 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 
0.73 (d, J = 6.8 Hz, 3H, 4-CH(CH3)2), 0.85 (d, J = 7.1 Hz, 3H, 4-CH(CH3)2), 0.86 (d, J = 7.1 Hz, 
3H, 2’-CH3), 1.85–1.98 (m, 1H, 4-CH(CH3)2), 1.92 (dd, J = 2.8, 2.5 Hz, 1H, 5’-H), 2.37 (ddd, J 
= 16.7, 6.6, 2.8 Hz, 1H, 3’-H), 2.53 (ddd, J = 16.9, 7.1, 2.8 Hz, 1H, 3’-H), 3.82 (m, 1H, 2’-H), 
5.33 (d, J = 3.3 Hz, 1H, 4-H), 7.18–7.43 (m, 10H, Ar-H); 13C NMR (100 MHz, CDCl3):  = 16.2 
(2’-CH3), 4-CH(CH3)2), 21.7 (4-CH(CH3)2), 22.6 (C-3’), 29.7 (4-CH(CH3)2), 37.1 (C-2’), 64.6 
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(C-4), 70.0 (C-5’), 81.5 (C-5), 89.4 (C-4’), 125.5 (2CH, Ar), 125.8 (2CH, Ar), 127.9 (CH, Ar), 
128.4 (2CH, Ar), 128.5 (CH, Ar), 128.8 (2CH, Ar), 138.0 (C, Ar), 142.2 (C, Ar), 152.7 (C-2), 
174.5 (C-1’); HRMS (ESI): [M+Na]+ calcd for C24H25NO3Na 398.17266, found 398.172724. 
 
(2S)-2-Methyl-5-(trimethylsilyl)pent-4-ynol (3-29) 
 
To a cooled solution (salt/ice bath) of oxazolidinone 3-28 (14.83 g, 39.5 mmol) in THF (1100 
mL) was added a solution of NaBH4 (7.47 g, 197.5 mmol) in H2O (280 mL) dropwise at 0 °C 
within 30 min. The reaction mixture was allowed to warm to room temperature overnight (~12 
h), and then quenched by adding saturated NH4Cl solution. The white salt precipitated was 
dissolved by adding a small amount of water. Most of the THF was removed carefully under 
vacuum, and the residual mixture was filtered to recover the precipitated auxiliary. The filtrate 
was extracted using Et2O (3 × 150 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated under vacuum (carefully). The residue was purified by flash 
chromatography (Et2O/petroleum ether, 3:7) to furnish alcohol 3-29 (3.56 g, 92%) as slightly 
yellow oil. Rf = 0.31 (Et2O/petroleum ether, 2:3); []D
22
 = −14.8 (c 1.0, CHCl3) {ref
180 ent-3-29 
[]D
20
 +11.4 (c 1.1, CHCl3)}; 
1
H NMR (400 MHz, CDCl3):  = 1.0 (d, J = 6.8 Hz, 3H, 2-CH3), 
1.57 (s, br, 1H, OH), 1.82–1.94 (m, 1H, 2-H), 1.97 (dd, J = 2.8, 2.5 Hz, 1H, 5-H), 2.20 (ddd, J = 
16.7, 6.3, 2.5 Hz, 2H, 3-H), 2.27 (ddd, J = 16.9, 6.3, 2.8 Hz, 2H, 3-H), 3.56 (d, J = 6.3 Hz, 2H, 1-
H); 
13
C NMR (100 MHz, CDCl3):  = 16.1 (2-CH3), 22.2 (C-3), 34.9 (C-2), 66.9 (C-5), 69.6 (C-
1), 82.6 (C-4). 
 
(2S)-2-Methyl-5-trimethylsilyl-pent-4-yn-1-ol (3-30) 
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n-BuLi (32.6 mL, 2.5M in hexane, 81.6 mmol) was added dropwise to a solution of alkynol 3-29 
(3.64 g, 37.1 mmol) in THF (90 mL) at −78 °C followed by stirring of the mixture for 1 h at the 
same temperature. Then, trimethylsilyl chloride (9.88 mL, 77.9 mmol) was added slowly and the 
mixture was allowed to warm to the room temperature within 2 h. The reaction was quenched by 
addition of 1N HCl (30 mL) and the mixture stirred for additional 2 h to cleave the silyl ether. 
The mixture was extracted with Et2O (3 × 60 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. Purification of the residue by flash 
chromatography (Et2O/petroleum ether, 3:7) afforded alcohol 3-30 (4.99 g, 79 %) as pale yellow 
oil. Rf = 0.44 (Et2O/petroleum ether, 2:3); [α]D
23
 = −6.01 (c 1, CHCl3) {ref
181
 ent-3-30 []D
23
 
+6.6 (c 1.12, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 0.13 (s, 9H, Si(CH3)3), 0.98 (d, J = 6.8 
Hz, 3H, 2-CH3), 1.64 (s, 1H, OH), 1.81–1.94 (m, 1H, 2-H), 2.22 (dd, J = 16.9, 6.3, Hz, 1H, 3-H), 
2.28 (dd, J = 17.2, 6.6, Hz, 1H, 3-H), 3.55 (d, J = 6.6 Hz, 2H, 1-H); 13C NMR (100 MHz, 
CDCl3):  = −0.07 (Si(CH3)3), 16.2 (2-CH3), 23.8 (C-3), 35.01 (C-2), 67.2 (C-1), 86.1 (C-5), 
105.4 (C-4). 
 
(2S)-2-Methyl-5-(trimethylsilyl)pent-4-ynal (3-31) 
 
To a cooled solution (−78 °C) of oxalyl chloride (1.53 mL, 17.8 mmol) in CH2Cl2 (75 mL) was 
slowly added in a dropwise fashion DMSO (2.53 mL, 35.6 mmol) while maintaining the 
temperature below −75 °C. After being stirred for 15 min at this temperature, a solution of 
alcohol 3-30 (1.53 g, 14.8 mmol) in CH2Cl2 (10 mL) was added over a period of 15 min, before 
Et3N (10.3 mL, 74.2 mmol) was added dropwise to the reaction mixture. The mixture was stirred 
at the same temperature for 1 h and then warmed to room temperature. It was washed with 1N 
HCl (50 mL), water (50 mL) and saturated NaCl solution (50 mL). The organic layer was dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (Et2O/petroleum ether, 1:9) to afford aldehyde 3-31 (2.40 g, 96%) as yellow oil. 
Rf = 0.25 (Et2O/petroleum ether, 1:20); []D
21
 = −8.12 (c 1.0, CHCl3); 
1
H NMR (400 MHz, 
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CDCl3):  = 0.12 (s, 9H, Si(CH3)3), 1.20 (d, J = 7.1 Hz, 3H, 2-CH3), 2.38 (dd, J = 18.4, 8.8, 1H, 
3-H), 2.54 (dd, J = 18.4, 5.8, 1H, 3-H), 2.48–2.54 (m, 1H, 2-H, ), 9.69 (s, 1H, 1-H); 13C NMR 
(100 MHz, CDCl3):  = −0.0 (Si(CH3)3), 13.0 (2-CH3), 21.2 (C-3), 45.1 (C-2), 87.0 (C-5), 103.3 
(C-4), 203.2 (C-1). 
 
Ethyl 2-(triphenylphosphoranylidene)propanoate (3-32)
146b
 
 
A mixture of PPh3 (7.24 g, 27.6 mmol) and ethyl-2-bromopropionate (3.57 mL, 27.6 mmol) was 
heated at 50 °C in a thick glass screw cap bottle for 10 h. Hexane (20 mL) was added and the 
hard white solid cake was broken into small pieces, washed in a filtration funnel with hexane (3 
× 100 mL) and the dried white solid was dissolved in CH2Cl2 (100 mL). This solution was added 
to a precooled solution of NaOH (1.10 g, 27.6 mmol) in water (100 mL) and the mixture was 
stirred for 30 min at room temperature. This biphasic mixture was separated and the aqueous 
layer washed with CH2Cl2 (2 × 50 mL). The combined organic layers were washed several times 
with water until pH of the water phase became neutral. The organic layer was dried over Na2SO4, 
filtered concentrated, and the residue dried under high vacuum to afford stabilized Wittig ylide 
3-32 (26.51 g, 96%) as yellow fine powder. 
1
H NMR (400 MHz, CDCl3):  = 0.43 (t, J = 7.1 Hz, 
3Hmajor, OCH2CH3), 1.22 (t, J = 6.82 Hz, 3Hminor, OCH2CH3), 1.58 (d, JPH = 14.4 Hz, 3Hminor, 3-
H), 1.60 (d, JPH = 13.9 Hz, 3Hmajor, 3-H), 3.69 (q, J = 7.1 Hz, 3Hmajor, OCH2CH3), 4.03 (q, J = 
7.1 Hz, 3Hminor, OCH2CH3), 7.41–7.67 (m, 15 H, Ar-H); 
13
C NMR (100 MHz, CDCl3):  = 12.1 
(C-3minor, J = 11.7 Hz), 12.8 (C-3major, J = 13.8 Hz,), 14.0 (OCH2CH3, major), 15.3 (OCH2CH3, 
minor), 31.6 (C-2major, JCP = 120.7 Hz), 32.7 (C-2major, JCP = 126.6 Hz), 57.2 (OCH2CH3, major), 
57.9 (OCH2CH3, minor), 127.8 (Cminor, JCP = 90.6 Hz, Ar), 128.3 (Cmajor, JCP = 90.8, Hz, Ar), 
128.3 (CHmajor, JCP = 12.4 Hz, Ar), 128.4 (CHminor, JCP = 12.4 Hz, Ar), 131.4 (CHminor, JCP = 2.9 
Hz, Ar), 131.4 (CHmajor, JCP = 2.9 Hz, Ar), 133.5 (CHmajor, JCP = 9.5 Hz, Ar), 133.5 (CHminor, JCP 
= 9.5 Hz, Ar). 
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Ethyl (2E,4S)-2,4-dimethyl-7-(trimethylsilyl)hept-2-en-6-ynoate (3-33) 
 
A mixture of aldehyde 3-31 (2.25 g, 13.4 mmol) and stabilized Wittig reagent 3-32 (7.28 g, 20.1 
mmol) in toluene (30 mL) was heated to 80 °C for 12 h. The reaction mixture was cooled to 
room temperature and filtered through a pad of celite to remove Ph3PO. The filtrate was 
concentrated in vacuo, and the residue purified by flash chromatography (diethyl ether/petroleum 
ether, 1:50) to yield unsaturated ester 3-33 (2.89 g, 86%) as yellow colored oil, E/Z ratio 15:1. Rf 
= 0.44 (diethyl ether/petroleum ether, 1:25); []D
20
 = +9.6 (c 1.0, CHCl3); 
1
H NMR (400 MHz, 
CDCl3):  = 0.12 (s, 9H, Si(CH3)3), 1.09 (d, J = 6.8 Hz, 3H, 4-CH3), 1.26 (t, J = 7.3 Hz, 3H, 
OCH2CH3), 1.85 (d, J = 1.5 Hz, 3H, 2-CH3), 2.23 (d, J = 6.6 Hz, 2H, 5-H), 2.67–2.79 (m, 1H, 4-
H), 4.17 (q, J = 7.3 Hz, 2H, OCH2CH3), 5.56 (ddd, J = 10.1, 1.5, 1.3 Hz, 1H, 3-H); 
13
C NMR 
(100 MHz, CDCl3):  = 0.0 (Si(CH3)3), 12.6 (2-CH3), 14.2 (OCH2CH3), 19.2 (4-CH3), 26.7 (C-
4), 32.7 (C-5), 60.5 (OCH2CH3), 86.4 (C-7), 104.9 (C-6), 127.4 (C-2), 145.2 (C-3), 168.2 (C-1); 
HRMS (ESI): [M+Na]
+
 calcd for C14H24O2SiNa 275.14378, found 275.143577. 
The ee of 3-33 after the Wittig reaction was determined to be 89.8% by chiral GC. 
 
(2E,4S)-2,4-Dimethylhept-2-en-6-yn-1-ol (3-36) 
 
a) DIBAL-H reduction: To a cooled (−40 °C) solution of ester 3-33 (1.76 g, 7.4 mmol) in CH2Cl2 
(40 mL) was added DIBAL-H (18.5 mL, 18.5 mmol, 1M in hexane) over 30 min followed by 
stirring the mixture for 2 h at the same temperature. Excess of DIBAL-H was quenched by 
addition of methanol (2 mL) and saturated solution of NH4Cl (10 mL). The mixture was allowed 
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to stir vigorously at room temperature for 1 h and the layers were separated. The aqueous layer 
was extracted with CH2Cl2 (2 × 15 mL) and the combined organic layers were washed with 
saturated NaCl solution, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography (EtOAc/petroleum ether, 1:4) to afford the 
corresponding alcohol (1.35 g, 87%) as colorless oil. Rf = 0.22 (EtOAc/petroleum ether, 1:4); 
[]D
20
 = −13.4 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 0.13 (s, 9H, C(CH3)3), 1.03 (d, 
J = 6.8 Hz, 3H, 4-CH3), 1.40 (s, 1H, OH), 1.68 (d, J = 1.3 Hz, 3H, 2-CH3), 2.15 (dd, J = 19.4, 7.1 
Hz, 1H, 5-H), 2.19 (dd, J = 18.9, 6.3 Hz, 1H, 5-H), 2.58–2.70 (m, 1H, 4-H), 3.98 (s, 2H, 1-H), 
5.24 (ddd, J = 9.3, 1.3, 1.3 Hz, 1H, 3-H); 13C NMR (100 MHz, CDCl3):  = 0.1 (Si(CH3)3), 13.9 
(2-CH3), 20.0 (4-CH3), 27.5 (C-5), 31.7 (C-4), 68.7 (C-1), 85.4 (C-7), 105.9 (C-6), 130.4 (C-3), 
134.5 (C-2); HRMS (ESI): [M+Na]
+
 calcd for C12H22OSiNa 233.13321, found 233.133104. 
b) TMS removal: K2CO3 (1.66 g, 12.0 mmol) was added to a solution of the foregoing TMS 
acetylene (1.01 g, 4.8 mmol) in methanol (15 mL) and the mixture was allowed to stir at room 
temperature for 3 h. The reaction mixture was filtered through a pad of celite. The filtrate was 
concentrated and the residual oil purified by flash chromatography (diethyl ether/petroleum 
ether, 1:4) to furnish alkynol 3-36 (0.628 g, 95%) as colorless oil. Rf = 0.3 (Et2O/petroleum 
ether, 1:4); []D
22
 = −13.6 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.05 (d, J = 6.6 Hz, 
3H, 4-CH3), 1.51 (s, 1H, OH), 1.67 (d, J = 1.5 Hz, 3H, 2-CH3), 1.94 (dd, J = 2.8, 2.5 Hz, 1H, 7-
H), 2.12 (ddd, J = 16.7, 7.1, 2.8 Hz, 1H, 5-H), 2.17 (ddd, J = 16.7, 6.3, 2.8 Hz, 1H, 5-H), 2.58–
2.70 (m, 1H, 4-H), 3.98 (s, 2H, 1-H), 5.27 (ddd, J = 9.3, 1.3, 1.3 Hz, 1H, 3-H); 
13
C NMR (100 
MHz, CDCl3):  = 13.8 (2-CH3), 20.0 (4-CH3), 26.1 (C-5), 31.3 (C-4), 68.6 (C-1), 69.1 (C-7), 
82.9 (C-6), 130.1 (C-3), 134.7 (C-2); HRMS (ESI): [M+Na]
+
 calcd for C9H14ONa 161.09369, 
found 161.093613. 
 
(2E,4S,6E)-7-Iodo-2,4-dimethylhepta-2,6-dien-1-ol (3-37)
182
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To a cooled (0 °C) solution of alkynol 3-36 (0.560 g, 4.0 mmol) in THF (5 mL), DIBAL-H (4.05 
mL, 1M in hexane, 4.0 mmol) was added and the mixture was stirred for 1 h at room temperature. 
In another flask, containing Cp2ZrCl2 (1.16 g, 4.5 mmol) in THF (10 mL) at 0 °C was added 
DIBAL-H (4.5 mL, 1M in hexane, 4.5 mmol) and the resulting white suspension of the 
zirconocene hydrochloride was stirred for 30 min at the same temperature. To this second 
reaction mixture, the solution from the first reaction flask, containing the di-isobutyl alkoxide of 
3-36, was added dropwise at 0 °C. The reaction mixture was warmed to the room temperature 
until it became clear (~ 45 min). This mixture of the vinyl alane was cooled to −78 °C before a 
solution of iodine (2.0 g, 8.0 mmol) in THF (5 mL) was slowly added dropwise. The mixture 
was allowed to warm to room temperature within 1 h. The reaction was quenched with saturated 
NH4Cl solution (5 mL) and extracted with EtOAc (3 ×15 mL). The combined organic layers 
were washed with 1M Na2S2O3 solution, saturated NaCl solution, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. Purification of the residue by flash chromatography 
(EtOAc/petroleum ether, 1:4) provided vinyl iodide 3-37 (0.850 g, 79%) as colorless oil. Rf = 
0.33 (EtOAc/petroleum ether, 1:4); []D
22
 = −0.43 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3): 
 = 0.94 (d, J = 6.6 Hz, 3H, 4-CH3), 1.45 (s, 1H, OH), 1.64 (d, J = 1.3 Hz, 3H, 2-CH3), 1.93–
2.08 (m, 2H, 5-H), 2.41–2.54 (m, 1H, 4-H), 3.98 (s, 2H, 1-H), 5.16 (ddd, J = 9.3, 1.3, 1.3 Hz, 
1H, 3-H), 5.96 (ddd, J = 14.4, 1.3, 1.3 Hz, 1H, 7-H), 6.43 (ddd, J = 14.4, 7.6, 7.3 Hz, 1H, 6-H); 
13
C NMR (100 MHz, CDCl3):  = 13.9 (2-CH3), 20.4 (4-CH3), 31.6 (C-4), 43.5 (C-5), 68.6 (C-
1), 75.4 (C-7), 130.5 (C-3), 134.3 (C-2), 144.8 (C-6); HRMS (ESI): [M+Na]
+
 calcd for 
C9H15IONa 289.0598, found 289.05864. 
 
(2E,4S,6E)-7-Iodo-2,4-dimethylhepta-2,6-dienal (3-38) 
 
To a cooled (0 °C) solution of alcohol 3-37 (0.83 g, 3.1 mmol) in CH2Cl2 (25 mL) was added 
Dess-Martin periodinane (1.59 g, 3.8 mmol) and the resulting mixture was allowed to stir at 
room temperature for 30 min. The reaction mixture was filtered through a pad of celite and the 
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filtrate washed with a mixture of saturated NaHCO3 solution (5 mL) and 1M Na2S2O3 solution (5 
mL) followed by washing with saturated NaCl solution. The organic layer was dried over 
anhydrous Na2SO4, filtered, concentrated and the residue purified by flash chromatography 
(diethyl ether/petroleum ether, 1:20) to furnish aldehyde 3-38 (0.81g, 83%) as purple colored oil. 
Rf = 0.30 (diethyl ether/petroleum ether, 1:9); []D
20
 = 3.38 (c 1.0, CHCl3); 
1
H NMR (400 MHz, 
CDCl3):  = 1.08 (d, J = 6.8 Hz, 3H, 4-CH3), 1.74 (d, J = 1.3 Hz, 3H, 2-CH3), 2.07–2.22 (m, 2H, 
H-5), 2.72–2.85 (m, 1H, 4-H), 6.06 (ddd, J = 14.4, 1.3, 1.01 Hz, 1H, 7-H), 6.21 (ddd, J = 9.8, 
1.3, 1.3 Hz, 3-H), 6.42 (ddd, J = 14.4, 7.6, 7.3 Hz, 1H, 6-H), 9.38 (s, 1H, 1-H); 13C NMR (100 
MHz, CDCl3):  = 9.4 (2-CH3), 19.3 (4-CH3), 32.9 (C-4), 42.5 (C-5), 76.8 (C-7), 138.6 (C-2), 
143.2 (C-6), 157.7 (C-3), 195.2 (C-1); HRMS (ESI): [M+Na]
+
 calcd for C9H13IONa 286.99033, 
found 286.990534. 
 
(4S,5E,7S,9E)-10-Iodo-5,7-dimethyldeca-1,5,9-trien-4-ol (3-39) 
 
To a cooled (−78 °C) solution of (−)-Ipc2BOMe (0.860 g, 2.7 mmol) in Et2O (10 mL) was slowly 
added a solution of allyl magnesium bromide (2.61 mL, 1M in Et2O, 2.6 mmol) under nitrogen 
atmosphere and the mixture allowed to stir at room temperature for 1 h. The resulting mixture 
was cooled to −90 °C using a toluene/N2 bath before a solution of aldehyde 3-38 (599 mg, 2.3 
mmol) in Et2O (5 mL) was added dropwise followed by stirring of the mixture for 5 h at the 
same temperature. The reaction was quenched by adding 10% NaOH solution (5 mL), 40% H2O2 
solution (5 mL) and the mixture was then stirred overnight at room temperature. The organic 
layer was separated and the aqueous layer was washed with diethyl ether (3 ×10 mL). The 
combined organic layers were dried over MgSO4, filtered, concentrated, and the residue was 
purified by flash chromatography (Et2O/petroleum ether, 1:4) to afford allylated product 3-39 
(461 mg, 66%) as colorless oil. Rf = 0.20 (diethyl ether/petroleum ether, 1:4); []D
21
 = 7.56 (c 
1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 0.95 (d, J = 6.8 Hz, 3H, 7-CH3), 1.61 (s, 1H, 
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OH), 1.61 (d, J = 1.3 Hz, 3H, 5-CH3), 1.94 (dddd, J = 13.9, 8.6, 7.8, 1.3 Hz, 1H, 8-H), 2.04 
(dddd, J = 13.9, 7.3, 5.8, 1.0 Hz, 1H, 8-H), 2.29 (ddd, J = 6.8, 1.3, 1.3 Hz, 1H, 3-H), 2.31 (ddd, J 
= 6.8, 1.3, 1.3 Hz, 1H, 3-H), 2.42–2.53 (m, 1H, 7-H), 4.02 (t, J = 6.8 Hz, 4-H), 5.08–5.17 (m, 
3H, 1-H, 6-H), 5.73 (dddd, J = 16.7, 10.6, 7.3, 7.1 Hz, 1H, 2-H), 5.94 (ddd, J = 14.1, 1.3, 1.3 Hz, 
1H, 10-H), 6.42 (ddd, J = 14.4, 7.6, 7.3 Hz, 1H, 9-H); 13C NMR (100 MHz, CDCl3):  = 11.6 (7-
CH3), 20.5 (5-CH3), 31.7 (C-7), 39.9 (C-3), 43.5 (C-8), 75.4 (C-10), 76.6 (C-4), 117.7 (C-1), 
131.5 (C-6), 134.6 (C-2), 144.9 (C-9); HRMS (ESI): [M+Na]
+
 calcd for C12H19IONa 329.03728, 
found 329.037211. 
 
(1E,4S,5E,7S)-1-Iodo-7-methoxy-4,6-dimethyldeca-1,5,9-triene (3-16) 
 
Proton sponge (662 mg, 1.1 mmol) and Me3OBF4 (228 mg, 1.5 mmol) were added to a solution 
of alcohol 3-39 (315 mg, 1.0 mmol) in CH2Cl2 (10 mL). The reaction mixture was stirred in the 
dark at room temperature for 3 h, diluted with CH2Cl2 (10 mL) and washed subsequently with 
1M HCl (5 mL), saturated NaHCO3 (5 mL) and saturated NaCl (5 mL) solution. The organic 
layer was dried over anhydrous Na2SO4, filtered, concentrated in vacuo and the residue purified 
by flash chromatography (Et2O/petroleum ether, 1:50) to furnish methyl ether 3-16 (301 mg, 
91%) as colorless oil. Rf = 0.25 (Et2O/petroleum ether, 1:50); []D
21
 = −4.23 (c 1.0, CHCl3); 
1
H 
NMR (400 MHz, CDCl3):  = 0.97 (d, J = 6.8 Hz, 3H, 4-CH3), 1.52 (d, J = 1.3 Hz, 3H, 6-CH3), 
1.94 (dddd, J = 14.1, 8.6, 7.3, 1.5 Hz, 1H, 3-H), 2.05 (dddd, J = 13.6, 7.3, 5.8, 1.3 Hz, 1H, 3-H), 
2.21 (dddd, J =14.4, 8.6, 7.3, 1.3 Hz, 1H, 8-H), 2.36 (dddd, J = 13.9, 8.1, 6.8, 1.3 Hz, 1H, 8-H), 
2.45–2.58 (m, 1H, 5-H), 3.16 (s, 3H, OCH3), 3.45 (dd, J = 7.1, 7.1 Hz, 1H, 7-H), 5.01–5.12 (m, 
3H, 5-H, 10-H), 5.69 (dddd, J = 17.2, 10.1, 7.1, 6.8 Hz, 1H, 9-H), 5.95 (ddd, J = 14.1, 1.5, 1.3 
Hz, 1H, 1-H), 6.42 (ddd, J = 14.1, 7.6, 7.3 Hz, 1H, 2-H); 13C NMR (100 MHz, CDCl3):  = 10.7 
(6-CH3), 20.8 (4-CH3), 31.8 (C-4), 38.2 (C-8), 43.5 (C-3), 55.6 (OCH3), 75.4 (C-1), 86.9 (C-7), 
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116.5 (C-10), 133.2 (C-6), 134.0 (C-5), 135.0 (C-9), 145.0 (C-2); HRMS (ESI): [M+Na]
+
 calcd 
for C13H21IONa 343.05293, found 343.052985. 
(3S)-3-Hydroxypent-4-enyl pivalate (3-46) 
 
A solution of silyl ether 3-25 (0.94 g, 3.1 mmol) and p-TSA•H2O (60 mg, 0.31 mmol) in 
methanol (10 mL) was stirred at room temperature for 1 h. After TLC showed essentially 
complete conversion, the mixture was treated with water (5 mL) and extracted with Et2O (3 × 5 
mL). The combined organic layers were washed with saturated NaCl solution (10 mL), dried 
over anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash 
chromatography (small filtration column, Et2O/petroleum ether, 3:7), to give allyl alcohol 3-46 
(545 mg, 94%) as colorless oil. Rf = 0.27 (Et2O/petroleum ether, 3:7); []D
21
 = 4.1 (c 1.0, 
CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 1.19 (s, 9H, C(CH3)3), 1.79 (ddd, J = 14.4, 7.6, 5.8 
Hz, 1H, 3-H), 1.86 (ddd, J = 14.9, 6.3, 6.1 Hz, 1H, 3-H), 2.11 (bs, 1H, OH), 4.11 (ddd, J = 11.1, 
6.1, 5.5 Hz, 1H, 1-H), 4.15–m, 1H, 3-H), 4.26 (ddd, J = 11.1, 7.6, 5.6 Hz, 1H, 1-H), 5.11 
(ddd, J = 10.6, 1.5, 1.3 Hz, 1H, 5-H), 5.23 (ddd, J = 17.2, 1.5, 1.3 Hz, 1H, 5-H), 5.86 (ddd, J = 
17.2, 10.6, 6.1 Hz, 5-H); 
13
C NMR (100 MHz, CDCl3):  = 27.1 (C(CH3)3), 36.0 (C-2), 38.7 
(C(CH3)3), 61.2 (C-3), 69.9 (C-1), 115.0 (C-5), 140.2 (C-4), 178.8 (C=O); HRMS (ESI): 
[M+Na]
+
 calcd for C10H18O3Na 209.11482, found 209.11472. 
 
(3S,4E,7S,8E,10S,12E)-3-Hydroxy-13-iodo-7-methoxy-8,10-dimethyltrideca-4,8,12-trienyl 
pivalate (3-47) 
 
To a solution of triene 3-16 (50 mg, 0.16 mmol) and allyl alcohol 3-46 (58 mg, 0.31 mmol) in 
dry degassed toluene (2.5 mL) was added Grubb’s 2nd catalyst (13 mg, 10 mol%) in toluene (0.5 
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mL) dropwise at 80 °C. The reaction mixture was stirred at the same temperature for 24 h while 
the progress of the reaction was checked by TLC. After cooling, the mixture was concentrated in 
vacuo and the residue purified by flash chromatography (EtOAc/petroleum ether, 1:4) to provide 
the metathesis product 3-47 (33 mg, 44%) as colorless oil. Rf = 0.25 (ethyl acetate/petroleum 
ether, 1:4); []D
22
 = 11.72 (c 1.0, CHCl3); 
1
H NMR (400 MHz, CDCl3):  = 0.96 (d, J = 6.8 Hz, 
3H, 10-CH3), 1.18 (s, 9H, C(CH3)3), 1.51 (d, J = 1.3 Hz, 3H, 8-CH3), 1.78–1.85 (m, 2H, 2-H), 
1.94 (dddd, J = 14.1, 8.8, 8.1, 1.5 Hz, 1H, 11-H), 2.03 (dddd, J = 13.9, 7.6, 6.1, 1.3 Hz, 1H, 11-
H), 2.17 (ddd, J = 13.9, 6.8, 6.6 Hz, 1H, 6-H), 2.32 (ddd, 14.7, 13.9, 7.3 Hz, 1H, 6-H), 2.44–2.56 
(m, 1H, 10-H), 3.14 (s, 3H, OCH3), 3.42 (t, J = 6.82 Hz, 1H, 7-H), 4.09 (ddd, J = 11.1, 6.1, 6.1 
Hz, 1H, 1-H), 4.19 (ddd, J = 13.4, 6.3, 6.3 Hz, 1H, 3-H), 4.23 (ddd, J = 11.1, 6.6, 6.6 Hz, 1H, 1-
H), 5.10 (d, J = 9.6 Hz, 1H, 9-H), 5.48–5.64 (m, 2H, 4-H, 5-H), 5.95 (ddd, J = 14.4, 1.3, 1.0 Hz, 
1H, 13-H), 6.41 (ddd, J = 14.4, 7.6, 7.1 Hz, 1H, 12-H); 13C NMR (100 MHz, CDCl3):  = 10.9 
(8-CH3), 20.7 (10-CH3), 27.2 (C(CH3)3), 31.8 (C-10), 36.2 (C-2), 36.8 (C-6), 38.7 (C(CH3)3), 
43.4 (C-11), 55.7 (OCH3), 61.3 (C-1), 69.7 (C-3), 75.5 (C-13), 86.8 (C-7), 128.3 (C-5), 133.3 (C-
8), 133.9 (C-9), 134.0 (C-4), 144.9 (C-12), 178.7 (C=O); HRMS (ESI): [M+Na]
+
 calcd for 
C21H35IO4Na 501.14722, found 501.147474. 
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15   Appendix 
15.1   NMR-Spectra for important compounds 
Additional spectra are included in the supporting information of the published papers from this 
work and are available free of charge via Internet at DOI: 10.1055/s-0031-1289898 (Synlett) and 
http://dx.doi.org/10.1016/j.tet.2010.10.028 (Tetrahedron). 
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ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
1
9
.8
7
3
0
.2
2
3
6
.5
2
3
7
.0
5
3
8
.4
7
3
9
.4
3
6
6
.0
2
6
6
.1
4
6
7
.6
5
7
2
.9
7
7
7
.0
0
9
8
.4
9
1
2
7
.6
3
1
2
8
.3
4
1
3
8
.4
9
 
Appendix  203 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
1
1
8
.5
7
1
2
3
.9
2
1
2
6
.7
8
1
3
4
.9
6
1
4
3
.7
9
 
204  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
Chloroform-d
 
80 75 70 65 60 55 50 45 40 35 30 25 20 15 10 5 0 -5
ppm
Chloroform-d
-5
.3
3
1
8
.3
3
2
5
.8
9
6
1
.7
7
6
2
.6
7
7
0
.4
5
7
0
.7
5
7
2
.4
6
7
2
.6
7
7
7
.0
0
 
Appendix  205 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
ppm
Chloroform-d
-5
.2
9
1
8
.3
5
2
5
.9
1
6
2
.6
9
6
9
.4
3
7
0
.6
4
7
0
.7
2
7
2
.2
2
7
2
.6
5
7
7
.0
0
1
1
7
.0
6
1
3
4
.7
7
 
206  Appendix 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
ppm
Chloroform-d
-5
.2
8
1
8
.3
5
2
5
.9
1
6
2
.7
1
7
0
.0
2
7
0
.6
7
7
0
.7
6
7
1
.2
4
7
2
.6
8
7
6
.6
8
7
7
.0
0
7
7
.3
2
1
2
3
.9
8
1
2
6
.9
2
1
2
9
.5
3
1
3
1
.3
3
1
4
3
.2
7
1
4
6
.9
3
 
Appendix  207 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
ppm
Chloroform-d
-5
.3
0
1
8
.3
3
2
5
.9
0
3
0
.1
3
6
2
.7
1
7
0
.4
0
7
0
.7
8
7
1
.6
1
7
2
.7
2
1
0
3
.3
9
1
2
3
.5
2
1
2
9
.0
6
1
4
6
.2
3
1
4
6
.8
4
1
4
9
.8
0
 
208  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
ppm
Chloroform-d
-5
.2
9
1
8
.3
4
2
5
.9
0
3
3
.9
0
6
2
.6
9
6
8
.5
8
6
9
.7
6
7
0
.7
2
7
0
.7
9
7
2
.6
9
7
7
.0
0
1
0
1
.1
6
1
2
3
.6
0
1
2
9
.0
1
1
4
6
.4
5
1
4
8
.3
0
1
4
9
.4
4
 
Appendix  209 
 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
ppm
Chloroform-d
-5
.2
7
1
8
.3
6
2
5
.9
3
3
1
.3
9
6
2
.7
0
7
0
.1
3
7
0
.6
2
7
0
.6
6
7
2
.6
6
7
6
.6
8
7
7
.0
0
7
7
.3
2
1
1
5
.9
1
1
2
9
.2
7
1
3
3
.0
1
1
4
2
.7
0
 
210  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
7
2
6
.7
8
6
1
.8
3
6
3
.4
0
7
0
.5
3
7
0
.8
1
7
2
.4
4
7
7
.0
0
1
2
7
.6
3
1
2
9
.6
2
1
3
3
.6
2
1
3
5
.6
0
 
Appendix  211 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
7
2
6
.7
9
6
3
.4
1
6
9
.4
3
7
0
.7
1
7
0
.7
6
7
2
.2
2
7
2
.4
2
7
7
.0
0
1
1
7
.0
6
1
2
7
.6
0
1
2
9
.5
7
1
3
3
.6
9
1
3
4
.7
7
1
3
5
.6
0
 
212  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
6
2
6
.7
8
6
3
.4
1
7
0
.0
0
7
0
.7
7
7
1
.2
2
7
2
.4
5
1
2
3
.9
6
1
2
6
.9
0
1
2
7
.6
1
1
2
9
.4
9
1
2
9
.5
9
1
3
1
.3
3
1
3
3
.6
6
1
3
5
.5
8
1
4
3
.2
5
1
4
6
.9
1
 
Appendix  213 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
6
2
6
.7
8
3
0
.1
2
6
3
.4
2
7
0
.4
2
7
0
.8
1
7
0
.8
7
7
1
.6
0
7
2
.4
8
7
7
.0
0
1
0
3
.3
7
1
2
3
.5
1
1
2
7
.6
0
1
2
9
.0
5
1
2
9
.5
9
1
3
3
.6
5
1
3
5
.5
8
1
4
6
.2
1
1
4
6
.8
3
1
4
9
.7
9
 
214  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
7
2
6
.7
8
3
3
.9
0
6
3
.4
1
6
8
.5
6
6
9
.7
9
7
0
.7
7
7
0
.8
2
7
2
.4
6
7
7
.0
0
1
0
1
.1
3
1
2
3
.6
1
1
2
7
.6
1
1
2
9
.0
1
1
2
9
.5
9
1
3
3
.6
6
1
3
5
.5
9
1
4
6
.4
4
1
4
8
.2
9
1
4
9
.4
5
 
Appendix  215 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
1
9
.1
7
2
6
.7
9
3
1
.3
5
6
3
.4
1
7
0
.1
1
7
0
.4
9
7
0
.6
3
7
0
.6
8
7
2
.4
2
7
7
.0
0
1
1
5
.9
9
1
2
7
.6
0
1
2
9
.2
7
1
2
9
.5
7
1
3
3
.1
2
1
3
3
.6
9
1
3
5
.6
0
1
4
2
.4
9
 
216  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
6
1
.6
9
6
9
.3
2
7
0
.3
0
7
0
.5
9
7
2
.2
1
7
2
.4
6
7
6
.6
8
7
7
.0
0
7
7
.3
1
1
1
7
.1
9
1
3
4
.6
1
 
Appendix  217 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
2
7
.9
7
2
8
.0
7
6
1
.1
3
6
8
.3
3
6
9
.0
1
6
9
.3
8
7
0
.5
8
7
0
.6
9
7
0
.9
4
7
2
.2
0
8
1
.4
9
8
2
.6
2
1
1
7
.0
6
1
3
4
.7
4
1
6
6
.3
9
1
6
9
.6
6
1
6
9
.8
9
 
218  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
8
.0
1
6
8
.9
3
6
9
.9
0
7
0
.5
6
7
1
.1
4
7
6
.6
8
7
7
.0
0
7
7
.3
2
8
1
.4
4
1
2
3
.8
8
1
2
6
.8
5
1
2
9
.4
2
1
3
1
.2
7
1
4
3
.2
0
1
4
6
.8
3
1
6
9
.5
4
 
Appendix  219 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
8
.0
7
3
1
.2
8
3
1
.3
9
6
9
.0
1
7
0
.0
6
7
0
.5
7
7
0
.6
9
7
6
.6
9
7
7
.0
0
7
7
.3
2
8
1
.4
9
1
1
5
.1
9
1
2
9
.1
9
1
3
1
.9
4
1
4
4
.1
6
1
6
9
.6
6
 
220  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
1
9
.1
7
1
9
.7
9
2
1
.5
8
2
1
.7
5
2
6
.0
8
2
6
.8
0
3
0
.0
3
3
1
.1
8
3
1
.6
1
3
6
.4
1
3
6
.4
6
3
8
.1
5
4
0
.8
5
5
3
.4
0
6
3
.4
1
6
5
.7
3
6
6
.5
5
7
0
.1
2
7
0
.4
2
7
0
.6
2
7
0
.7
7
7
2
.4
2
7
2
.9
4
7
6
.6
8
7
7
.0
0
7
7
.3
2
9
8
.4
8
1
1
5
.1
9
1
1
5
.4
1
1
1
9
.7
0
1
2
1
.6
9
1
2
7
.6
0
1
2
8
.2
9
1
2
8
.3
4
1
2
8
.6
1
1
2
9
.5
7
1
3
0
.4
6
1
3
3
.1
4
1
3
3
.2
2
1
3
3
.7
0
1
3
5
.6
0
1
3
8
.4
8
1
4
1
.3
0
1
6
1
.0
0
1
6
3
.4
7
1
6
4
.7
5
 
Appendix  221 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
6
1
9
.7
7
2
1
.6
0
2
1
.7
7
2
6
.7
9
3
0
.0
2
3
1
.1
6
3
1
.6
1
3
6
.1
0
3
7
.9
6
4
0
.7
8
6
0
.6
5
6
3
.4
1
6
6
.4
8
6
8
.8
5
7
0
.1
0
7
0
.4
2
7
0
.6
7
7
2
.4
1
7
6
.6
8
7
7
.0
0
7
7
.3
2
9
8
.6
1
1
1
5
.2
2
1
1
5
.4
3
1
1
9
.7
1
1
2
1
.7
2
1
2
6
.4
9
1
2
7
.5
9
1
2
8
.3
0
1
2
8
.6
1
1
2
9
.5
7
1
3
0
.4
3
1
3
3
.1
3
1
3
3
.2
1
1
3
3
.6
9
1
3
5
.5
9
1
3
6
.1
0
1
3
7
.2
5
1
4
1
.2
5
1
6
1
.0
0
1
6
3
.4
6
1
6
4
.7
5
 
222  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
7
1
9
.6
4
2
1
.6
4
2
1
.8
1
2
6
.1
0
2
6
.8
0
2
9
.8
4
3
1
.1
6
3
1
.6
1
4
0
.7
5
6
3
.4
1
6
5
.4
7
6
6
.3
7
7
0
.1
0
7
0
.4
2
7
0
.6
0
7
0
.7
5
7
2
.4
1
7
6
.6
9
7
7
.0
0
7
7
.3
2
9
9
.0
3
1
1
5
.2
7
1
1
5
.4
8
1
1
9
.7
8
1
2
1
.8
0
1
2
7
.6
0
1
2
8
.2
6
1
2
8
.3
0
1
2
8
.6
3
1
2
9
.5
7
1
3
0
.4
2
1
3
3
.0
9
1
3
3
.1
7
1
3
3
.6
8
1
3
5
.6
0
1
3
6
.0
3
1
4
1
.1
4
1
4
9
.0
1
1
6
1
.0
1
1
6
3
.4
8
1
6
4
.9
1
1
7
6
.0
2
 
Appendix  223 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.1
7
2
1
.7
1
2
2
.0
1
2
6
.1
6
2
6
.7
9
3
1
.1
6
3
1
.6
1
3
5
.6
3
3
7
.1
3
3
8
.4
7
4
0
.7
0
6
2
.4
7
6
3
.4
0
7
0
.1
0
7
0
.4
2
7
0
.6
6
7
0
.7
4
7
2
.4
1
7
2
.9
8
7
6
.6
9
7
7
.0
0
7
7
.3
2
1
1
5
.5
0
1
1
5
.7
2
1
1
9
.8
2
1
2
2
.0
4
1
2
7
.6
0
1
2
8
.3
4
1
2
8
.6
4
1
2
9
.5
7
1
3
0
.3
5
1
3
3
.0
3
1
3
3
.1
1
1
3
3
.6
8
1
3
4
.3
9
1
3
5
.5
9
1
3
7
.4
3
1
4
1
.0
9
1
6
1
.0
8
1
6
3
.5
5
1
6
4
.8
0
1
6
9
.3
6
 
224  Appendix 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
2
1
.6
9
2
1
.9
9
2
6
.1
4
3
1
.0
8
3
1
.5
5
3
5
.6
1
3
7
.1
3
3
8
.4
6
4
0
.6
9
6
1
.7
1
6
2
.3
6
7
0
.0
2
7
0
.3
2
7
0
.4
0
7
0
.5
9
7
2
.4
6
7
3
.0
0
7
6
.6
8
7
7
.0
0
7
7
.3
1
1
1
5
.4
8
1
1
5
.6
9
1
1
5
.7
3
1
1
9
.8
5
1
2
2
.0
2
1
2
6
.5
7
1
2
8
.0
3
1
2
8
.3
3
1
2
8
.6
5
1
3
0
.3
4
1
3
3
.0
2
1
3
3
.1
0
1
3
4
.4
0
1
3
5
.9
7
1
3
7
.3
6
1
4
1
.0
9
1
6
1
.0
7
1
6
3
.5
5
1
6
4
.8
3
1
6
9
.4
6
 
Appendix  225 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.7
8
2
1
.5
8
2
1
.7
5
2
6
.0
6
2
8
.0
9
3
0
.0
2
3
1
.1
6
3
1
.6
0
3
6
.4
1
3
6
.4
5
4
0
.8
4
6
5
.7
3
6
5
.9
8
6
6
.5
5
6
9
.0
4
7
0
.0
9
7
0
.4
1
7
0
.5
7
7
2
.9
4
7
6
.6
9
7
7
.0
0
7
7
.3
2
8
1
.5
0
9
8
.4
8
1
1
5
.1
9
1
1
5
.4
0
1
1
9
.7
2
1
2
1
.6
8
1
2
6
.4
7
1
2
7
.6
2
1
2
8
.1
9
1
2
8
.3
4
1
2
8
.6
1
1
3
0
.4
5
1
3
3
.1
4
1
3
3
.2
2
1
3
4
.6
6
1
3
6
.1
5
1
3
7
.2
0
1
3
8
.4
7
1
4
1
.2
9
1
6
0
.9
9
1
6
3
.4
6
1
6
4
.7
7
1
6
9
.6
7
 
226  Appendix 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.7
5
2
1
.5
8
2
1
.7
5
2
6
.0
6
2
8
.0
7
3
0
.0
1
3
1
.1
4
3
1
.5
8
3
6
.0
9
3
7
.9
6
4
0
.7
6
6
0
.5
8
6
6
.4
7
6
8
.7
9
6
9
.0
1
7
0
.0
7
7
0
.3
8
7
0
.5
5
7
0
.6
8
7
6
.6
9
7
7
.0
0
7
7
.3
2
8
1
.4
8
9
8
.5
9
1
1
5
.2
0
1
1
5
.4
1
1
1
9
.7
1
1
2
1
.7
1
1
2
6
.4
7
1
2
8
.2
9
1
2
8
.6
0
1
3
0
.4
2
1
3
3
.1
1
1
3
3
.1
9
1
3
4
.5
9
1
3
6
.1
0
1
3
7
.2
2
1
4
1
.2
2
1
6
0
.9
9
1
6
3
.4
5
1
6
4
.7
5
1
6
9
.6
6
 
Appendix  227 
 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
1
9
.6
3
2
1
.6
3
2
1
.7
9
2
8
.0
9
2
9
.8
3
3
1
.1
3
3
1
.5
9
3
5
.6
8
3
7
.8
0
4
0
.7
7
6
5
.4
8
6
6
.3
7
6
9
.0
2
7
0
.0
7
7
0
.4
1
7
0
.5
5
7
0
.6
9
7
6
.6
9
7
7
.0
0
7
7
.3
2
8
1
.5
3
9
8
.9
9
1
1
5
.2
6
1
1
5
.4
8
1
1
9
.8
0
1
2
1
.8
0
1
2
6
.4
9
1
2
8
.2
9
1
2
8
.6
2
1
2
8
.6
8
1
3
0
.4
2
1
3
3
.0
9
1
3
3
.1
7
1
3
4
.5
4
1
3
6
.0
4
1
3
7
.3
2
1
4
1
.1
4
1
6
1
.0
0
1
6
3
.4
7
1
6
4
.9
1
1
6
9
.6
9
1
7
4
.0
5
 
228  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
2
1
.6
9
2
1
.9
9
2
6
.1
4
2
8
.0
7
3
1
.1
3
3
1
.5
8
3
5
.6
0
3
7
.1
3
3
8
.4
6
4
0
.6
8
6
2
.3
4
6
9
.0
0
7
0
.0
6
7
0
.3
7
7
0
.5
4
7
0
.6
7
7
3
.0
0
7
6
.6
8
7
7
.0
0
7
7
.3
1
8
1
.5
3
1
1
5
.4
7
1
1
5
.6
9
1
1
9
.8
2
1
2
2
.0
1
1
2
6
.5
6
1
2
7
.9
9
1
2
8
.0
3
1
2
8
.3
1
1
2
8
.6
3
1
3
0
.3
3
1
3
3
.0
1
1
3
4
.3
9
1
3
5
.9
5
1
3
7
.3
9
1
4
1
.0
6
1
6
1
.0
6
1
6
3
.5
3
1
6
4
.8
1
1
6
9
.4
6
1
6
9
.6
9
 
Appendix  229 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20
ppm
Chloroform-d
2
1
.7
1
2
2
.0
1
2
6
.1
4
3
0
.8
4
3
1
.4
5
3
5
.6
0
3
7
.1
0
3
8
.4
2
4
0
.6
8
6
2
.3
4
6
9
.2
0
7
0
.0
5
7
0
.2
1
7
0
.3
8
7
0
.5
2
7
1
.0
9
7
3
.0
1
7
6
.6
8
7
7
.0
0
7
7
.3
1
1
1
5
.4
8
1
1
5
.6
9
1
2
0
.0
2
1
2
2
.0
4
1
2
6
.5
8
1
2
7
.9
9
1
2
8
.3
2
1
2
8
.6
7
1
3
0
.3
2
1
3
3
.1
1
1
3
4
.3
8
1
3
5
.8
9
1
3
7
.3
5
1
4
1
.0
5
1
6
1
.0
7
1
6
3
.5
4
1
6
3
.8
4
1
6
5
.0
1
1
6
9
.5
9
 
230  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
3
.5
6
2
5
.8
7
3
7
.9
2
4
5
.4
0
7
6
.6
8
7
7
.0
0
7
7
.3
1
1
0
3
.5
3
1
1
5
.5
4
1
1
5
.7
5
1
2
2
.1
8
1
2
4
.8
4
1
2
6
.5
5
1
2
7
.4
7
1
2
7
.9
1
1
2
7
.9
9
1
2
8
.5
5
1
2
9
.8
3
1
3
3
.0
5
1
3
6
.4
7
1
3
8
.1
3
1
4
0
.1
8
1
6
1
.0
5
1
6
3
.5
1
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7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.2
0
2
6
.5
4
3
8
.1
1
4
6
.1
7
7
6
.6
8
7
7
.0
0
7
7
.2
0
7
7
.3
1
9
4
.6
7
1
1
5
.1
5
1
1
5
.3
6
1
2
3
.0
9
1
2
5
.8
9
1
2
6
.7
1
1
2
7
.5
4
1
2
8
.5
1
1
2
8
.6
3
1
3
0
.5
5
1
3
3
.0
3
1
3
4
.0
7
1
3
4
.2
7
1
3
7
.6
8
1
6
0
.9
1
1
6
3
.3
7
 
232  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.0
7
2
6
.1
1
3
0
.9
1
3
7
.7
0
4
6
.4
2
1
0
9
.7
5
1
1
5
.1
4
1
1
5
.3
6
1
2
5
.9
4
1
2
6
.8
1
1
2
7
.3
4
1
2
8
.4
7
1
2
8
.5
5
1
2
8
.7
0
1
3
0
.0
9
1
3
0
.5
0
1
3
3
.3
0
1
3
5
.2
8
1
3
7
.4
7
1
4
4
.3
5
1
6
1
.0
2
1
6
3
.4
9
1
6
9
.0
1
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7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5
ppm
Chloroform-d
 
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
ppm
Chloroform-d
-5
.2
8
1
8
.3
5
2
1
.7
9
2
5
.9
2
2
6
.2
7
3
1
.1
8
3
1
.6
1
3
7
.8
8
4
6
.2
1
6
2
.6
9
7
0
.1
2
7
0
.4
2
7
0
.7
4
7
2
.6
4
7
6
.6
8
7
7
.0
0
7
7
.3
2
1
1
5
.2
5
1
1
5
.4
6
1
1
9
.7
0
1
2
6
.5
9
1
2
6
.7
7
1
2
8
.3
3
1
2
8
.4
7
1
2
8
.6
2
1
2
8
.9
6
1
3
0
.4
8
1
3
1
.4
7
1
3
3
.1
4
1
3
4
.5
8
1
3
7
.6
2
1
4
1
.2
3
1
6
1
.0
5
1
6
3
.5
2
1
6
4
.6
1
 
234  Appendix 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.7
9
2
6
.2
7
3
1
.1
0
3
1
.5
7
3
7
.8
8
4
6
.2
2
6
1
.7
5
7
0
.0
6
7
0
.3
8
7
0
.4
2
7
0
.5
8
7
2
.4
8
7
6
.6
8
7
7
.0
0
7
7
.3
1
1
1
5
.2
5
1
1
5
.4
4
1
1
5
.4
7
1
1
9
.7
2
1
2
6
.5
9
1
2
6
.7
7
1
2
8
.3
4
1
2
8
.4
7
1
2
8
.6
4
1
2
8
.6
9
1
2
8
.9
7
1
3
0
.4
9
1
3
3
.1
4
1
3
4
.5
9
1
3
7
.6
2
1
4
1
.2
4
1
6
1
.0
6
1
6
3
.5
2
1
6
4
.6
2
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8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.5
8
6
1
.6
8
6
8
.6
4
6
9
.1
2
7
0
.2
5
7
0
.7
2
7
2
.4
0
7
6
.6
8
7
7
.0
0
7
7
.3
2
1
2
7
.9
1
1
2
9
.7
9
1
3
2
.8
8
1
4
4
.8
3
 
236  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
85 80 75 70 65 60 55 50 45 40 35 30 25 20 15 10
ppm
Chloroform-d
5
0
.6
0
6
1
.7
1
7
0
.0
0
7
0
.3
4
7
0
.6
1
7
2
.4
4
7
6
.6
9
7
7
.0
0
7
7
.3
2
 
Appendix  237 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
8
.0
9
5
0
.6
6
6
9
.0
2
7
0
.0
1
7
0
.6
4
7
0
.6
6
7
6
.6
8
7
7
.0
0
7
7
.3
1
8
1
.5
1
1
6
9
.6
4
 
238  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
8
.0
6
4
1
.6
5
6
8
.9
8
7
0
.2
0
7
0
.5
2
7
0
.6
1
7
2
.9
6
7
7
.0
0
8
1
.5
8
1
6
9
.6
9
 
Appendix  239 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
ppm
Chloroform-d
  
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
3
.9
3
2
5
.2
6
2
6
.2
1
4
4
.7
3
4
6
.9
2
7
7
.0
0
1
1
0
.4
4
1
1
2
.2
5
1
1
3
.2
7
1
1
5
.1
1
1
1
6
.1
2
1
1
7
.9
7
1
1
8
.9
5
1
2
0
.8
3
1
5
4
.9
7
1
5
5
.3
2
1
5
5
.6
8
1
5
6
.0
3
1
5
7
.7
2
1
5
8
.1
3
 
240  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.9
0
7
6
.6
8
7
7
.0
0
7
7
.3
1
1
1
2
.4
1
1
1
5
.3
0
1
1
8
.2
0
1
2
1
.1
0
1
2
7
.4
3
1
2
9
.8
0
1
3
0
.2
4
1
4
7
.0
2
1
7
9
.5
9
1
7
9
.9
3
1
8
0
.2
8
1
8
0
.6
2
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10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.4
3
7
6
.6
8
7
7
.0
0
7
7
.3
2
1
1
6
.6
3
1
1
9
.3
5
1
2
2
.0
9
1
2
3
.1
1
1
2
4
.8
2
1
2
8
.5
8
1
2
9
.2
2
1
4
0
.8
9
1
4
6
.8
5
1
4
7
.1
7
1
4
7
.4
9
1
4
7
.8
1
 
242  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.5
0
2
1
.7
3
7
6
.6
8
7
7
.0
0
7
7
.3
1
1
1
5
.5
3
1
1
8
.2
9
1
2
1
.0
5
1
2
1
.5
9
1
2
3
.8
1
1
2
7
.0
1
1
2
8
.4
2
1
2
9
.2
2
1
2
9
.4
5
1
2
9
.8
3
1
3
0
.2
0
1
3
1
.2
2
1
4
2
.3
0
1
4
6
.0
5
1
5
3
.4
7
1
5
3
.8
0
1
5
4
.1
4
1
5
4
.4
6
 
Appendix  243 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.2
8
5
7
.3
4
5
7
.7
0
5
8
.0
5
5
8
.4
1
1
2
2
.2
0
1
2
4
.9
6
1
2
7
.9
7
1
2
8
.7
6
1
2
9
.4
0
1
4
0
.2
4
 
244  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
ppm
Chloroform-d
 
140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
1
.1
5
2
7
.7
7
2
8
.1
7
2
8
.5
7
2
8
.9
7
7
6
.6
9
7
7
.0
0
7
7
.3
2
1
1
8
.1
4
1
2
0
.8
7
1
2
3
.6
0
1
2
6
.1
4
1
2
6
.3
3
1
2
6
.4
0
1
2
9
.5
2
1
3
9
.8
4
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8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Methanol-d4
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Methanol-d4
2
8
.8
9
2
9
.2
9
2
9
.7
0
3
0
.1
0
4
9
.0
0
1
1
9
.3
2
1
2
2
.0
4
1
2
4
.7
7
1
2
7
.4
9
1
2
7
.5
5
1
3
1
.3
0
1
3
3
.5
4
1
3
4
.4
3
1
6
8
.4
8
 
246  Appendix 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
8
.0
3
3
9
.9
1
6
8
.8
5
6
9
.8
3
7
0
.1
3
7
0
.4
4
7
0
.5
0
7
6
.6
8
7
7
.0
0
7
7
.3
2
8
1
.8
2
1
2
6
.4
0
1
2
7
.6
8
1
3
1
.9
4
1
3
5
.7
3
1
6
6
.2
7
1
6
9
.5
9
 
Appendix  247 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
ppm
Chloroform-d
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
ppm
Chloroform-d
2
7
.6
9
2
8
.0
9
2
8
.4
9
2
8
.9
0
3
9
.9
2
6
8
.6
6
6
9
.8
4
7
0
.0
2
7
0
.4
5
7
1
.1
7
7
6
.6
9
7
7
.0
0
7
7
.3
2
1
1
7
.7
8
1
2
0
.5
1
1
2
3
.2
4
1
2
5
.9
7
1
2
6
.4
5
1
2
7
.7
0
1
3
2
.1
3
1
3
5
.2
8
1
6
6
.6
0
1
7
2
.2
0
 
248  Appendix 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
ppm
Chloroform-d
1
1
.6
3
2
0
.4
9
3
1
.6
9
3
9
.9
1
4
3
.4
9
7
5
.3
8
7
6
.5
7
7
6
.6
9
7
7
.0
0
7
7
.3
2
1
1
7
.7
5
1
3
1
.5
0
1
3
4
.6
3
1
3
6
.0
4
1
4
4
.9
5
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7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
Chloroform-d
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
ppm
Chloroform-d
1
0
.9
0
2
0
.6
7
2
7
.1
9
3
1
.7
6
3
6
.2
0
3
6
.7
7
3
8
.7
1
4
3
.4
4
5
5
.6
7
6
1
.3
3
6
9
.6
8
7
5
.4
6
7
6
.6
9
7
7
.0
0
7
7
.3
2
8
6
.7
8
1
2
8
.2
6
1
3
3
.2
7
1
3
3
.9
1
1
3
4
.0
4
1
4
4
.9
1
1
7
8
.6
8
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